var title_f9_16_9472="Early coronary atherosclerosis";
var content_f9_16_9472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatty streak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-section of a human coronary artery demonstrates the early atherosclerotic changes of a fatty streak with thickening of the intima (short arrow) and a soft lipid core (long arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles E Rackley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9472=[""].join("\n");
var outline_f9_16_9472=null;
var title_f9_16_9473="Polyestradiol: International drug information";
var content_f9_16_9473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polyestradiol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Estradurin (CH, DE, DK, ES, FI, NL, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4089368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Polyestradiol Phosphate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Estrogen Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of advanced, inoperable carcinoma of the prostate",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Deep I.M.: 80-160 mg every 4 weeks for 2-3 months, followed by 40-80 mg every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection, as phosphate: 40 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10521 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9473=[""].join("\n");
var outline_f9_16_9473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369785\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089368\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089369\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089370\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089372\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821142\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089373\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10521|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9474="Urinary incontinence in women";
var content_f9_16_9474=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Urinary incontinence in women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/16/9474/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9474/contributors\" id=\"au4227\">",
"       Catherine E DuBeau, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/16/9474/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9474/contributors\" id=\"se1605\">",
"       Kenneth E Schmader, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/16/9474/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9474/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/16/9474?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      URINARY INCONTINENCE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Urinary incontinence, also known as urinary leakage, is an embarrassing problem that affects millions of women. Although it is more common in older women, it can affect younger women as well. Urinary frequency, the need to run to the bathroom frequently, is another bothersome problem that can affect women.",
"    </p>",
"    <p>",
"     There is no need to live with urine leakage or frequency because effective treatments are available. This article discusses the different types of leakage and the tests that may be done during your evaluation. The treatment of incontinence and frequency is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"      \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about incontinence is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"      \"Clinical presentation and diagnosis of urinary incontinence\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"      \"Treatment of urinary incontinence\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF URINARY INCONTINENCE",
"     </span>",
"    </p>",
"    <p>",
"     The two most common types of urine leakage in women are urge and stress incontinence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Urge incontinence",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with urge incontinence, there is a sudden, overwhelming urge to urinate. You may leak urine on the way to the toilet. Common triggers of urge incontinence include unlocking the door when returning home, going out in the cold, turning on the faucet, or washing your hands.",
"    </p>",
"    <p>",
"     Some people with urge incontinence also have to go to the bathroom frequently during the day",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     night. Frequency is defined as the need to urinate more often than other people (normal is considered to be eight times in 24 hours).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Stress incontinence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stress incontinence occurs when the muscles and tissues around the urethra (where urine exits) do not stay closed properly when there is increased pressure (\"stress\") in the abdomen, leading to urine leakage. As an example, coughing, sneezing, laughing, or running can cause stress incontinence. Stress incontinence is a common reason for incontinence in women, especially those who have had children.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Mixed incontinence",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with both stress and urge incontinence are said to have mixed incontinence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Overactive bladder",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with overactive bladder have a sudden, overwhelming urge to urinate, but may or may not leak urine before getting to the toilet. People with overactive bladder often have to go to the bathroom during the day",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     night.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other types of incontinence",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to stress and urge incontinence, there are other, less common types of urinary incontinence.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The bladder does not empty completely, causing leakage when the bladder becomes overly full. This is called overflow incontinence.",
"      </li>",
"      <li>",
"       Incontinence may be caused or worsened by medical problems, medications,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       difficulty with thinking clearly.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      INCONTINENCE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Although leaking urine can be difficult to talk about, it is not normal at any age and is often treatable by exercises",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     medications. Talking about it with your healthcare provider is the first step in getting help for this problem that is affecting your life. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"      \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Important questions to discuss include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       When do you leak? (when you get a sudden urge, with",
"       <span class=\"nowrap\">",
"        coughing/sneezing,",
"       </span>",
"       or does it occur without warning?)",
"      </li>",
"      <li>",
"       When did your leakage begin? Has it worsened or improved over time?",
"      </li>",
"      <li>",
"       Have you tried any treatments to reduce leakage?",
"      </li>",
"      <li>",
"       Do you ever leak stool (smears or pieces of stool)?",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Bladder diary",
"     </span>",
"     &nbsp;&mdash;&nbsp;A bladder diary is a record of how much urine you make and how frequently you go. You may also be asked to write down how much fluid you drink and activities that caused leakage (",
"     <a class=\"graphic graphic_form graphicRef50194 \" href=\"UTD.htm?5/31/5631\">",
"      form 1",
"     </a>",
"     ). This diary provides useful information about the cause(s) and potential treatment of your leakage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Simple tests may be done during an office visit to determine the type of leakage you are experiencing. This may include a cough test, when you are asked to cough while your doctor or nurse watches for urine leakage.",
"    </p>",
"    <p>",
"     A urine test (urinalysis) is usually done to look for signs of infection or blood in the urine. Blood tests may be ordered to measure the kidney function.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Urodynamic testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;A urodynamic test is a test that measures how much urine your bladder can hold, what makes you leak urine, and determines if there are problems emptying the bladder. This test can be done in the office, and may be recommended if you are planning surgery for urine leakage or if the cause of your leakage is not clear.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      INCONTINENCE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment options for urinary incontinence are discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"      \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H131\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3356799\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/60/11202?source=see_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/9/35987?source=see_link\">",
"      Patient information: Urinary incontinence in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/56/35714?source=see_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3356825\">",
"     <span class=\"h3\">",
"      Beyond the basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/0/19456?source=see_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link\">",
"      Stress urinary incontinence in women: Choosing a type of midurethral sling",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=see_link\">",
"      Stress urinary incontinence in women: Transobturator midurethral slings",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/urinaryincontinence.html\">",
"      www.nlm.nih.gov/medlineplus/urinaryincontinence.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Urogynecology Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mypelvichealth.org/\">",
"      www.mypelvichealth.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Association for Continence",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-BLADDER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nafc.org/\">",
"      www.nafc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Simon Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.simonfoundation.org/\">",
"      www.simonfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/uiwomen/\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/uiwomen/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Continence Worldwide (Continence resources outside the United States)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.continenceworldwide.com/\">",
"      www.continenceworldwide.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/16/9474/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/16/9474?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9474/abstract/1\">",
"      Herzog AR, Fultz NH. Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 1990; 38:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9474/abstract/2\">",
"      DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46:683.",
"     </a>",
"    </li>",
"    <li>",
"     Fantl JA, Newman DK, Colling J, et al. Urinary Incontinence in Adults: Acute and Chronic Management. Clinical Practice Guideline, No. 2, 1996 Update, AHCPR Publication No. 96-0682. Public Health Service, Agency for Health Care Policy and Research, Rockville, MD. www.ahrq.gov/clinic/uiovervw.htm (Accessed on September 07, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9474/abstract/4\">",
"      Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med 2006; 144:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9474/abstract/5\">",
"      Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988; 71:812.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_16_9474=[""].join("\n");
var outline_f9_16_9474=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           URINARY INCONTINENCE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF URINARY INCONTINENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           INCONTINENCE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           INCONTINENCE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FORMS",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?5/31/5631\" title=\"form 1\">",
"           Bladder diary PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9475="Treatment of status epilepticus in adults";
var content_f9_16_9475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Treatment of status epilepticus in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 655px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that all infusion rates should be adjusted to individual patients; maximum doses listed are not always required.",
"    <div class=\"footnotes\">",
"     * Cardiac monitoring required. Phenytoin or fosphenytoin may be ineffective for toxin-induced seizures and may intensify seizures caused by cocaine and other local anesthetics, theophylline, or lindane. Patients with toxin-induced seizures should receive phenobarbital, midazolam, or propofol infusion as second line therapy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      EEG and cardiac monitoring.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9475=[""].join("\n");
var outline_f9_16_9475=null;
var title_f9_16_9476="Dimethyl fumarate: Drug information";
var content_f9_16_9476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimethyl fumarate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/31/4596?source=see_link\">",
"    see \"Dimethyl fumarate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16562890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tecfidera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16424379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Fumaric Acid Derivative;",
"     </li>",
"     <li>",
"      Immunomodulator, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16431773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple sclerosis (relapsing):",
"     </b>",
"     Oral: Initial: 120 mg twice daily for 7 days; then increase to the maintenance dose: 240 mg twice daily (Fox, 2012; Gold, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16431774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16431775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16431776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F16431777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious infection: Consider withholding treatment until infection resolves.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16562891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tecfidera&trade;: 120 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tecfidera&trade;: Capsule, delayed release: 120 mg (14s) and Capsule, delayed release: 240 mg (46s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16570580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16431779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally with or without food. Administering with food may decrease the incidence of flushing. Swallow capsules whole (delayed release); do not crush, chew, open the capsule, or sprinkle contents on food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16424331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsing forms of multiple sclerosis (MS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16431657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dimethyl fumarate may be confused with dimethyl sulfoxide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16431942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Flushing (40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (18%), diarrhea (14%), nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infection: Infection (60%; placebo: 58%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (8%), skin rash (8%), erythema (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (9%), dyspepsia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Proteinuria (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphocytopenia (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Increased serum AST (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening: Eosinophilia (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16431712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16431713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatitis/irritation: May cause rash, pruritus, or erythema. There are case reports of contact dermatitis resulting from dimethyl fumarate (DMF) exposure after use as a fungicide and desiccant in the shipping of furniture (Bruze, 2011; Gim&eacute;nez-Arnau, 2011; Ropper, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Flushing: Commonly causes mild-to-moderate flushing (eg, warmth, redness, itching, burning sensation); flushing generally appears soon after initiation, and improves or resolves with subsequent dosing. Administration with food may decrease flushing incidence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal events: GI events (eg, nausea, vomiting, diarrhea, abdominal pain, dyspepsia) commonly occur with use; GI events generally occur in the first month of use and decrease thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic effects: Transaminase elevations (usually &lt;3 times ULN) were observed, generally occurring in the first 6 months of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lymphopenia: Decreased lymphocyte counts may occur with use. Prior to initiation, a recent CBC (within 6 months) should be reviewed to identify patients with pre-existing low lymphocyte counts. Obtain CBC at least annually (or more frequently if indicated) during use. In trials, mean lymphocyte counts decreased ~30% over the first year of therapy (then stabilized), and lymphocyte counts increased (but did not return to baseline) 4 weeks following discontinuation. No difference in incidence of infection or series infections has been observed in treated patients when compared to placebo; consider temporarily discontinuing therapy in patients with serious infections. Has not been studied in patients with preexisting low lymphocyte counts.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F17917929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F17917927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16431708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16431709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women exposed to dimethyl fumarate during pregnancy are encouraged to enroll in the Pregnancy Registry by calling 800-456-2255.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16431710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16431711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if dimethyl fumarate is excreted into breast milk. The manufacturer recommends caution be used if administered to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F16431717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take with or without food; taking with food may decrease the incidence of flushing.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16431781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (obtained within 6 months prior to use, then at least annually during therapy or as clinically necessary)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16431718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     DMF and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythyroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidative stress. The mechanism by which dimethyl fumarate (DMF) exerts a therapeutic effect in MS is unknown, although it is believed to result from its anti-inflammatory and cytoprotective properties via activation of the Nrf2 pathway (Fox, 2012; Gold, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16431720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : MMF: 53-73 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: MMF: 27% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Undergoes rapid and extensive presystemic hydrolysis by esterases to its active metabolite, monomethyl fumarate (MMF); MMF is further metabolized via the tricarboxylic acid (TCA) cycle with no CYP involvement in metabolism. Major serum metabolites include: MMF, fumaric acid, citric acid, and glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: MMF: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: CO",
"     <sub>",
"      2",
"     </sub>",
"     via exhalation (~60%); urine (16%; trace amounts as unchanged MMF), feces (1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative--Fumapharm/Biogen Idec,\"",
"      <i>",
"       Drugs R D",
"      </i>",
"      , 2005, 6(4):229-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/15991882/pubmed\" id=\"15991882\" target=\"_blank\">",
"        15991882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bovenschen HJ, Langewouters AM, and van de Kerkhof PC, \"Dimethylfumarate for Psoriasis: Pronounced Effects on Lesional T-cell Subsets, Epidermal Proliferation and Differentiation, but not on Natural Killer T Cells in Immunohistochemical Study,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2010, 11(5):343-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/20553063/pubmed\" id=\"20553063\" target=\"_blank\">",
"        20553063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruze M and Zimerson E, \"Dimethyl Fumarate,\"",
"      <i>",
"       Dermatitis",
"      </i>",
"      , 2011, 22(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/21291637/pubmed\" id=\"21291637\" target=\"_blank\">",
"        21291637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox RJ, Miller DH, Phillips JT, et al, \"Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(12):1087-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/22992072/pubmed\" id=\"22992072\" target=\"_blank\">",
"        22992072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gim&eacute;nez-Arnau A, \"Dimethyl Fumarate: A Human Health Hazard,\"",
"      <i>",
"       Dermatitis",
"      </i>",
"      , 2011, 22(1):47-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/21291643/pubmed\" id=\"21291643\" target=\"_blank\">",
"        21291643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold R, Kappos L, Arnold DL, et al, \"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(12):1098-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/22992073/pubmed\" id=\"22992073\" target=\"_blank\">",
"        22992073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ropper AH, \"The 'Poison Chair' Treatment for Multiple Sclerosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(12):1149-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9476/abstract-text/22992079/pubmed\" id=\"22992079\" target=\"_blank\">",
"        22992079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88899 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9476=[""].join("\n");
var outline_f9_16_9476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562890\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424379\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431773\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431774\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431775\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431776\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431777\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562891\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570580\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431779\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424331\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431657\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431942\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917929\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917927\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431710\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431711\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431717\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431781\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431718\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431720\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/31/4596?source=related_link\">",
"      Dimethyl fumarate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9477="Mechlorethamine: Pediatric drug information";
var content_f9_16_9477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mechlorethamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"    see \"Mechlorethamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/5/22613?source=see_link\">",
"    see \"Mechlorethamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mustargen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"      see \"Mechlorethamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lymphoma: MOPP regimen: Mustargen&reg; (mechlorethamine), Oncovin&reg; (vincristine), procarbazine, and prednisone: I.V.: 6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 of a 28-day cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brain tumors: MOPP regimen: I.V.: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 of a 28-day cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.4 mg/kg or 12-16 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single monthly dose or divided into 0.1 mg/kg/day once daily for 4 days, repeated at 4- to 6-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intracavitary: 10-30 mg or 0.2-0.4 mg/kg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mustargen&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intracavitary: Dilute dose in up to 100 mL NS; paracentesis is performed to remove most of the fluid from the cavity prior to administration; inject drug slowly with frequent aspiration to ensure that a free flow of fluid is present; change patient's position every 5-10 minutes for 1 hour following injection to distribute drug uniformly throughout the cavity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"     <b>",
"      DO NOT ADMINISTER I.M. or SubQ",
"     </b>",
"     Administer I.V. push through a side port of an established I.V. line over 1-5 minutes at a concentration not to exceed 1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F191719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in sterile water for injection;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, aztreonam, filgrastim, fludarabine, granisetron, melphalan, ondansetron, sargramostim, teniposide, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, cefepime.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Highly unstable in neutral or alkaline solutions; use immediately after reconstitution; discard any unused drug after 60 minutes (although manufacturer reports only 15 minutes of stability after reconstitution, other studies indicate it is stable longer)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy of Hodgkin's disease, brain tumors, non-Hodgkin's lymphoma, and malignant lymphomas; palliative treatment of lung, breast, and ovarian carcinoma; sclerosing agent in intracavitary therapy of pleural, pericardial, and other malignant effusions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, encephalopathy (high dose), fever, headache, lethargy, sedation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, maculopapular rash, petechiae, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, hyperuricemia, oligomenorrhea, spermatogenesis decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, metallic taste, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia (onset 6-8 days, recovery 10-21 days), hemolytic anemia, leukopenia, lymphocytopenia, pancytopenia, secondary leukemias, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis, tissue necrosis (extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, herpes zoster infection, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mechlorethamine or any component; pre-existing profound myelosuppression; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with myelosuppression; patients with lymphoma should receive adequate hydration, alkalinization of the urine and/or prophylactic allopurinol to prevent complications such as uric acid nephropathy and hyperuricemia. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; disposal of mechlorethamine powder and solution be followed",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid inhalation of dust or vapors and contact with skin or mucous membranes. Avoid contact during pregnancy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; mechlorethamine is potentially carcinogenic, teratogenic, and mutagenic. It may cause permanent sterility and birth defects. Mechlorethamine is a potent vesicant",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; extravasation of the drug into subcutaneous tissues results in painful inflammation, erythema, and induration; severe tissue damage (leading to ulceration and necrosis) and pain may occur; promptly infiltrate the area with sterile isotonic sodium thiosulfate (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     molar) and apply a cold compress for 6-12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5715163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential are advised not to become pregnant. Use only when potential benefit justifies potential risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Avoid exposure during pregnancy.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, hemoglobin; serum uric acid in lymphoma patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent that inhibits DNA and RNA synthesis via formation of carbonium ions which can attach to nucleic acids at the N",
"     <sup>",
"      7",
"     </sup>",
"     position of guanine; cross-links strands of DNA causing miscoding, breakage, and failure of replication",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Incomplete after intracavitary administration secondary to rapid deactivation by body fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Following I.V. administration, drug undergoes rapid hydrolysis to a highly reactive alkylating intermediate; unchanged drug is undetectable in the blood within a few minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: &lt;1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;0.01% of unchanged drug is recovered in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/5/22613?source=see_link\">",
"      see \"Mechlorethamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to physician any pain or irritation at the site of injection, fever, sore throat, bruising, bleeding, shortness of breath, itching, or wheezing",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 4-7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ater JL, van Eys J, Woo SY, et al, &ldquo;MOPP Chemotherapy Without Irradiation as Primary Postsurgical Therapy for Brain Tumors in Infants and Young Children,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 1997, 32(3):243-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9477/abstract-text/9049886 /pubmed\" id=\"9049886 \" target=\"_blank\">",
"        9049886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9477/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorr RT, Soble M, and Alberts DS, &ldquo;Efficacy of Sodium Thiosulfate as a Local Antidote to Mechlorethamine Skin Toxicity in the Mouse,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1988, 22(4):299-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9477/abstract-text/3168143 /pubmed\" id=\"3168143 \" target=\"_blank\">",
"        3168143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krischer JP, Ragab AH, Kun L, et al, &ldquo;Nitrogen Mustard, Vincristine, Procarbazine, and Prednisone as Adjuvant Chemotherapy in the Treatment of Medulloblastoma. A Pediatric Oncology Group Study,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 1991, 74(6):905-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/16/9477/abstract-text/2033450/pubmed\" id=\"2033450\" target=\"_blank\">",
"        2033450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12574 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9477=[""].join("\n");
var outline_f9_16_9477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709028\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191690\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048424\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048417\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191670\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191656\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048428\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191719\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048419\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048427\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191718\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048431\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048416\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048415\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191664\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191666\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5715163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048423\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048414\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048430\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048421\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048432\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12574|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=related_link\">",
"      Mechlorethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/5/22613?source=related_link\">",
"      Mechlorethamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9478="Erythema multiforme target";
var content_f9_16_9478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical target lesion of erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plaque from a patient with erythema multiforme shows a central erosion on an erythematous base, surrounded by a pale edematous rim and a peripheral erythematous halo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9478=[""].join("\n");
var outline_f9_16_9478=null;
var title_f9_16_9479="Bard sewing below GEJ";
var content_f9_16_9479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Bard EndoCinch sewing location below gastroesophageal junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from C.R. Bard, Inc. Copyright &copy; 2001. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9479=[""].join("\n");
var outline_f9_16_9479=null;
var title_f9_16_9480="Nasogastric and nasoenteric tubes";
var content_f9_16_9480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nasogastric and nasoenteric tubes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Richard A Hodin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Liliana Bordeianou, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9480/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/16/9480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H522921860\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric and nasoenteric tubes are flexible double or single lumen tubes that are passed proximally from the nose distally into the stomach or small bowel. Enteric tubes that will be removed within a short period of time can also be passed through the mouth (orogastric). This topic will review the indications, contraindications, placement, management and complications of nasogastric and nasoenteric tubes.",
"   </p>",
"   <p>",
"    The management of postoperative ileus and bowel obstruction are discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522921867\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric tubes are indicated for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of ileus or bowel obstruction &ndash; Gastrointestinal decompression using nasogastric tubes is important for the treatment of patients with bowel obstruction or prolonged ileus. Nasogastric decompression improves patient discomfort, minimizes or prevents recurrent vomiting, and serves as means to monitor the progress or resolution of these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"       \"Postoperative ileus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"       \"Small bowel obstruction: Causes and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of medications &ndash; A nasogastric tube may be needed to administer medications, or oral contrast for computed tomography, to patients who cannot swallow or who are neurologically impaired.",
"     </li>",
"     <li>",
"      Enteral nutrition &ndash; Nasogastric and nasoenteric tubes are used to deliver enteral nutrition into the stomach (gastric feeding) or into the small intestine (post-pyloric). (See",
"      <a class=\"local\" href=\"#H332908\">",
"       'Enteral nutrition'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stomach lavage",
"      <strong>",
"      </strong>",
"      &ndash; Lavage may be needed to remove blood or clots to facilitate endoscopy. (See",
"      <a class=\"local\" href=\"#H522921904\">",
"       'Gastric lavage'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332720\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric intubation is contraindicated in patients with esophageal stricture because of the risk for esophageal perforation, and in patients with basilar skull fracture or facial fracture due to the potential for intracranial misplacement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasogastric tubes should also be avoided in patients with esophageal varices because tube placement may trigger variceal bleeding which can be life-threatening. In patients with a bleeding diathesis, minimal trauma to the pharynx, esophagus, or stomach from nasogastric tubes can also lead to severe bleeding and, thus, tubes are avoided whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332941\">",
"    <span class=\"h1\">",
"     TYPES OF TUBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric tubes are made of polyvinyl chloride (PVC), polyurethane or silicone and come in numerous sizes. A variety of tubes are available for gastrointestinal decompression, or the administration of medications or enteral formula (",
"    <a class=\"graphic graphic_table graphicRef52488 \" href=\"UTD.htm?32/53/33628\">",
"     table 1",
"    </a>",
"    ). Nasogastric tubes made of PVC (eg, Salem Sump&trade;) are relatively stiff and therefore more irritating long-term, and are used primarily for gastrointestinal decompression. The most commonly placed nasogastric tube size in adults is 16 Fr, although larger and smaller sizes are available.",
"   </p>",
"   <p>",
"    The Salem Sump&trade; tube is the most commonly used tube for gastrointestinal decompression. The tube has two lumens. The larger lumen is connected to intermittent wall suction for aspiration of gastric contents or, alternatively, it can be used for irrigation, delivery of medications or enteral feeding. The smaller lumen vents to atmosphere (equalizes the pressure in the stomach once the gastric contents have been emptied), thus preventing the distal holes from adhering to and damaging the stomach mucosa.",
"   </p>",
"   <p>",
"    Nasoenteric tubes are more flexible, have a smaller diameter (3.5 to 12 Fr), vary in length (15 to 170 cm), and may be weighted or non-weighted. Although nasogastric tubes can be used as enteric feeding tubes, a feeding tube cannot be used for gastric decompression because its soft walls tend to collapse when suction is applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H333338\">",
"    <span class=\"h1\">",
"     AREAS OF CONTROVERSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522921874\">",
"    <span class=\"h2\">",
"     Prophylactic placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine prophylactic use of nasogastric tubes for gastric decompression following",
"    <span class=\"nowrap\">",
"     abdominal/gastrointestinal",
"    </span>",
"    surgery. When selectively applied, only about 10 percent of postoperative patients require nasogastric decompression. If the patient develops a prolonged postoperative ileus or postoperative small bowel obstruction, then a nasogastric tube is indicated. (See",
"    <a class=\"local\" href=\"#H522921867\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Postoperative nasogastric decompression after major abdominal or thoracic surgery has been used extensively since its initial introduction by Levin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/3\">",
"     3",
"    </a>",
"    ]. It was thought that such decompression might reduce postoperative ileus, pulmonary complications and anastomotic leakage after gastrointestinal and thoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/4\">",
"     4",
"    </a>",
"    ]. However, data do not support this belief and most clinicians argue against",
"    <strong>",
"    </strong>",
"    prophylactic use of nasogastric tubes following surgery. &nbsp;",
"   </p>",
"   <p>",
"    Numerous trials have shown a lack of benefit from prophylactic nasogastric tube decompression in the postoperative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. A meta-analysis of randomized trials and nonrandomized studies published prior to 1995 found that, although vomiting and distension were more common when nasogastric tubes were not routinely used, other parameters were improved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/9\">",
"     9",
"    </a>",
"    ]. Management of postoperative nausea and vomiting has become more effective with the introduction of antiemetic agents that do not cause drowsiness and respiratory depression (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ). The management of postoperative nausea and vomiting is discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=see_link&amp;anchor=H1324456782#H1324456782\">",
"     \"Overview of complications occurring in the post-anesthesia care unit\", section on 'Postoperative nausea/vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A later systematic review identified 28 trials in which patients were randomly assigned to no nasogastric tube or selective nasogastric tube placement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/10\">",
"     10",
"    </a>",
"    ]. A range of abdominal surgeries were included in these trials, including biliary, gastroduodenal, colorectal, gynecologic, trauma and vascular surgery. An analysis of eight of these trials found a significantly decreased time to return of bowel function measured as a weighted mean difference of 0.46 days (95% CI 0.28-0.64) in patients who did not have a nasogastric tube compared with those who did. Among 19 of these trials looking at pulmonary complications, a separate analysis identified a trend toward decreased pulmonary complications, but the difference was not significant. No significant differences in the rates of anastomotic leakage were found between the two groups.",
"   </p>",
"   <p>",
"    An updated review of the original meta-analysis included four additional trials which resulted in similar decreases in the time to return of bowel function with narrower confidence intervals but increased heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/11\">",
"     11",
"    </a>",
"    ]. As with previous analyses, patients who did not have a postoperative nasogastric tube had significantly more gastric upset and vomiting, but no significant differences in the risk for incisional hernia as a result. The risk of pulmonary complications was significantly increased. (See",
"    <a class=\"local\" href=\"#H522922051\">",
"     'Pulmonary'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similar data suggest that patients undergoing thoracic surgery also do not benefit from prophylactic nasogastric decompression and may be harmed. A small randomized trial comparing 22 patients treated with routine nasogastric decompression with 18 patients without decompression after esophagectomy found a higher incidence of anastomotic leak in the patients treated with prophylactic nasogastric decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of these data, allowing a postoperatively-placed nasogastric tube to remain following recovery of anesthesia should only be considered in cases where postoperative bedside placement may be difficult, such as in patients with hiatal hernia, prior stomach or bariatric surgery, or in patients who may not be able to cooperate postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522921904\">",
"    <span class=\"h2\">",
"     Gastric lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric tubes have traditionally been used to evaluate patients with hematochezia, especially when no concomitant hematemesis is present. It was thought that nasogastric intubation and lavage would distinguish upper from lower gastrointestinal bleeding by confirming a gastric source for blood per rectum. However, the use of nasogastric aspiration and lavage alone has a low sensitivity for predicting an upper GI bleeding source. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079470#H5079470\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Nasogastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although commonly used in the past, gastric lavage is no longer routinely used in the treatment of poisoning. The specific indications for gastric lavage in these patients are discussed elsewhere. The specific indications for gastric lavage in these patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993923#H18993923\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Gastric lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H9#H9\">",
"     \"Decontamination of poisoned children\", section on 'Gastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332908\">",
"    <span class=\"h2\">",
"     Enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasogastric sump-type tubes are often initially inserted for gastrointestinal decompression and then used to deliver medications or enteral nutrition when decompression is no longer needed. Although less prone to clogging, use of a sump-type nasogastric tube in this manner should be limited to a short period of time and the tube replaced with a softer, specifically designed enteral feeding tube to minimize potential complications. Whether to administer feedings into the stomach or post-pyloric into the small intestine is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At what point a nasogastric or nasoenteric tube should be discontinued in favor of percutaneous or surgical gastrostomy tubes for enteral nutrition is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522921948\">",
"    <span class=\"h1\">",
"     TUBE PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most nasogastric tubes are placed at the bedside in an alert patient. Placement is usually straightforward; however, some patients who have unusual anatomy (eg, gastric bypass, hiatal hernia repair) may require nasogastric tube placement with fluoroscopic or endoscopic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Placement for decompression",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729983\">",
"    <span class=\"h2\">",
"     Alert patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an alert adult patients, a soft 14 to 16 Fr Salem sump&trade; nasogastric tube provides an adequate diameter for gastrointestinal decompression. The tube, which is coiled in its packaging, should be straightened by pulling on each end prior to placement, and lubricated. Several small randomized trials have found that instillation of local anesthetic spray (eg, preservative free 4%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    spray) helps control gagging and will ease some of the discomfort associated with tube placement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/14\">",
"     14",
"    </a>",
"    ]. The spray can be intermittently repeated to help lessen discomfort associated with the ongoing presence of the tube. (See",
"    <a class=\"local\" href=\"#H522922000\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient should be seated with the head tilted toward the chest. The tube is introduced into one of the nares and advanced horizontally (",
"    <a class=\"graphic graphic_picture graphicRef76398 \" href=\"UTD.htm?2/42/2728\">",
"     picture 1",
"    </a>",
"    ). If any resistance is met, the contralateral nostril should be used. When the tube reaches the posterior nasopharynx, the patient may feel like gagging. It is helpful to take advantage of the patient&rsquo;s swallowing mechanism to help passage of the tube into the esophagus and then into the stomach. The patient can be asked to swallow as the tube is being advanced, but it may be more helpful to provide the patient with a cup of water to drink using a straw. If the patients gags excessively or cannot speak, the tube may have entered the trachea. The tube should be immediately withdrawn and placement re-attempted.",
"   </p>",
"   <p>",
"    Once the tube is in the stomach and its location is confirmed, further manipulation of the tube is performed depending upon the intended purpose. In general, tubes for decompression are positioned in the gastric fundus and connected to low intermittent wall suction. If the nasogastric tube has a venting side-port (eg, Salem Sump&trade;), continuous suction can be considered. It may be practical to use continuous suction initially to rapidly evacuate accumulated fluid from the stomach, but as the amount of drainage lessens, return the tube to intermittent suction, which will decrease the risk of injury to the gastric mucosa. Although the vent port of these tubes should theoretically prevent mucosal injury, the vent port frequently malfunctions essentially converting the tube from a dual lumen to a single lumen tube.",
"   </p>",
"   <p>",
"    Tubes intended for feeding can be positioned into the antrum, duodenum (postpyloric) or jejunum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729975\">",
"    <span class=\"h2\">",
"     Intubated patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an intubated patient requires a nasogastric tube, we suggest avoiding blind nasogastric tube placement due to the risk of inadvertently placing the tube into the lung, which can occur even with an inflated endotracheal balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/15\">",
"     15",
"    </a>",
"    ]. The best approach is to use a laryngoscope to advance the nasogastric tube into the esophagus under direct vision. However, experienced clinicians, such as anesthesiologists who regularly deal with intubated patients, will employ an alternative technique of placing a finger inside the patient&rsquo;s mouth to guide the tip of the nasogastric tube into the esophagus. If resistance is felt or the tube begins to coil, a laryngoscopic is then used. Regardless of how the tube is placed, its position should be verified before instilling anything into the tube. (See",
"    <a class=\"local\" href=\"#H522921978\">",
"     'Confirmation of placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An experimental esophageal guidewire-assisted technique was evaluated in a trial that randomly assigned 480 patients to the experimental technique or a conventional control technique of nasogastric tube placement with head flexion and lateral neck pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/16\">",
"     16",
"    </a>",
"    ]. The guidewire-assisted technique consisted of esophageal guidewire placement with manual forward displacement of the larynx. The first-attempt success rate was significantly improved for the guide-wire assisted technique (99 versus 57 percent) compared with the control group. However, the technique used in the control group (head flexion and lateral neck pressure) may not be the most reliable blind technique. Also, there remains concern over the potential that a guidewire could perforate the pharynx or esophagus, and the additional cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H474385320\">",
"    <span class=\"h2\">",
"     Placement for feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft, small caliber tubes are used for feeding to minimize patient discomfort. To place an enteral tube, the stylet (for tubes smaller than 12 Fr) is placed into the enteral feeding tube and the tube is lubricated. As with nasogastric tubes, the tube is placed into one of the nares and advancement of the tip is aided by having the patient swallow. Once the position of the tube is confirmed, the stylet is removed. It is important that the stylet is",
"    <strong>",
"     not",
"    </strong>",
"    replaced because doing so can lead to gastrointestinal perforation. (See",
"    <a class=\"local\" href=\"#H522922014\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522921978\">",
"    <span class=\"h2\">",
"     Confirmation of placement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1488977108\">",
"    <span class=\"h2\">",
"     Radiographic",
"    </span>",
"    &nbsp;&mdash;&nbsp;We always confirm the position of enteral feeding tubes radiographically before formula or medications are given. Although malposition of nasogastric or nasoenteric tubes most commonly involves curling of the tube within the esophagus, placement into the bronchial tree is not uncommon and can lead to disastrous consequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62549 \" href=\"UTD.htm?6/33/6674\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H522922014\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ideally, the placement of all nasogastric and nasoenteric tubes should be documented with a radiograph of the lower",
"    <span class=\"nowrap\">",
"     chest/upper",
"    </span>",
"    abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/17\">",
"     17",
"    </a>",
"    ]. However, confirming the placement of nasogastric tubes used only for gastrointestinal decompression (Salem Sump&trade; type) is probably not necessary provided the patient does not have any respiratory complaints or difficulties, and the position of the tube is adequately confirmed by clinical means. Patients who cannot express their problems (children, infants, intubated patients) should always have radiographic confirmation of tube placement prior to any use of a nasogastric or nasoenteric tube. (See",
"    <a class=\"local\" href=\"#H1488977140\">",
"     'Clinical confirmation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The tip of a decompressive nasogastric tube should be positioned into the most dependent portion of the stomach. If the tip of a Salem Sump&trade; type nasogastric tube is found to be postpyloric, it should be withdrawn into the stomach. It should not be allowed to remain in a postpyloric location because these stiff tubes have the potential to damage the duodenal mucosa. Whenever possible, we prefer to place feeding tubes in a postpyloric position to minimize risk of aspiration related to distention of the stomach with feeding. However, the postpyloric placement of feeding tubes does not eliminate the risk of aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1488977140\">",
"    <span class=\"h2\">",
"     Clinical confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a Salem Sump&trade; tube is positioned, the main lumen is aspirated. If gastric contents are returned, the tube can be tested by flushing with 20 to 30 cc of warm water with a large syringe (eg, Toomey), and the water immediately suctioned back into the syringe. If most (about 70 percent) of the water can be retrieved, the tube is likely in the proper position. If an insufficient amount of fluid returns, the tube should be readjusted and the test repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/18\">",
"     18",
"    </a>",
"    ]. It is important to realize that auscultating over the epigastrium during air injection into any tube is",
"    <strong>",
"     not",
"    </strong>",
"    an accurate way to evaluate tube position since the tube may be in too far, or not in far enough. If there is any question about the position of the tube, a radiograph should be obtained.",
"   </p>",
"   <p>",
"    Nursing staff should be informed that the tube placement was only confirmed clinically, and instructions should be given not to administer any medicines or feeds through the tube without radiological confirmation of placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H731125\">",
"    <span class=\"h2\">",
"     Tube fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the nasogastric tube is in its proper position, it should be taped securely to the nose, but care should be taken not to push the tube up against the nares because pressure ulceration or necrosis can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/19\">",
"     19",
"    </a>",
"    ]. The nasogastric or nasoenteric tube can then be secured to the patient&rsquo;s gown with a safety pin. (See",
"    <a class=\"local\" href=\"#H732026\">",
"     'Nasal alar ulceration or necrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Various commercial tapes can be used for this purpose. A retrospective comparison of three types of tape (pink tape, clear tape, &ldquo;butterfly&rdquo;) in 264 taping episodes reported an advantage for pink tape with a significantly increased time until failure of the securing method (100 versus 56 and 30 hours, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/20\">",
"     20",
"    </a>",
"    ]. Duodenal tubes stayed secured significantly longer than sump-type tubes for all taping methods (86 versus 41 hours). The results were independent of patient alertness, confusion, mobility or use of restraints.",
"   </p>",
"   <p>",
"    Other, more aggressive methods of securing nasogastric or nasoenteric tubes have been described and these can be used when the risk of losing the tube justifies the intervention. For example, placing a suture through the membranous nasal septum and securing it to the tube has been described as an alternative to adhesive tapes. However, significant soft tissue damage can occur with chronic tension on the columella [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/21\">",
"     21",
"    </a>",
"    ]. Bridles that pinch the membranous septum provide an anchoring point and are commercially available as an alternative to suturing but their safety has not been prospectively evaluated and routine use is not recommended. In patients with distorted anatomy such as due to facial trauma or head and neck surgery, a fine bore suction catheter can be looped around the nasal septum to secure the nasogastric tube in place (",
"    <a class=\"graphic graphic_figure graphicRef51735 \" href=\"UTD.htm?23/36/24128\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522922000\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of nasogastric and nasoenteric tubes should be checked frequently by irrigating the tube with water every four to eight hours. At the same time, the drainage from nasogastric tubes placed for gastrointestinal decompression should be documented to help judge the progression or resolution of obstruction and the need for supplemental intravenous fluid. Fluid and electrolyte replacement for nasogastric losses depends upon the volume and nature of the loss. .",
"   </p>",
"   <p>",
"    Many patients experience oropharyngeal discomfort, which usually resolves in 24 to 48 hours. Local anesthetic spray applied to the oropharynx may alleviate some of the gag reflex and discomfort associated with the presence of a tube [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/14\">",
"     14",
"    </a>",
"    ]. New onset of gagging or respiratory difficulties in a patient with a nasogastric tube should raise the concern of migration into the oropharynx and indicates the need to re-evaluate the position of the tube. Any tube that does not appear to be functioning properly should be evaluated and may need to be removed, and replaced if still needed.",
"   </p>",
"   <p>",
"    Nasogastric tubes should be removed when the indication for placement no longer exists. For example, in patients with a small bowel obstruction, a decrease in nasogastric output and the passage of flatus suggest a resolution of the obstruction and that the tube can be safely removed. A trial of nasogastric drainage to gravity or nasogastric tube clamping are advocated by some as interim maneuvers prior to nasogastric tube removal to minimize the need for tube reinsertion. In contrast, others argue that clamping should not be performed, because it increases the risk of aspiration by allowing gastric distention in the presence of an impaired esophageal sphincter. There is little evidence to justify or discredit this practice. (See",
"    <a class=\"local\" href=\"#H522922051\">",
"     'Pulmonary'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nasogastric tube removal is generally uneventful (",
"    <a class=\"graphic graphic_picture graphicRef64523 \" href=\"UTD.htm?11/41/11926\">",
"     picture 2",
"    </a>",
"    ). If resistance is met upon attempted removal of a nasogastric or nasoenteric tube, removal should be abandoned and radiographs obtained. Nasogastric or nasoenteric tube knotting can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H522922014\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522922014\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522922030\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the gastrointestinal tract, malposition, coiling or knotting of tubes can occur anywhere along the course of the tube, including pharynx, pyriform sinus, esophagus, stomach and duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/24\">",
"     24",
"    </a>",
"    ]. Pharyngeal and pyriform sinus misplacement can be recognized in a patient who complains of significant gagging or emesis. In patients who may not be able to complain, a laryngoscopic examination easily reveals the misplacement. Fluoroscopy or endoscopy may be needed to safely remove a knotted tube.",
"   </p>",
"   <p>",
"    The presence of a nasogastric or nasoenteric tube impairs the normal function of the lower esophageal sphincter, making the patient more susceptible to reflux of gastric contents which may lead to esophagitis, gastrointestinal bleeding or pulmonary aspiration. The development of new onset epigastric or chest pain suggestive of acid reflux may indicate the development of esophagitis and, ideally, the tube should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/25\">",
"     25",
"    </a>",
"    ]. For patients who continue to require the tube, suppression of gastric acid secretion may be indicated. The treatment of gastroesophageal reflux is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasogastric tubes can cause gastritis or gastric bleeding due to chronic irritation or pressure necrosis due to suctioning of the gastrointestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/26\">",
"     26",
"    </a>",
"    ]. This is usually recognized when the aspirated gastric contents becomes guaiac positive or grossly bloody. Patients with bloody gastric drainage require further evaluation and, whenever possible, the nasogastric tube should be removed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9384?source=see_link\">",
"     \"Acute hemorrhagic erosive gastropathy and chronic chemical gastropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522922051\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for pulmonary complications is increased in patients with nasogastric tubes. Avoidance of the prophylactic postoperative nasogastric decompression decreases pulmonary complications and has other beneficial effects. (See",
"    <a class=\"local\" href=\"#H522921874\">",
"     'Prophylactic placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A systematic review identified 28 trials in which patients were randomly assigned to no nasogastric tube or selective nasogastric tube placement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/10\">",
"     10",
"    </a>",
"    ]. Among 19 of these trials looking at pulmonary complications, a subanalysis identified a trend toward decreased pulmonary complications in those patients who did not have a nasogastric tube, but the difference was not significant. However, an updated meta-analysis that included four additional trials did find an increased risk of pulmonary complications (odds ratio 1.45, 95% CI, 1.1-1.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/11\">",
"     11",
"    </a>",
"    ]. Pulmonary complications were increased in patients with a nasogastric tube undergoing upper gastrointestinal surgery, but not in patients undergoing colorectal surgery.",
"   </p>",
"   <p>",
"    Intubation of the lung and inadvertent administration of medications, radiocontrast media or enteral formula through the malpositioned tube (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62549 \" href=\"UTD.htm?6/33/6674\">",
"     image 1",
"    </a>",
"    ) can lead to pneumonia. Pulmonary abscess may result [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/27\">",
"     27",
"    </a>",
"    ]. Tracheal perforation and pneumothorax have also been reported. Proper placement and positioning of these tubes and radiographic confirmation of position for any tube used for the administration of medications or enteral nutrition can help prevent these complications (See",
"    <a class=\"local\" href=\"#H522921948\">",
"     'Tube placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732026\">",
"    <span class=\"h2\">",
"     Nasal alar ulceration or necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, improperly securing the tube or placement of too large a tube in an unconscious patient who cannot convey their discomfort can lead to pressure ulcers and even alar necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/28\">",
"     28",
"    </a>",
"    ]. Frequent re-taping of the tube to decrease pressure on any particular point may help to prevent this complication. Other methods of tube fixation may be needed. (See",
"    <a class=\"local\" href=\"#H731125\">",
"     'Tube fixation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H731958\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to potential perforation of pulmonary structures or the gastrointestinal tract, nasogastric and nasoenteric tubes can perforate other structures in patients with certain pathologic conditions. Patients with prior esophageal or gastric surgery are at risk for gastrointestinal perforation and infants, children and patients with facial trauma are at risk for cribriform plate perforation and intracranial intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9480/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730309\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasogastric and nasoenteric tubes are flexible double or single lumen tubes that are passed proximally from the nose or mouth distally into the stomach or small bowel. They are used for gastrointestinal decompression in the treatment of small bowel obstruction or prolonged severe ileus, administration of medications or enteral nutrition, and occasionally for gastric lavage. (See",
"      <a class=\"local\" href=\"#H522921860\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H522921867\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasogastric and nasoenteric tube placement is contraindicated in patients with esophageal stricture, and every effort should be made to avoid their use in patients with esophageal varices or a bleeding diathesis. Nasal intubation is contraindicated in patients with basilar skull fracture or facial fracture; these patients should undergo oral tube placement. (See",
"      <a class=\"local\" href=\"#H332720\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using prophylactic postoperative nasogastric tubes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although nasogastric or orogastric tubes are placed in the operating room for gastrointestinal decompression during surgery, the majority of these tubes should be removed once the patient is alert and recovered from anesthesia. In the past, routine postoperative gastrointestinal decompression was thought to speed the return of gastrointestinal function following thoracic or abdominal surgery. However, the time to return of bowel function was not significantly changed and could even be delayed. (See",
"      <a class=\"local\" href=\"#H522921874\">",
"       'Prophylactic placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasogastric and nasoenteric tubes are available in multiple sizes and lengths (",
"      <a class=\"graphic graphic_table graphicRef52488 \" href=\"UTD.htm?32/53/33628\">",
"       table 1",
"      </a>",
"      ). Dual lumen sump tubes are most commonly used for gastrointestinal decompression. Although sump tubes can be used for the administration of medications and for enteral nutrition, these tubes are stiff and irritating. Specifically designed, flexible, small-diameter enteral tubes are preferred for long-term nutrition. (See",
"      <a class=\"local\" href=\"#H332941\">",
"       'Types of tubes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of nasogastric and nasoenteric tubes can be placed at the bedside. For tubes that will be used for gastrointestinal decompression, confirmation of the tube&rsquo;s position by clinical means is usually adequate. However, a radiograph should be obtained to confirm the position of any tube that will be used for the administration of medications, or for enteral nutrition. (See",
"      <a class=\"local\" href=\"#H522921978\">",
"       'Confirmation of placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proper functioning of nasogastric and nasoenteric tubes should be routinely checked every four to eight hours by irrigating the tube. The drainage from tubes placed for gastrointestinal decompression should also be documented to help judge the progression or resolution of obstruction and requirements for supplemental intravenous fluid. Tubes are removed when the indication for their use is no longer present. (See",
"      <a class=\"local\" href=\"#H522922000\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of nasogastric tubes are a consequence of tube placement (eg, perforation, pulmonary abscess), chronic irritation of the gastrointestinal tract (eg, gastritis, ulcer), or altered physiology (eg, reflux) due to the presence of the tube. Proper placement and confirmation of positioning should prevent many of these complications. When gastrointestinal reflux, gastritis, or ulcer is identified, the tube should be removed (ideally), and other treatment measures instituted as indicated. (See",
"      <a class=\"local\" href=\"#H522922014\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/1\">",
"      Ferreras J, Junquera LM, Garc&iacute;a-Consuegra L. Intracranial placement of a nasogastric tube after severe craniofacial trauma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/2\">",
"      Ba��kaya MK. Inadvertent intracranial placement of a nasogastric tube in patients with head injuries. Surg Neurol 1999; 52:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/3\">",
"      AL, L. A new gastroduodenal catheter. JAMA 1921; 76:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/4\">",
"      Sagar PM, Kruegener G, MacFie J. Nasogastric intubation and elective abdominal surgery. Br J Surg 1992; 79:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/5\">",
"      Inman BA, Harel F, Tiguert R, et al. Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. J Urol 2003; 170:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/6\">",
"      Otchy DP, Wolff BG, van Heerden JA, et al. Does the avoidance of nasogastric decompression following elective abdominal colorectal surgery affect the incidence of incisional hernia? Results of a prospective, randomized trial. Dis Colon Rectum 1995; 38:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/7\">",
"      Yang Z, Zheng Q, Wang Z. Meta-analysis of the need for nasogastric or nasojejunal decompression after gastrectomy for gastric cancer. Br J Surg 2008; 95:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/8\">",
"      Daryaei P, Vaghef Davari F, Mir M, et al. Omission of nasogastric tube application in postoperative care of esophagectomy. World J Surg 2009; 33:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/9\">",
"      Cheatham ML, Chapman WC, Key SP, Sawyers JL. A meta-analysis of selective versus routine nasogastric decompression after elective laparotomy. Ann Surg 1995; 221:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/10\">",
"      Nelson R, Tse B, Edwards S. Systematic review of prophylactic nasogastric decompression after abdominal operations. Br J Surg 2005; 92:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/11\">",
"      Nelson R, Edwards S, Tse B. Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev 2007; :CD004929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/12\">",
"      Dennis M, Lewis S, Cranswick G, et al. FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke. Health Technol Assess 2006; 10:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/13\">",
"      Kelly G, Lee P. Nasendoscopically-assisted placement of a nasogastric feeding tube. J Laryngol Otol 1999; 113:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/14\">",
"      Gallagher EJ. Nasogastric tubes: hard to swallow. Ann Emerg Med 2004; 44:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/15\">",
"      Wang PC, Tseng GY, Yang HB, et al. Inadvertent tracheobronchial placement of feeding tube in a mechanically ventilated patient. J Chin Med Assoc 2008; 71:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/16\">",
"      Kirtania J, Ghose T, Garai D, Ray S. Esophageal guidewire-assisted nasogastric tube insertion in anesthetized and intubated patients: a prospective randomized controlled study. Anesth Analg 2012; 114:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/17\">",
"      Baskin WN. Acute complications associated with bedside placement of feeding tubes. Nutr Clin Pract 2006; 21:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/18\">",
"      Ellett ML. What is known about methods of correctly placing gastric tubes in adults and children. Gastroenterol Nurs 2004; 27:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/19\">",
"      Banerjee TS, Schneider HJ. Recommended method of attachment of nasogastric tubes. Ann R Coll Surg Engl 2007; 89:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/20\">",
"      Burns SM, Martin M, Robbins V, et al. Comparison of nasogastric tube securing methods and tube types in medical intensive care patients. Am J Crit Care 1995; 4:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/21\">",
"      McGuirt WF, Strout JJ. \"How I do it\"--head and neck. A targeted problem and its solution: securing of intermediate duration feeding tubes. Laryngoscope 1980; 90:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/22\">",
"      della Faille D, Schmelzer B, Hartoko T, et al. Securing nasogastric tubes in non-cooperative patients. Acta Otorhinolaryngol Belg 1996; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/23\">",
"      Palta S. Nasogastric tube knotting in open heart surgery. Acta Anaesthesiol Scand 1999; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/24\">",
"      Agarwala S, Dave S, Gupta AK, Mitra DK. Duodeno-renal fistula due to a nasogastric tube in a neonate. Pediatr Surg Int 1998; 14:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/25\">",
"      Newton M, Burnham WR, Kamm MA. Morbidity, mortality, and risk factors for esophagitis in hospital inpatients. J Clin Gastroenterol 2000; 30:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/26\">",
"      Metheny NA, Meert KL, Clouse RE. Complications related to feeding tube placement. Curr Opin Gastroenterol 2007; 23:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/27\">",
"      Malik NW, Timon CI, Russel J. A unique complication of primary tracheoesophageal puncture: knotting of the nasogastric tube. Otolaryngol Head Neck Surg 1999; 120:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9480/abstract/28\">",
"      Lai PB, Pang PC, Chan SK, Lau WY. Necrosis of the nasal ala after improper taping of a nasogastric tube. Int J Clin Pract 2001; 55:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15070 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9480=[""].join("\n");
var outline_f9_16_9480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H730309\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522921860\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522921867\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332720\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H332941\">",
"      TYPES OF TUBES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H333338\">",
"      AREAS OF CONTROVERSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522921874\">",
"      Prophylactic placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522921904\">",
"      Gastric lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332908\">",
"      Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522921948\">",
"      TUBE PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H729983\">",
"      Alert patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H729975\">",
"      Intubated patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H474385320\">",
"      Placement for feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522921978\">",
"      Confirmation of placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1488977108\">",
"      Radiographic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1488977140\">",
"      Clinical confirmation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H731125\">",
"      Tube fixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522922000\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522922014\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522922030\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522922051\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732026\">",
"      Nasal alar ulceration or necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H731958\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H730309\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15070|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/33/6674\" title=\"diagnostic image 1\">",
"      Misplaced nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15070|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24128\" title=\"figure 1\">",
"      Nasal bridle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15070|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/42/2728\" title=\"picture 1\">",
"      Nasogastric tube placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/41/11926\" title=\"picture 2\">",
"      Nasogastric tube removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/53/33628\" title=\"table 1\">",
"      Nasogastric tubes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9384?source=related_link\">",
"      Acute hemorrhagic erosive gastropathy and chronic chemical gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9481="Tachycardia overview algorithm";
var content_f9_16_9481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78734%7ECARD%2F73601%7ECARD%2F81052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78734%7ECARD%2F73601%7ECARD%2F81052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    The tachycardia overview algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 664px; background-image: url(data:image/gif;base64,R0lGODlhMAKYAtUAAP///wAAAICAgH9/f4iIiERERLu7uxERETMzMyIiIszMzFVVVe7u7pmZmd3d3WZmZqqqqnd3d0BAQL+/v8DAwD8/P6CgoODg4CAgIGBgYNDQ0DAwMLCwsHBwcBAQEFBQUJCQkF9fXx8fHwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAwApgCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vaECwMHCw8TFxsfIycrLzM3Oz9DR0tPGF77XgwED29zd3t/g4eLj5OXm5+jp6uvs7e7fIhTY838B9KsV8vf7ePb8p/n+CZzjb+CogAYTsimo8BPChhDLMIy46SHFi14mYrxkcaPHKxo3LQigwGDHjyilhDQ0MoBLBE5GlmxCIECELAoCwASAgKST/5o3C51MSbTJykIjIUSR+dMmTp1TgBoaWrQqkqOEkg6JEOABgJoEarpMoFQmhAALAIwkkNNlALZuAzBokMBl2iEMAhzomcABgANu0wJ2CYGp2LcAuBYAvKCtSwaEqFqdPATroJYuIzA4cABAgs5DahZQS/Js2rVDcnaWmhPmgwAN8OoF0CDA6CF1DbQWIlNqXQdcCfwlKVWoPsrIi1gWpHXIyNc3IRRwC9MsWtIEHGCWK/VwZtmdd3N1C2E3aQXbA0AIzpO4U+PJ41du1FyIAbclAeuGar36W9SAMVCTV+YVkddqaIlGWnkBJMCbe15thVhPCgw41XHyIbdcINvt1P/TXWL15F9J0yXQE1uAIRAgAz3JRZdbwglxIGAFMMCiXj2VRZhhcSnAHoU3yhUZhhlOtuEsB6oiWZEoHSlLkqksyaRHTk6ph5RWXlRllndgySVEW9pxn3IG0BFAmUMUEKNDRH5JJRH3NWiFmkLQyYSdSIx5hJ6VoYnGmVf5CQCeQ9TmUmyVeOlmQhPxSQWhTUBahKNwTgRoGpcakemgaxpBAGiUKLroQI36M55PlbUY22uHGgobnWIloMB9PR2ggKuIAqBAiwvU1aAD1DFAa4MlAdoSApANYQBgB8SmZgEOCgFsmXR9lUBdyO5qF6sBOOCrrADodCinX401E23Rhtr/5qgUlSqEekcg9ikRD8Bkp5oK2JrYAveVWYBXkBKwEwCUAgvBfSUtkNaZAkOGQKcHCNfAAQwUgIBfQ0yLrrUObNaAwERs6tlN8naGr74RpMXAA+Amui67YE7qDwF1PZDsu2Xe58CnY5HLqasN6vkAwJ0CoJ1ODeipwHSH6klzuAZw21XG3b7rAKQaV0vAbQk0cDQCsQG6slteAaqzmkA7CCzGLsP8ZqVFNBtymRH0BW/dgwZ18rlCAxyUpwncB1m9AOSVtD8IlG1Aw0dE/BXFksI2qINbC9F1aA7CW5vDiifm4N6eiOr2PQzFmcBmL90c7lj+juWgoQ3ASnbftI0r/8RhDdwYOGB1Hf6SX8a6lSvBzDpbdLk6Uc71x8IDwKoDLSZQNuvkHubV2hy9PLpBYYq8PRmif39N94KKP0b45vMSZvpnoM9+Luu/D7728mMTfxKV11+F+/rTotFZEXKC025jBu9VwYD9KF8UgOWSAKKBf/2ThUYKsBjVLWGA/0BgFHJyrvbRL4K7mAiwFHC5cNHlAQbw1fC+RTNsQSZWszoTbGBIhIm5RDjHEpYMa9M628zFH0NLDH7wwrTOBO+G4VIVbQbTqWXpxXjQIqJLDqAxwTWogS8hmLhkxa2dvaRYvmIVTLR1HWlVLQ0QBOErJgKy/JVRbhAAlRZv1xeP5f+rJCm7j3DuuC8iFOBvjHuYHnFGMxs9rDZCCCK8ZHYzhlGRXPL63N+I4LiJVexilbpZEBUpHJY5YFoIU8vCysRB540GMZ6cFsiI8KnheVCNpCuCr1wCvDIx0C1sw6BnGpA2PaUNTj0pgAKkhsKCnCmIX3kAIp3nFZp1RXVccdwxI0QnQFXLAME8F/bCdbXjRVM4y8IeoNxoAKdljlrRSiHUvnKbM30NUSVUQxphyYrSCSlv6/yLK+0jpPx1jY/8FAJAkbCABzAuoIQ8HQMSQACdQc+BcitCTlSpUIaus1rOgahwPlWx4wm0aha7yzjbWU7ElU0ppVzAKctETszBYZ7/9FQFQx5wlyXmM4U9wwtf/Bkb6/HJen40F2maZswe1mhQOLLZYJClLLJBLUgWtebnhKqs4vmsqQ0UwlnQNFKcxUknfnleiIrFUpLiznL7NANMY4qK+1FioWntQv6UQClErJWtpnBrJNxCwDA44ABKuaBe7XBXvJJisIaVQmETGwrEMvYJi32sJxzLhrrqQYNkkNQVNOuEyEqWE/+bGhUs+wXSYgGzVEBtEeaaBNVeVQvVVCCujuDZz2pighXkg2lBosDT9hZ/fQ1UpDw6J+KyUo5DqK1tMSFCkpQQNtLDqeRSw6sxQc8tJa0VHodoxtQNS1/SZUjFplhFuVyxK1kc/xYXcTnWcIUxi2SsqdFadKZlBpGG3e3Kdd+TSFx+qySHWVqLvGLRzRzMVwRwVTPV1C3MCMedwSpUuoig3OVago0wceNd4CjHVc5xATs5U78GddIkGGzE//oLOO2pSa9w0nl9AaVPFLbOUj7glJ2MMcMGRgSV4sy+D+Bjylh5GxrnS1AiS0AEcuInCmrRAdWqluOKsDmasbQvkPSTwQrHsg4m94MWlqks41JLo8XljEYbCdjG9NySJrKZNbvZ0oTXN+xR6pvEE2dZvTqzc26MYH4m5zuJ0GYg/zI0y6vT8MTGLWVOmE5r2ww2vYbmBtB3Z7dBZmznPK5tGqHCYZ4Ei//rRDI0RRQJVraHkUUMRIjminCGo53janKEiQ4KASLdM9T0lLhwoXTGK2UnzlzqnLQw2aGJGygrd7JqJCtlczwJcqYgXTWBgWbKIwPAWTBNRxtFNWowMRwTQB3qvdKrphO76bdYSWd7kPCKbmYm6nRyMyf2jnaG6kmlsqrtS3V119QJKy3b+2+GNS812ALUdPbSTKemBjAP2O8knUfL6DXcJUsTDvbyEiMnviVW3crfjQ7wbXtLztNFIHe5H0HZJNh6DazNU8v/sCwLvnLlsJj5vhGzhr8Glq467wMCJv5AMOP8sEfngsqTroigl3vpTEeE00MN9agbYuphrrrVCYH/dQtrfeuC0MY7xk72spv97GhPu9q3EQ+wp4IacI+73OMuAQnM/e54z/sxrOH2vhMBGH4PfC4AL/jC04Lwhk/8KxCv+MargvGO7x8F9E75ylu+GXW/vOY3v3mjR14MArA750dP+tKb/vSoD70APu8GyLMeDq5/vRliL3s20L72TJi8NDIvDc/7Xfdy573cfX90AVRg7eSowOplb3zkv0P5ihfAANQwgOW/Xvp2qH70p58G7TOf+3TwvuGx333rs5784Te/4NF/BvGfH/xzcP/64S8FCvUYVUiQf+TZ/wX7Owf/RqB/fsd+EMArsREgSOB/D+JlRSCAjYd+CFgcTICA/0eggOeRBA7odui3GdFCAF5BgUZggUyBgeq3f+AXgfy1BCBYBCIIgA1YggMIfqoRAYiCGRFwGGTRHi0RGzyCREOQgYkHgf1kEweycCVhQ3phgzioFB8yLj3IcwAAhFvHflIjHCuoIEDCGefhG2gmhYUnhC9EhLNREwtwIGxzhbbRHgqwGZ3RG07xG0LghVHHf7QRTcMBGdJBHWp4hzKRHj8nh4EHhuWiGbNhGhRnF3eobUwDFfYXIH14ZoEFiEmHfoVREn/lIIDhF/qxGxRyHw7ihg70gzD4gOA3HWXyGrlTiGVUOJmYicOxHzDRiXICigE4ihoIfsDhKwXgF2Jxg/8vwYhuAS5PiH+S2HfodzUwUjiq2BhuMWuZESLAKFTDOBPFiHN0SAbVCHbX+AbZWG7bKAbdaHXf2AbhGGbjCAblyHTnuAbpuFzr6AXtWHz0Fwfx+FnN53zhAH3Md3z4yA76aHjABw3CBw3E53YBCXcDCXcFeX62iHtocHsO2QUYEBceEJFrMJFuUZEWGQYZEBcfsJFp0JFu8ZEg+QUWEBcgUJJncJJukZIq2QUXEBca8JJlEJNuMZM0yQUb4BIYkJNlsJMB0JM+uQUd4BIZMJRjUJQBcJRImQUc4BIW0JRh8JQBEJVSeVoBwHdXmRFZuZVXIAEb4JVfAJZiaQUC0AH/ZdkFZ5mWVKABHMCWW+CWcDmXdFmXdnmXeAkIB5l6fNmXzbCQoOeXgjmYhFmYhnkMtseP/biYjNmY3vCPcSB2jjmZlFmZlnmZmCkOXZcE79gQ9bgFm5mXmmJ78+gRn6kFoSmaIUOaVXGaWZCaqvkurFkUrnlasXkGsFkEnakQtQkSt1lAs0kUvWkFuamaxTkEu6kEhpgaqzgLw3lAvykRwUkEyGgbG5WCRLCcHyVfVGAeFqgEEpgG7FEFz5laZqCdutKcZXmcQnCN9icdg4gE6JkT3DkFBQIF4RkI5TkFGqEV9wme2DkE86me9gkVe0gTAUoFUMIF6CkIK1gI7AkA/9cIcTHiGHIxGNdxFggQTAxAn+iCiODBF5oYGMOxIz5xGMKhGIxhoQwwgkKgomV0KkVzKmmBokK0AAfgixIzGGlhiKhBo3HYkGrQn/Dyn/iToP0mXx56BUaKoETnCw/KddNZKHExGvmZG4YYHPS5G6gIHrXTV7lhHm54E7/BHoBRIe/hokJkhe5xE9PxcxoaGm/YLaeio7sBFD76FnFKBPupEkbgn8DYEntEXyyKoT2qExzqoS+iniJCGCV6HRhaGCeajDDKjG7RogBIRiSBqQ0CAUV4oZ0xXp2qhqqhK4QqRTfkoRBQFymig0iEhMglozeao0RAo9MhHNOhLYI6Hf/IciAiaoOimoNN+Ba8ChlACgcR+o0+khvFcSrqYYhAQZ/ewV9JIh5xwSDMRhJ++CNtmgTcih53Q62LSADbynNgIRUamqcEIKo816dRQKS/Fous1hk9kStXeiZZ+hZbChVdOgQU8ldyFKYGOqaeQaeIcabFoab1+n8QACynExdsuCALRTEUUqoLWwRcEUAeWhcKwInzaoae4hRvWqcCaqD9djFp2BMl5SComCS1MRoImBQTeyMrS3ENsKdykKzzWDGI0hNe1HCjkRSGeKv7ymNeSoYKkhQ5ES20KCHCQSEWcoFOq4ZS8aZGcBYMJVovaq76ChV4yh9QiLVBaiZ/WqT/wLiGs+EqyNKs1wqtNiGtZzZJjSgXzoqtC1iuT9utSKC283apsyEEWoiAOVKxaRthAuUrtrKv4XG2ScIt8qUVXBEB44mqiFEXWkG4MBEc1QoVCCi46oG5a8quxvUnU/qiTIMAShEkI5cjZ+FUijpLazIjPrS68NISkgpgPfKtqqum3ypEetEph4G6yINx4wkWS8RvJXIiwRuJQoopISsxUwMkfysE9WohSfus10G0aNGkauiJ18sgTAshtToh4iu1LAgbI5ErC6qFMvsZN8IgcnSx4yttgkExtKKGC4o6bFO16jG5RSC2sUK9JGGt6zqGkFo17UuxAwwVkyu2yFq6/2ewoKbgrlAQEo4rwGjbGRjqFapbK6wbFwRyHYsKhe3BO2vowbVroriLH7rbIpjaQRtcOJhBMdOrhaIqvK27cI/qQJixi4qaIoyrF46BbVv7u2u6WtSRuoARI6CruXpBI2FIhKfLhAucuR+XxJEJwWYgwaVAwU8QoU/wnaAQtWUQsUzAxYygs63ZvKSrB2LMCadyVGaQn0iAxougxrTJxrgZnWSAx8Kpx8DJx2Lgx0rwxn5Ax3vgxU5AWZSCQLt1QILCWaEgFpH5W3VAyJGAyHqgyEZhBFLjSqTVyPEGN1cgyn40ukvgWrcTXHuQF5acT338ylUgyfwJwbB6gS0BGP8QoKEiYiPjSgRktIufKmf0VRMOch8LwMvWiURc0SJLBrFIeKgbusyIoakMCI6ALJ1FgEx7shKm3M1fsCm0nMqyTGSAkBMEUc5TMM7vWrogu4BkuCBnMRq3mrFH4L60kheX6q/T1R4Q8BoGMM9IRWkOwq2L4xR3ahMCPR0E3R5xNQaczAQawc3H+xbfckvIol5kNSZI2FDioi+IVhMKZi0pokPzhV1+NGAPQm8jvTWigUtpsjVdQza3hEIqRJ3BEl/UySsY/UNvJqqdIV2uxDQ1EkaoakRl4mBJNC4dTS/NYzFZtV+bciokJBwGBi0ugdWPJC6wgStOJDdYbRus2jH/RTSaa3CNF/yIOIS9aaGliHsuu6HPaMy3ZLgXSSqxs8EeSdEdTpGu1yGzhZs6aBDRqezJcRE7f1Mw6hFKNMZq+MRP/uJAVlZD3FFRHq0WJOVHo6EzgbQmVRY4w5bSbFM7AnIbHHYEBuNhPcbKBgNkgjMEp405hnTZmdQnn+IX1bRRkqQEhONkOuNjsOxrErYxTsZDnvFgG2UyMVJJkDMaxs1Qrx0vWsyKDdatb5qva2LPuGG/9Da9ISg5N52nnprXb7FQ4pvQESDeEiy/ZUDYSjDRDoRNthFDArWIh0NHAEcw2UQ7iCYElsZet/EvbIYo4qxx3UJM/z1wBCQydpLg/yE3GrdES6lh34OGG7nCaV3dakIUMRGOZsjkgXWFZ9NUJw+GTvo938fVM9TmLQQuKM5kM5IGNuSiJ7H1ZCtuNXRC4ylqxMpRukO81mu4cB/c1v/BV6MdzB3j3YDrcFwRLepN3oMRG6qLhF7x5BrscO2XzX3syaHIG8U0OOEGG7ymOI5SUPy9ypYTHQ9uNM0yJs12yma2M0yV5v3Gbe/ycyRO59u2SqdGL2FurxMG3M7z58imsd3S57K9ULRtBBPFMJZ9UYEeQFuGNyv+5kYgN9aW5zq+TpQeFLMGOSuW5x812uEy3Upg3qQuBv7rrSRMCO7dWoYtPEwjK7pjcr4DVv/5Pev0zUzmjDy/cRhpMSbvprJwjj2YwTxXZOeHyDZ2AnIOkC9dIV0TZutnlTHVxTuSI+TFlFXSXgREbdI7pzhQVeLETVV14jrksjbDninzxlQcp+n+UE3UAztfbTxzxClf1eWYvAT6/ERowBk2dwSrPgivfhWAEHMDAVeVRTESrc7QedaluREFL91/gPD8wFdtMHRG4fDmCfFrTLaCHAb7vgXs3AeqHLLxM/FmHfLhDMEwLTPCFvPejspwACnfTM4448qv5QQq3+Np8MhJAPQFxPHsMvLB7SmsPPN7wM6utSnoTJ5aPgYTRKLxQvQwj/SCpQQl/5pW/xNJjwcWjwb/YQ8GRj9O10JvOkM2lcMt9k6lWdXROg1DQO27JBHWWs2LQsXVvHRwcyTVSe1dHz1MuHQmYSQ7xDL3tQjyfnQ9gFX1VWBZY49QyNr1NPH1dxD5ZYD5XVD2V9YxbW4P+cNave1Rm/NHoTEwQsYv9yTcdeLcgMJQqR8uur3zbm5WTCVICtc5+c0pqR/dR9Dzq+ntIVwS/9VF+LXKNXE0aG8PClbTQg1obkEEc2/4aQjVU9PUQ8D2txbV9CUoVF1ggOVMiOqo1h9xNO3M1vISLaIUVM1uOrHCJCFdHrg8/dLPzY/l7oVFUNHT3wUEisaBASAgAElAgVBINALRhyMamCKk/4BIVaH0fsHhZEBcNp/BgoE4YDAWkk8DuZmsEw7RxJLgbWCjHAywChQcFgIQGqCq9rYO+ggSrBiYAOaSmBj1ANoAGvYsvTCfxgweqqwwAR4eOt1eVzVTHQMgwwYE0HZ5d8m+CqJuvRIiXgEUDroiFrwk3Y6KEAhWk6AY6gAOGgAgDrT7qi8DijIJFAIg3pbg5hwKjMsekAraAw7hjpXSlUA/9yQ5oNLnAZwCzdApyLYA4QEDAQeygsPvS0KJ6GCBU1IwToM5fcJcy+YlAMEEAj0loQJhjpsCrkqVUlIAgQM/5Ba6cqCMYi9fPoGeUcMGWj45dJC8WaklFMg4xiDcU/+ywJWdBMm6VJSaZJslWeeUkXTjD94XTAyRtYmmZFWrTupi/WKCFQw6m19yBdXb65eXlwwQGGOAKounTQH2KMlGWAqmP1Uc1KGSiopNcVps9dGUuI6lyoMCFHKWBzEfAJVlprRKiYFDReuOdQYZoEE2mQVq5/N0Z9KDcv+SGHiS+PRWiR0vfwJ0b+S+oqYUBIvi8ZfbJhCIm7O2PLLRVLV7/95Lcnx5AEPBQLZNHVmeB531NHWm5570qwSqcMPfuIpv0ggqCUeuSPo7xh9GuAmODAUmwcINRKZryxXCqDDgKyP6myMLMPIyz0PygNFpm2sAQMAVfugCI5u1FASgmG7/mEtqGy9uwS8Mu+YKoIsFDOqjsqmqKk6dCOSrDC2MwpjxiG9g261HGCNL6ki1dHtOiRmTsIhHJLlySpJLtknuxaiiTM/KNuYBgAHaJFTzgGmAAWnMGJOgKkluhimvrw99Qo/PPwENVNAzOhxUrz0zqWqOxxCbMJD9rHAmHwAgZJMO+hxIRpVJSmMEi1EKtISwBJ6szL6sMonPtMoYTES11qIAUM2S7KhyHelo1fSKKIzJxklYExFvPwS6gFQBA0gjwIEGw0QUQ8Tu0VWsJi3MYxL2WKkqAiLitANTXR1YTtNgkxFvL2cNTWONdNlt111eCn0XDXTlfdfOekfh9gxR//DtFyh+AY3AKT39TcLPghFOOKh4FR6jYUOlqwnhwHYB+OGGozL3YhD9PXjjjx9muGF6QS7Z5JNR/pPkdj0OallaL9Ywo14s9rDmXkRWeOWUee7Z5593TrdlJeA8I4JJQR3YNHaLdq5ipW3uQzWcdfk4aJ+mvhnhqX/u2ms+rx50aA2hBmMBqDVVWus/HfqCazHW3ituQqveOGxesi7b5YyOVoLT0E4DJEGnvy7c8HMRHlo7s/IYETIldgJl4E2GKOKITgS/hFNutogC1WeJHXUjyDi96lkdaZKiwnEYEC4KAjZxpQn8DqlCagMmIxeQZjis++K7fZl5bjQUWKDtTv8A78gLtDKe9vDnoT8DeEAVX5rGPioHeNk+ElBbTm5KoRUPbbjx5q26dDyOa66L4ZKdcRxwy608+8EpAWhOMk21lS4vI+eEgaeA3T3LdJ6oFIES0QVoWSFWYDAATZQ2Ek5J7ABwmZqraLMEQMhugoCAS/RAaLLp/al6FvtRJ94xuVTAbHHXSYwn3LHCyISnH4kRjj6cNpj++GMmProHsipzQuWoJx9u0Z8BopOf2r2mdyADXv/as4xmqCV/OeoCR2j1gJOsrn5BktQXADNFWGRwH5H4xkHSopAtZhFpIXTjw0bIpxJCrUZE0Fr3gBGP1hTNE0Qi352UoKWJzOx8JDL/kfs8IxWa8C5Pc+qOVRjAADyiCQlrGtyXmmg1nyxxEbR4hRE3E5w9OMkUZoHgF5pTK21YcGYwrM9sclPKVL6RlgWL44fG1gjG2YIbd1QagrSgr0a4wXWIAZasFBMrBRKSQoBIgOy4kEibRAUWyHrdfibxSDVh4QCTrBa0apMfXPgOjnqRRIpMIYlIdk+QsbFVXYyXkWw8MJJwYh45puVHS5DJV1aq5T/9dUsPVc9d/Hrbw2ZZr/9tzSeQ0k+B2gAYW+BxWMukVhkEMQbIhCsKBSgCR8m4Dz24xHYXTShAUZougZqHoOxqXilBtpMP+muhtkzp026a05Elbl06fV5N/wPq0zIMT6hFVRlPjWo4oPZrpUl16lOxhlSo/myp+GrqVLGa1X1IVasoq2q9rlowmQGQkO86aFetylW0luyr8rqqhhJxl3Y1DQ0n1ZOF0GXXuyanPHxda3oSV4EBDJawhTXsYRGbWMUulrGNdexjIRtZyVaAnDs1jzuWwLt2HY+sZdDreM76V3eFVS8UEMBpUZta1a6Wta117Wth21oJSCC2tbXtbXHrWgo40UOY/RJtnllMbmCQG4zpZRNOskEvjAqkxmhJSDvDKSfYwiYLJIyUYsUAkLbBMf3J3a4iNR/PGZcPTtguXgPHKxf1oTUs2Vx5n5AsTDTXCAlokMamSv9arJ5WtIYCHiOy4w7AnIiR5fuG+JiUhDTRxCZ22snnDNgQvEbQIHCAghsmaRKUPERW0+CRKcQhknw4OCxZetuCJfbhuFBKwl/60ozMx+AlxGMcLG7PQ07SmsFpVb9T5W9/BfXWKsjKE7kLhCsjQxr5uOg707oNtr7olQG50xSMsUJq0Mso5nhHnNbIDh44IQoskyJBuGnNIBpg5FcGhxDHIsOT17PWHkP1x0AGlJDlqg8slZJIS9EnSO5lJhtjJDmyqfERqcWiQXP3zVChE6W8GMiU+HnJU0KvpVmRAG7t2Xp1esBZEEIl5aF1zk+ts53B1lvj6KOYoxzpElQliu3/5rnIgHCuswx9IVIeo1INaJWDMIHNaLln1uJFXaxB8mtGpzcA8YiI5sIMklPN19awkUlXS+3UU6PaQ9k2Q2i5He6gilsolSV3ULxdBnCfm90qbbcYtv1uvsib3gBNd1HjXW/p6ZvfIby3UPPd7zD8W+AFHxTBdRpwg2914Q3vGcJzqvCGQ9zhFUe3wCW+8ABIluMd9/jHQR5ykY+c5CU3+ckPS/GUZtzguXX5y2Eec5nPnOY1t/nNcZ7z1mLc3Bb3+c+B3i+WB53oRTf6XoZ+dKUvnelKSHrToR51nz9d6lW3Or+pfnWtb13cWef618GOVq+Hnexld5dpdf7y2aad/+1td/vb4R53uc+d7rfdrdIFQNu67/3ta+f73wHPWr8HnvCFty1tlz520Sq+4IxPfM9/7nixQ57okj+65d+N+axqnt6cD7rnw42BVHig3qKvAumVbvoooJ7sqg8A64GegVR8oN6yrwLtlW77KOCe7LoPAO8FHhUxWCAVIEB1JbL7BeJXwfgLP2aelbD8KDRf6sEYfvENLh0xXCAVGkD1O9apNO5XwfsWpxgYxh+F8kedMNvv/sL9CoANRAED56ZrEuYfgPpbXJI79kL+9y/qImAaSAYAGy7+OiAKMoDcoMgLEjAAFrDiUKGNHFABpS4goKAMHjACDS7+OCAKLEDc5v8Bvz4wAELQ5wLtC0rwBKHub6JADFbwAFcmCi6A28Il0twmAGqw4RqAdxBAs9JDB68uA9VNCLOvy8BAAjYg3A4jO5RACStOgGIF+rwACodwZazw8joA47YQ6gSgC83OYMDQ6DSAAwSuDKMODcMwCdRwDd3wDeEwDuVwDu0M7Qyv7u7OQyzgDv+OBX1iD/kwEPuwTwSxEHGOpQQL5RTR5CiLTyQgBBYxEksuBCRALx5REjExEzWxsCgRazbxE0FRspqqpVCqrc5AAiZgqiagEoMCFbduFaPK6Eaxp4zKFM3AFaEKFlsxFbVOF/Hm6GbxqWyxDHDxqXzRJ4rR6o5xXoD/kaVosaiGUQySMamWkRemUeqq8duasTxIEaCiMQyusaiyEQ3CEerGkQ22cTy6saHaaD8IZ6huR1C+MQl5EYQ+CwzO8RbrUS8A5h6DR1780V3yEbDMox8psGeIimC48RmTYAsSZJb4qjnWxCXiMQwM7W1WIf78h/KQcR8xhHfwyGcCUgkGUho9Evkyo9P8YmBGki0QZd3+pCXTpSQ5xgtQ8ha0xiALRyfFoG+sgTRSoayCEYwOoB5UiReaAx3cpqy6BSNXah6/YBrxYEZCsmdkkibp8QsG0BqeJAx40jxgkk9k0lCw0mHAYCs/oSvB4Cu7JiHT4i7KAjYGzhnBYAiC/6g/Zoc2yCB25JLJrMASiAu+LhJ3hkySRooMrElJ7CtY8IIje0Equ4cI8Kh0FAgUCgK56IuuFoDGROl16EsSYsWDNCgL6kC45kAdTOQLyrIKPXIA5YpyyCt1IqU034toBmYzqa0KHiT5RoFTlKXaQDMRRFM2ZacdNmdZjGEA8StQVhNdXLN+piM2lYs2pwNUJuEAIMQYPnMxZUU6PKoTOOW6UiU0WqcN9DJziHMdimlg4IQKssKuhtIvjMESVuR+Ds0acAJpdM2MNMgmBhNy0iEjyeAWKicgdKwxHdEj1ekAtGhgXiQAeEfGjsQhmGEJXEEZAEwj6qTF1oggDCLUFP8CDmDsG7xBxbxgNZ/wJB8gD17DYhYMROtgRL2gQl9CG9yMUqpkLaYhQ/NkQnEMJTw0s9IoRg3sNLAzfwSSFX8RDAaDRY/rC150SEW0SF0SwyyMDHzUQLdBnQBDajSsQrh0Gj5iDPjTKN0hRsvmckYCPunSC4wMIPJhnvaSO5pD14hpzW7ldpIoQn4hhu5iy0ZNCaCSNVEJIF5HhwoDFsSszBrAG2oDAczHTY0DzmzF0DohN9TMJlBBY1A0CcrxE8hBFMCsNESBNpogU5XAUY/AfMisylLBi4SIUmWpK021AFAVCmaKXZrzDK5BVJVsaWoVVVvENFp1CWLJRRrAiAj/4ETO5BSqYlmrAcmk6VRXTQnWhEEu6SDNUh2fsX/aq3/k1EUcTZuGFTDd4M9UyVzTxJLmoAgwoY6wwSj8b1BTtFDjoCQMiVkXB9MO4ACSDAi7ZCpC7SEq9Un4aUq9ADuMUjWVtCO/4Gx+shK0kx/Q9WD/KEn8FQ+aAdTSgsOWs0cHtp/yFEqI1E2PlAoHZVfNBiSyZ2KHRD4sltNcUjs4FiPWg0u9KdESIPyi9VyLBFDpZ3kQQF/60m3a1G+c4gEWQFfCVdjI9dAA89VE9Um4y1poQ6LuBzEbRz/kFUE/BDLx8zf1QF+Xhr5wdFb8D0w8EzgLFtZeRz1LZw4UQJIi/61TAQAyXw1B7CMUSoo6S2N54MCSakzZdrM682Vt1Utk4eNt/fYk8GgBkElXG5YZVSRuQZU29tZtxcc4OWFmiZUMPrNrvbMIds0TRjdapdaHHsmaWCgJosKL2HQhhdExrdEj21JvesFuPzWl3BJfVNapwvLOjrYWaXcXdjdlejcMdNd2dSp55eV3kyp4j0p2nYpePZV5hWp5X3Fy900Whxcai5ccsdentLcXuVcbvZd6Y7IdOwp38cV673Z8z2Asz0AjmfN8xXcv6NcM9tcM7HdjoJdtODNQ/nc8+hd9uTUMHPIoQcUikWYiVXJxnHdhwvcUFVRbUQmD9yLYNJhPyv9XMTqYgcVSLVWtXaS3DKA3KmAGHZoNRpqhUlp4PrICAgABUrkiFQYYDQpYf9vorCD4XldIN77XTRZ2JJNyytZS2tyXT+BXKkO4aEv4efHXgjN4Fw7YgQVlh0GLKYECeiEkMVhYR6LihfkBP5AGAZJiDgBEotwgD4pgEj5Hh9OtJe+lXWFqW5GOIe3yHr4rLzOQL5sjPJlgdUCBcvJDuC71mTykiffxu/gSpM6GOwcjH8oCQr6BMhP50/5mHcirc9LHPD64OKSAvNZTEu6LI2YMknMHQJ4rnDrKNDC5JSR1LABCkjGBQajBVcKioiLVxCpBuUZnOrjlcgITkU90iuf/Mgla401QBFogFUIphSIcxMQSBBUSBAoulBwkiWhHM1LoixTYq4KmKzSu0z+VKZMlgUWxQZJ5TRgSlluU9h07YYjLgj7j1D5DLD8bmA8IeclEQUah+UMYuYpvggFMVEvTjI+ZA0mJwRgC+hY4eLmQoCc8JJSLNk3yBKHvEh/AYCXGFEks9SnGYWb6ub4cQMfkFp9N9wEsoiCuFRQioxnMdNVSIiaGiz9l9Jhj8SPxI9SoIjSgGRHgQqgbMsGwICvQAQmAssRmAkR91DH2gCyuFMPOIX2wiHdwlgAQ+hUCIkkg4MzkOT5VwpNWJB8cg071c0BKWhQSiTJO2AwG+ouG/ygQri3OmCACJiRIEDVSikwqInpUa5kSKhqZifGC7UDJhMiuCQCvkTWQcAVbeEg29hoHx5qWrY06DiAeJISHbmgaFEFpNUN1nceFSimGKEOn5w2IhYEB0GEBDDOopfmTFVnByAibtYEcrqVbEplRMeHMWlRAzIGzRwkWsuEl4gxNKFsLFoCH7nie1dcOkuJbkyJcHalOpyyDnGDGMiEeOO2tNzJBUSkpHOmgu1Y4dhlJ81XPCEQpKDY7ZFYvLPpyKE1DL1tzwsJE19VSTGxHeiS9ZZkkeglOkaMNILo6WDp9PgwPLjQspIkk4GKPZsNnLxYfCdtoxyExEKGqm0GFyf9YHcwYPzNCjevJE9x4Dvx1JaHE0lZhSWh2QNopJSRjS7uWilA2qQfmgr63KpWWac36UqDlaS9kWKJ6OhCk1XDIPOI6kNzDaSE5zkpkUqTDX52JbD2FDgwiPo5pOX3ConUlc1lXq7v2yVVid6zpWqrhunoEpBT5v5MpEQQcWW+ZQdukojqWKbRDiFghEIKpHIYJ2v6WJCscRBAhHqLiKgIaEci4pDIhKVK1huHCjTGD0TXXR6ptFdZEiaEWgYhFHyClGY6bpGwBDLCA1lppiH0qyT0ErH/GostD1bHKoLiYwnfaQ56tPBISWbTcip+420xdp1DdPNBy1QM9K/kk2Kf/6qWO3AwCuDzwINd5ISHPz4B3HSx7Pad+3ahYPeqW/efEGnzBOxeHPSrld+m23ee6XaiuXRzDnVDNd9aD7txPvYL1URXXvV7bPbWLbhQTMRT53bAa8Wshsd8FnhPr3VMDfuARPuEPqxP5QuEdXhObyg7rbvD4Lg/NAxD/juL3zg97AeMN8bU0/uNzi+PLTeRN/uWeB/ToTN77TeXpsOtYHshcHtVm/uVpPub7q+ZlHudtvt50Ht94vvOCvuczb+gnD++MnujP7ecBLunZjemVvqugPuGcfumrPupvvvGuHuax/vO2fuWRvuuBbuoj7uu5jezFXtv0LvAs/nDy7uTn/67txWbt4T4Q5T7tv0DiM97s8UXv657tEK9d/P7vC+/u8R5k0N7rzS7xD58Qu57x2w3yG38XJN/iKp/cLn/yyyDzG47zz57vNX8vXA/26HD0wc70Q/9hfA/46HD1wc71U79hpC8AqO/lZ7/2te72Y79h0i8A1u/le//3tS74d79hDFDpjx/skr/4EWYDo975ww76mR9hYlDpqx/srn/6bckIlZ4Gy877tR9hslDpxx/syj/88eULH38MwU790b9g2lDp4x/s5v/97f/+8T//9X//+R8IAMIhsWg8IpPKJbPpfEKj0im1ar02L4Itt+v9gsPiMblsPqPT6vX2IqWw4//yOb0uoGABcDu/71/j5QkOElGIDCAmKi4yNjo+QkZKTlJWWl5iigRCCVRgfoKGio4uVgjkdZKqrrKGmhLCClJUxNba3uIuVWw+CQzkAgdTDZxi+QojJxsRKzfPNkNHN+9KHUtfAzMb/2J3D2p72z6Hk5dHUUdZm69PgVups8cnuctbjdfjl6Nzcuf7F9GjAu+fvIAEndw7qBDZvl79FuIzWO0hxHISKx5JiHEjoYZOBnK0WOwKyJDSLprUQyvPgQPKHgQIoCAlFo9NStJkEiEAASIEeCpBIHMJSoc5sRUNqRHAgZgxIzhp+WRBAAgAIARYIMVA1qNXbDLBuTOAASH/P6ECoGqVZQAGRBQEQJBHLZKdPYf8JMAggEsjQmcqSXqTotcke/sOkZoEq9YjgjcubeoWiuImdKtgRVt4CtglOBPEfGA2ANrLWCS/jTu3al2geF0j+Ut05DvCDJoWSNwWAFy5ec4WMV2lN5LDRaTaNcIYyWOMkXcLEdoAQAGZVGMWcMDUZfKmCn7GTAABfFy4WhUIDZD9cPUDgHk7lTvWNfkI3WUyqB6TgPmNnZWUhBUCLTEAl1PkyUVeT0JdR0B1CDBwmFAJOHAdabrFBEF+4a312n4ANNAUXwga+OFOBTQlWl7bgSiiSwx+6BhtVYBEnnZM7UbcbxcSIRwVOhph/xwRlR2xnIybDfGcUxBglZ16PQKFXJRDjZYbXf0lcAADXEHIFwA/NTYaVMBVN15XQtynwE6iCdEfRv8lURJVBMz5JY90AQeaA0IZwFUCAMDUgHENPInaEDqqxUCWk9kJFWhwHXBjWqwd6mVyfK5IIF+S8skVYgDNKBBhQgkFlYURiFiVAvplJ6BQBYDX007pRVAidAi2GFOYbbLqwIb7pQqBhevxVV0CM0mV1688uRoXowA0V9Fzz4IGk1UEgPYUi2lCoJ9qV2ZF3F5teWmkmJNatVMEpqWpQLbumQQnEiA54FRMCd7JmoUZ/kWcXcYRZ2ibquHollAd7lsVTLqiC/9AhfYykJxambq0cFd/CblMqFMMBNexAfxZMHy+LUroA01SF0AD9f55KVnAQWkVcTALUXIAD6xZqW9DzGkcysnylLMQKFd3lxDRQjStT+HB5xJwUkLlXVMGEEfVdFhqyaXPZ55LZlVgDqEuju+t6WZF8h5R45mgGfATm1bbyWZ0MvnLk3FgNyUpfCEnuuhrcg9xWwAPT1enZP8+SnHgeWPs5ZHbFGFxhiITZ2tcyyVqKVAT88gza8AJWKm9CLgbk3s6YutUBACrBjR/7yqwXHJDIL2QktoKftd1pbLoAGgoygQeqbw1RXpX6GHna7lcN4qm6XfV57t63g3rgNkQoW3/BEigrbUmA+kVWLydTiGvQN168YWbW+BpNmlVvyLQ4WjkO3VATwoUj39ch9s7HcUl2g8AjfsUEWqXNop4x065ydveahapIWDufZrTS+JuFhyVjax5Q8iS3pz3AI81rVF364rrwnYz2cEGWhvLyVKQ5EIhZK8IOLFFxlxoQO095Ce+EZwD2Oc+CKzKKQuIoIY0J6LpfC8mjNKfXEIUmiIEUVfV++HuSDMu7LjFddVDodFU+MIWvhBJMSTCDGtRQyTdUIaEucXsCpPGf4AxjIUZ4xDKKMdbvLGOa7RFG72Sx3zE8Y45oaMQ7CjIWPwRAIY85BUSWY9AwmdXV7geFVbE/0glEFKRexQGoVLIBB+tI5GLvOQwVkgTSPZHNsphXhIoOQVLMkFHqhwkLz6yyVvI5gB/OmMS1GKuWvzyCaK8JS42RMAlAMkcjpQHKllpBVdKAZbIJJgYazkYaexlZ1OhVEFMyY9kLGdFfWylamZZC3PO5osrIUIDsmU8rVAldnEhVYGO5y3BMYySCsLKn7iyAFv1JC8R7EmqtBKseAJgPrKanjPxkUmQALQI8xni/p40PqAwwELCkkmqbuOSjC6JCAtrChC7MsXrkLRZEMpVV5bFn6440XHphBw0diK/JiRTJOqEorMGBk+ZEI0nWHvPBslyvTwNjk8wKcvAnMYsk/+mkG2ICt6FypSmgzx0k5AiQuiG1hWYEACpDzNaPHUklToVAWxqud6c1FqVoL4UX/axoE8P08HAeNMoUEreW9IjE1JNLorZAZE7zVOfFbXzXm8BjfjKaq+eQICx5czKh34lHpa6JJ4unUdelbLOc/l0UvLUil3Mk8z5qIp5CTPTAw4gl4c5hQEChepClzRVBdBFXS4jaj6yagTYKjFw3iJAOEmzWoE51jdSEZgJe7LWrqTuKXXyZVfsArrywK4/FpMkczp7zSOgdW7TmZsCHCAVm32wp5FsWF5686ya0e1bVArho4jTKS/1TUub8pya6IrXnaZmpeuNJxeHWiV0HdX/v0IQkXOnJNunyqWtT3ou36gKFasCBZ0OtWZYCGM46HAVZMspmtugRNb4KjeznmxemUzrpbN4jUnVFapqaFY2rvGQCcNMa7Y6B6L4JBFZMrFXXGjWHzzxhGaB81LVZALcIbvEvvjxEmoOtl3Rlo4vvC2gdyHzWSEktjxQHW1CaXyeewrFtamVJHmGspOQMVEyKzKWUPSS5oNR0c3PK/OC5usP30KxeAJDkIxFxKY2KwCkGUrugj+qUSK052BHvpcVI/3WGfckpqKpnov3rOMue+YhW1XyEKTzFz8BgIM6m8ykr0VjAQ8pa/LFrYMJxCUBTlnFGvIbAHiIUA9yFsCk//QKoKkQzHIoanDN2PFeeYchC6YZZDOJIkwLC1VXZ9qdIY7LrOPcFicOb4C91k/8ANhgWvO1u8IeNi0nYoVjd+OKBxivMpg9BQ2To8TCWGY8IMlu7HE41P/Ghb2lgG9szKcA7yU4qKX15YFzpNgQh0XBJ24FfrPD3+QgyxW48qXcBMNBRPB4LSROBY4/AVZhrLjFS7nuIZiXqUcgD3epcxeVMwHnSSALyYvQ8yR4XOSDELoRiA6AnxdVvVIwOQQDMISY0nsIKHeCzn/sFNEgD2T389YDFq7MhseJmEswOhOQnhOMr2Mp4JF50f/kuy4KoepNkLsRpk6FoINcEGTHS//ej+704iQA7k9gesr+nlD/HdPuOe9iO4lg3kMv4DaNMQAC7vp1VKwRAXeB33v3rgSk91jZNNcOAUSEgKjr1IVgVLxP+PYAizWgkypTOXiOBQBuq0z2UUfp7fvkdGyBBkIe35Ou6nWvLf3eSWXhCqMeAPIETAf305lPiR4gexVlyVnDTw/goE8FwvtdOYkvy+4YYPyeWojxITOLNr+0/n9UnCuucYDCFQV3zwPd8DWLegRsT/+2JQBTRQDgpB6SrB7b8Rjx0NsDyAXOwQr+zMS63F5A/YncYYuk8NzvUchtNIDHLUDfCUG9QADeAYpovJ5IPV/0UeDtdQjZEYpsJUD/hASeB4qGec1EAyAAAUIB+CGd71jFwojGy6yU5sHc11CIzbGTvTwAARCg8wmBU1heAdbGEdAdEfpEbhhAtkwH7B1djxWB9yXGTc2bP6CdORxgEpCHiohIBd4cAcgeyPQeYSGhSAFOBn7c/nkcGPKGt3Rg8h1dpCjbEDhhqkVfWTRe6nSd0OEgFApdATxAHvZPCVoBD+of/qDeExqA5HwQH57gHILZ+2FLAoZgIHYT5lHh/b0WIy7QdEDApzAgU/QE6NlLvehNvZQFeOhgOJRhOZzhj4miw7BG/1EHWjwgvEidIVZg+7gfBvreHRKiB+bdK+5FHzpjASAAm/XTGHJc/+MlRgMQAMlABVb0UG6YFzUuQC5OYsAByB71HLZsGSZ+Y/PJxTRiiwyqn+MdQGPQiXkpHHxEITmwnCcCCqzx3fnFRA+tIS2GHxHoIVOg3hgKQSeGEtjZzsOloS+2HqSFx590UgPQ3tXFYeN1pEZ6iR0KHfRtn64YQFOABjUKHVYgoPQMSCESFj5BiP4sYXgMDs2FH/EdpCRWAeHxYapFIhFwnIV0IEuqTBLpEuMp4dGlBxFSW9dFBEUe0CmGYA4igchBJDCmy58E0E98If8FoMMUgAGgynidYzzsIjlonAvh30KAX8tVQfw5BUfay/vdYRYyjX4kAF5y2xfOIqBcHf/pmd4l6qJVHsRbboZ53dSbqGPY0SUhBORkCpNiEgRjWuY6zOVmQkFleuZMGeDDhWZvRea8iF1p/hdNqaYTtGU4aCYW0N3cWVRhxOXgneZVlp3+VRII5h/rEQRotqbGvFyZSVsShBkCIGASqBxwIkEret0SkJzZjZ1vRsFszlxuuFN0YlJu4tARZN0M+mHRWWda9R11CpDgVYHQ3SZlYiYZpSYUYOfd8aZzIsF8umdx/lNa1NxVYBCgqCdWRkF7IgF6rgPR2d/Seaca/dYBQJ6BPgGBLthyrmd5MpwpilRRymeA0mcR2KeA5sJrekMcSSB4KeP1fdxPAFdPkMX5rRT/741iTBAKMlIH9zlMeixAtgSg0/nkmPyl0t1hAWSLkO6X9BGmjCKhyiTAI2rhRfVdQzoB032jz/mhNT6RyPElT6Co0QXdj0LIwlAIraSoyoAMX1wHVFzf+S0hFjbFGFqpgl3ce+pR5KAj1XHoFCDdhxoBfn6DnAISaf5hFBYAYv4YDN7iETanzIngBZInMNJoAWDh4HzgEEyn0y3AeRwAAPpKVwZpbsxoqrFoQLliA7JoY4xhK8LFLYIcDtZpd7pbWhEgCUKq340jLBrBC3KpBm4qTV4q8QDg8nFcAniq/uEqyHFlpmnJrHLFP36mn2oSnfYVw7CKWxjpm4oGivrk/1Een4sin4eS37YCmfusWC2IaDe0UDu9oxCsJTv5Va0CZaJSWwNI5BU6qhyqHC3qYaUSYtx5YwrSq8qRXKLSaun1JYuWhUEqqVmA3Lzu4ILCZ9tRaZD2BC06iEKCWbvmqjN6X7CO16AKXcDGotMt4kGyp5PcyODcKynGKYYKYv9MqVnE4PeE6pe4hLKS4gsugG8IocEYjQjmadsMYc8aoXbwqSCUKzYshTUyCqEUAVbcxRImQDjupLHGbOD1njSqDKOa5xNOh5AiIS1OqhAwX/j1aqqeZNSJHMD+ncD2nwgmFBvGoUNWykyEbTq+Kj7q4wLI6sROra3WjNS6q9iO5//Gkt95vAzIgWz4Ra1/9pBvHCvN5gffMutlsmxEAs7DnF4nMmEcLmvKOsDIDg4YkoUmxuvPki4nsknR5sHRXoNGIOzn8ibNYkfb6KS7MqXV8pxSdq3p0Ov4IADc0qJPRt6EpOSFnO2/hmzcsWh4lIVfwi3KZemfLAwCLGyrumo6rBHl3QsB7C0w1upK7kft9S2lDi5N9qgzJm7Q1S5OYmmbdq3krq6zDgTDwmw9JijHCaPnLq44lu3OCuI8qszPxuP/9lrWVu2d9mlxDicm6oPDzukCR0HFSY43OsXuqge1Mu/X7uT6ggbbiGtSlik1GuW3yij4tuTtIrDROusjAer/cOqpMnQmBD8OScTnzlFoLKlsSLCuNMSmDE+DAxdSDfuwcDbBC4/cgRzFDkdDD/twMsRwE9OO/AqxaioxNDAxFAfDE7+Shd4REctwFTvDw+lHpsZGT+yFGcvEcKVnAaNxusICyeneZjCdFQJKfyqBhNqQFC8eFhhxynAxW64wM7VwBLRf2GhFKx5yzYoGV6hJIieyMCBd6ckxED+rKN7GYzIBHqORHqeVENGfwR7BC9vdbELnIKBcH7uc6rXwuopfQkmyBDrigjVAK7oyd+wKlxynkjIpklKfT2Jf8CUbHH7iJN/tkhlixVRwFzqF1VlQrjLWmTLzL6Pf8TFtCYYI//u5j/CRBU+McTZwctj431mq7hIYsSYX8Q0jUiD3G2kSyhEigXuQTjz3RCwTinbAM3qgRxcxMn/enqmyoktw01ra4AVyYM8xwAPY3hxRspxcWBe94gFAxc8V6xGXhbBiJJi1BUHP2wBrXjW/Hgc6JEdzL1CMbTBU3AHcVKLiMrxoq5fo6EyMMoumx8pUsPDAdDs535Aylna8tMXYYuEp3Eq7cROAsTLEUSgiwQK88k+4xVCmxVKD2EKGIse9LiIGs4yebc9ZrEIXMwQBomGGh0J6HOgG7kKqLYhgbApqokerSAFE1pGGRs/tRACF6Dc/YQepNMfF8su4M0NCRUxPoP/73SFczIQTnsmsfqrVbtBfMxVfR4jmcUXzWq9obobrVl5CuUQ1+0Q+XoVrxR0Bll4itx/JaSXKcWo3srLG9iF3HgX4uRY5BiNYBpTT7e/4Cq7yKi7gnu0AC64D7EkNat2XwBrSwcXkYsFJo15eW+7Vys1BgyRgb+OfiBw3ZmHcnrXNOfcTnXImHtoj/h39NuvLKVpZanaloDExEiBcnDeV3ot2QK+O2qT5pfX+JZHb5XC7YW9rdOxGWh1ojI+eZCwSqm+Zuqv3IWXKuBabtNZkIGWlPlFdV+7bHqw4GyzJnSBf38gLClAQsp3AHmJuEHZa5AbKXTesaHhpr4Vj25//hU/2ao5mN0AoBGsxGuply7GcxTzAJ/cei8fhGPvkksYtbke3M9q0dSevzf24CR6kXmMRj9elOmdcCyNDjC/wjHcyX6DzwHkxBBd1MlwxFueClQ+xXYP50UB52kl5mUODmH8xmZd5lyPDlzcxKnPGQk/xOGu5m4M5nAsDGP3EDcueYkNByVqBAyiqRWczb9Gfp+1LPwYOoabM/Jw2nSeBmhIB+O3EJeI5Gv6xDus5FvN5MJxrTAB6yJReCm/tJC0AGffaq3S2dmhl4GQJ3W6OvqRQfgh6yzrdXnyltxJCiMOQnR/BbcxqEWw6u235Aoc6MCxFK8IkEnCjcIOq9zrI/0+k6dW1L190rY36nDV2UQ46Yb3Ms1OyCcs0TJkYAW4JOiGLZapFHp146Ez/obZPO8XCShrz7ihKCuGFiMWmXzYjX5rNBPiOIfWlrY36Mkck+3Auey5oRGT/9BFEex5KLraw3UTfYQCFSH5Eqt6YjLHnxiBeKgJcdnPphqLFyBHUS25cYDV/o5AiIFCEosZridVSbFmWtFlwqlA29DLanEhHNnWIBs3zOt9RR8cLtDFWhCh5Qis4/dNDvSK8gipHDpFRaLRPqc2PL1mXrMWiLPyOnLfHqFPAiuNq08cD45+oBVXkorrfRegNmVvkfEhSSCCGbsXn3Vy/PeoxnUFKb//qMqESsrjX91C1yFZu6K+GQkQi7cEfOL4ASIAEPL7jU7JCgNFPl7cc0mzXqsj41nbjKqytll7kei94rjrbOWHpaccryjq8TNf7tCQR4Lp6Mi1cWIWGH6MchmWydn5Z+yMSSOkOobT9Bh5vL+QJ7j6jbDTiS25qb0TDI8MWqLksACrm82agj5f8CYW7iq/1pEi2uynYqzzqgxy5KfoY6w5rYMUDCQEDQLrLmw7qDTnBT4f2j6/80RWUMp2gPwAQLBiIwCFBACwCy4YhAAA8HgDDodhgWAMIBqEAKCAdAYeDuHRA1Wt22/2Gx+XsgWB+x+f1e4DAzgcMFBwkFKSoKEz/VFxkbJyroOATGHCstLyEqsPcBPTj/ATFPAwlLTWFg5SkPGUl1Ww19YSdpVUbrcXNDUzdm9T9JXwFtpQdNra8PVYG5tXzXYZ+E44uLKa+3kvG3g5tznvmhp4O7/0jP2/TRl9X9MYDZ/8dj4+zpg9Xv9fPc7+D3581D+AaewOjURAxQOFChg0dPoQYUeJEihUtXsSYUaOISL0qaAQZUuRIkg0rmDPIpmBKZRf8vIQZU+ZMmjVt3sQ5U4KEnD19/gSK8wIfCkGNHpW5E+nSpR1ZEkT5VOqylVMBVrUKDWtWrrC2dl33FewvsWPNbip7FltatV6jtoVrCcOSJR7inptL/9fuXbJv+f4llIFugA+AtwmmW9hwLbaLHbexMBjE42iR6U6m3Kpx5scXBmvg3PJz6FObSRvesATD6WOpA6xmTcp07LsdlmSgDcx2ANy5P832rZbDEgvBcw0PUNw4JuDLxy4Z6pwWdOnE/FYHLGED9lnauTtq/l2qgA7iWZE3vyh8eoMaOLAv5R5+tevz7d/HH2h9fv79ze/3L0ABgwOQNguYQjBBBRdksEHlADiwQQknpHDCB+MpMDYJQiipQw8/BDFEkUKQQI0NRUQxRRU9JFGfDFmTYIIBQ5mgRChinDGOGl2sDz4cc+RkxxtlBNINIel58bQfi7zkyCWZVONIDP97ZO9JKBtxksgroZCSnSRJs3JLRbIUk0sbkaQyvTDLJITMMrsMK03z1ozmgSUU4MxNMeFE58vQnmRgsCWQ2IOAACJQxFBE13BiAdL0DIeBAoqI4k5TDjiADSsYEITPc/zkbE0i8ARE0UQPZQMCVEODFABD6VogDVUdvWTWQgNAotE7TNUj0EzdwFTTADgNxFNyQM1M1ABIJUIJCBSYNIACHFBgMAKqpcvXSY9IIABaX8UVgGYHxXYJYsvlItoEIACAASWWgGDUajNV4Ixlq6UVoFZNhcAIYoeJIAB2VV1UDl4VCXaNTTs9c8oAlWWWLggSOICBBgKYAop5XUXVV47/p+jWAVNDJsIAJzI9GApTnWWAYnfDhUJeSoloQA18Ddp31YCv9TYJuqbluIhDtS0Czwa0cFRSunh29OglfoXi5QDWBTfaLQAIeFCsvT3A6mGz7lkNK/A0AoBgoV0C6GCVxnRYhnl8WMs1Ro15WQDKXQIBB94111SPTR2Vb3hH/XtVNUxdmIh+3a5bgY0vzvtfnM+0kldFb1ZDCZ4T4DiCwheoFoHOA874bm99TYMNZ8fg3NnOX58UArAj4PfqNgKO4GIkgnX54imC1dxsxgExNhxkKYO4cSgoTt3n3Yc1dIrCER01+rmXLbx0lVFl2eXg636WUjVoxlxfyuV+fWum/13tdgnae1bU41lrR0CB9g9wvGc7l8hX+MFeZtfKBLa1COxse4hSmtZsNrUCVMxs+BOU6IJFt4UVq2FekpN4kicuu93NaqCzAgI2NQRzUQpwdgPXsghHKRIOz2/RQgC7pCYwVUmLUlrAmOn6p4+cIapfCWAAvjamKCeILn6UmlXo0re1B5QvC2TIXABqFsUAospUsTPgx9agKs6t4V0Z490BmvdAMAywgsS7YJzixiZG5AxWnLrZu4iAqKzNUX49c1oO+TYtIdLlAISKGt8y5TpeZe2P6ovaGcAVw1RZioxo4x8ZHdAtEQ6PD8XjxvEeQyc2otFE6BvEpKYYD1V94f8UmNyGJh3DyU7uoVWAsFfB4hE7VqByLRn8DitbmYdXMsmW11DlYnSpBFIlgpiEKF9melmkX1IjmIYZ5rJs5Qa6zeGYg0imHBY2TasscxlOCEQADNCIMDiimdF4ZnZAqboOGrOdgchmHM7YlVZBbgnag4I48VBOPICzDfpkgz/VAFA5EFQR5TRom9LYJ1xyx0ozhAAx8UU0/PkMT+B63xLWZdE1NKB9jqJZGRWwR2r1TGYoo8u6+BaBm+UxaUWYVEXjUc8uviGhihDoHHIKgJu6oaehBOQizqmVhmLHSt+z6ERN2DNiGmqHHPvCNU0nOjs1oJRjMCUUNHezk67BUF//WFgfjTi0pT6VHDRlZxH2R4ZX1Y+nZ6hZOcFVzDFErn0JcIITLmaAum6BATld6yQ1elG6hI4JYxinE/7aPgLYcwpeMNTelsZTvtKFC2+7Rzr/YqUzSvR0SGTqslwHBQhYTXRSTSGqumWnALbvUFy9FxJNKzw4eot+dzRrOOo5mAcQIAHN02e18PSAL4SLAJkKQ7XG+YYxQMCfTiAUQZu704QmgKUENS7npBCF3wUVChfrAl7ZlwaELhcAzcUsmtboRZgl9bOZslVTwyY8AyhRqkr0qkZNh9LrglRgG7NCfa9mhTSItXO4pQda1bDdgY7To1AwAOf06QQHhOHBbYCk/xSf+4R81tdqTeBwg9u11gdcuMMAeHAVxlAGKH7XXiIzJYPLm+FRXnKhnypqdR7Kt4jGVgigddQxMdrWq0kVxa5FwhMJJcfX9qyGMQ0aEcba5KZpQXpATvD52GDi8Q6UXcJNQnHHGQHOJfemDxBdoEDMKYGKE83t0nCI88ku8Iqridh1cBcLgABaHXJ5PmSrKX3LgJYhwc1plmJ6HeYfXe7yDrulyxSilan9iSxveErpOOVaWDVUYWpSJCFeQyxOT3cLxGyo9BkS8NjC6vPCqlqup3H1qpB5IZFFOAJlS51oC8KN0et0tB68yYefLsPWvxgqVXIsnUYHW0daVkSxj//hgAOwC9k3PtayndNsZ79h2DNKtjI0yxduR+PYEJazVHr67QGF+xjjvsuaIpDVNrhWgXfgpyB2ejh673sP/Mx3HALOCYCuG9p8GPjhllAoehPC33eQNiASPgd3GwPecQlT2uTwcIF7lw8PPzcV0o1wj8th4pcouHnXkLMpGqrGaihvhwOlcjyEvA3+vil1aW7TnRMi5nio+DAuDpc12fzmHJbiqiPMhEoxwZ6jvBgUtrsFpufRtxp1LPtC+NcnmOGebKB6otfagKdvemqYhuvTwUZXV5fZC7+11zjlyHUi4C+wbjZlARCVM9EBwNRu+LnGRr6rhgd08G/QOcR7DlT/G/u6P0UvvOHz2eea9WsNbx541LnLUyT4FgwF2yl4B11ocC5gCtQuJuddBbUoiA7g16poBByVXTBE19prQOyRwaC3JPRdnAS4LAIIkFcwTCHlK14xAPaVALyWVoq5f3AY7r50jHn6ADWjfmMj7Sp695ULd82rFMXpfa5fni6CPXvQlhX2BuResdnPOmTJwDdDVzZycAg6MIbeFshvHOnj7Cs0OC79yjwOm7o8owIiKAAF8KcGeLFjK4AHACd7q7EJYystcDsosLDBkDAE5Kere4B/gb4M9LspcjPe8qcDPLEwiICMWT4CeIAFuJj2a7vao6wO86dDOpos8DjRi7zp/+Iw6DoxKABCsKM561Kugeo87ZqC7fKzjoIe8fIt8qo/NUAvb8M249G25ei/5fE4fwKo67PCASKzzzO8MkAA40PAzJFAt7EuAFAVGDuv6ys9fBIxMkOvMtQ7DYS91KvBPVSYCowrElwAR1Eu4PuXFDQ+a5swiiGV5RuDTHm+P6xCXeu6FiODFkOxB6Q3GtuwBvPEdNMnBiAxLqtBFSOD5HOx8zs2Gas/GsO/LMykLTSOjDs/v/vC/4OwuyqjqeEcyKmxmErDG4y+wQo1WmMrWBG583qxNci0XmQ+FGMCs8uhGoScAfSr/NoCErSfT5M7uji1zas0gEKArFq+JDC0mv9JtALIwAGyRCg4pOPiQTV4wzgMuTdTM8Vaxg7DxzgDOzpzmzRMwhO7sD3rM0Cqx0BTGSAqNMrqx5dbOVlMJVoMjnIbiIhjhWoZo145APM6x4GqmbbKwHE0mSC0AjGUNQJARjnsNCswtVBrM5NxSX80PzJQNVa7kxqEQ4BKyZU8NhIygvrbNYiMEom8pfUyC4wkBSe4Nz6IgL4zk0/iDKMLEqMEJor0DYvstoiUSsqgttujEat0JqzMDa3cyqgcEjbJv75Aylqgyn2kDXYTkLXUhf1TCyupl697gxmSJTg4Oa/qtyA8PD3guJSQy1n4S2xQSrRUr1/bMkQBM2q6LAP/gMqOm4OQ+0SHG0zDPLjtiaRaSExSMLrCFDGgE0t0IkvaoJNASb0FkpwoQzunA8cwYEevsyJ6Az+qqyhaSz35I7+7sk073IdznKSSM4XQDIW3VDxeOk2iass1AMSbqynBG67iWkIb3L00KMS76UjMFExNa6LY6x/fUrkiTILTk6nJ6crD6SLTG7vaq80zQJQ9g0P8ybUskJ3CurotOAN2ec+AszrNmzq4gs8EcKwxwJP3a5+4OoMH6KveCgPxY0b+Ia7lUUf786vwqzG6zAW7PIswGQLhFLwxurAII0YS5CcD1cAG8E50k7oS40DA1JgP8ycKZIlzVAAxlDrX473t/8zRceKzjtS9B3PH8RoDJKjQBXO9oIpOATW+zkMu3lMD8IrA8zSbykOuL6CwYyPPZVyArEpSFZUugRFCNuBQXPBQs7CSKqixXJsb3qNMMPvSEzVD7PTR3wtMNjPA8GxNlYkxRFszK50KN8ohbCRBFQWDmhmDRckCygzJ1eoCU9InWzNU7IQwBVQAJ71BCuMnBzw/VGSxwagwMVBI7nNRRI0CUxJTDwNHfztTxkhNDUGftcohN7XCSUOUtsI0BARGfrLNXKU3mNxT9dOeYxvKULNNTRyIjzwvMiREQ9QnPgMo4GO9Kz22SZ0WZ7VUL2pDNFRDrDlUQEsD5jMlHeXDZv8Vmb4z1ieY04WkAjE8NDgLRzNtTmV7zrN8tM5kH+jUKBL8VTBwlOPCk0BJMi3ggmsdJ1tTFxLUwMEqowMYxmf8QI2Cor3aRQIkVWqxAgh1UduMFUqCV5n8tHnlysyKVRgBNnyNxfWshCp4TYJbPGx4VVpI07Ewy7M8zEBAgL78hMVUhpmdhZoFi5vdypztD6B1i3v9ps1EPKbtNKfdBqPlD6TVjJNVEvRhSmmBA74kJ+/KTMLczK/NMpZdBOT8N+Nsg4np00CYJLAEBao9D6sFE2D7yjdAgMmszEQYOLHtp7AVzOHU14KKWehE20AIvDfYqKzlPbAJQeFbMByii3f/fdlNgNvSkNs/ATaNdINqeU1dfavDshvF4k2e8qjBGKXcrDvCSj9+czndzFQHAj7ULRqeap/9ydtlMFqlNFs9MFsHRDfyWoB+KTC98bx2qbZzHR+ixITKjYXLDZV16hbjNNE1ALMKpb0qNb0cxRPZ4yla2dvvLD7txZrxFC/iq1IVNdANA0/Ve4Dfyj1qyNnAuivVXZY9+7r7rDb42z7fpD/KIr/LWxQKY59+UbmZQzGoCTjuJQXmLQWh7YrVRFXqVdYS7UDdA1V7mpob3NZ9VEQMns51fVHumxgOHlZsHcJoyN0jvC7zKgAtJYMHe7AnnNIoTNjfssExBcsCmCIK/wtRV6m7JZtPQALQyFveehU3502WWRWDQ7LVmIHT+rGbOdVJcuVOP1yu6EQ3PX1R8W0DEN68LHBcfVTEG0TYa0jhEYs0LiunFWtUBKDB5vFUAYyxjJmxD4POHbYsycnRgREjTRziUmBg2UBi5EGf0g2bJj4vXIVNOpXG5QKXb5VGXmsXIhC1EH5kGd1HBosABxLWEDZhDUbhwI2DAaozgSSoNYYiaoVHhBRXLmXIXItXNQPg3z2cEOTO5YJYekvg3GoSI363Qd6klJWK3V0Ho001jcLJ+s1YOCOUnqRYlgRKWBbZv5vSvhPgS50sKAiYYAwqNwZkX7Y4YF4lYWYJVf+ZXPMh20tw2U/YqEVY5wUGZ6ETZ2EiZ5Wl13S2hJ0FBbVVhLY1hUAOBQfmCqLtNqnND4AGBYHOCoI+qMJ1SyKGX1FmpnjWv3mGpnWaJIh+Rj0wKGLmObhkBKrkJ5/9Z4kGEoT+DYtWpzYgIY0OyWolOUIgaT4QaYfGBYPGD5TmBIW2ijBJwyT1qZrRyKSTwJOkwQQdFn3q39Gd4a/zLUoiRXDsujNwlGgpAAb4X/obQVMdu6fTJ6vmFPZrBZy+D51GC5XeLPRp4VSFA7GTsIM8YEmZAtOjrCmsPfFV4C2LQgfIggv10qwaPcclQoE5Lirc6ntc0g4LbEO7zlqiHA7/WZHIluzJjogWMdm2DECt9SmH1SdVJANQdUg61r6U6ihOtNBNfQJUZTAYpDFXPOwvqNSRNoDV/lYu+2Y1iJAK0e2k4Ind9u2YuBAMUlq2xkWwq0BchlJOoeK6fuU+dIOEZEkxZZfSA+zmfsjRg+VB5L48LLNF+b3mZuRTouhw7iSengo6CVPvkmQNtr4psljKiubO2z6F+7Torpn9iTqP7cWrPlZVk+9tNNWFjWSLBevwLumBMG++SPCnYGh9aBnlLebxlufyRmtyq2d107hllfCKpvDhtmcj2XC2ZKMFZ4kGdzSzTukOd8wPz1cEr/DYIPGUMPFdQvGdfnHWiHGD/5jxVqpxW5gQnsiFovjtIVcQpSDyBnEKbjgRymbyJnfyEQlx/ehtJO/QKT/yKxcAI8fyIwdycsjtLQdzLQfzLQ/u5n2KHE8ENCcENb8LNr9slnBzQYjzTrhxAqlztZjzcpiKPNdzZ+NzcsiLuhiIQA+AvRj0wTD0fSD0RGeTRccPxFgCxdgHSCeMlKB0SZ/0wcB0Nrl0/LCMJcCMffj0AAh1gBj1UteHU98lVb8Pz6AL0AAIV18CWB8IWQ8AWt8HW8d1NtH1/HAN2BiIX38KYU8JYt8lY7+P3eiNgVD2p2j2lHj2XYr2+0COMr+Han8KbE8Jbd8lbscP6kgJcGcJcf83CHJvJXO3D+8o8e2QCnVf925z9/xADzgvj/God3rvtnnnD/lgCX5/Cn9PCYDfJYFn8YI3+INH+IRX+IVneLMQ8jH/7SRfhoeHeKOQeDmg+Ir3iYvPeI0fco73eKC4+Kv4iCdn8pMAppI3eZFA+W9Q+ZXPiJYniJeH+SaXeTUQAJqv+Yq4eYP4h30QCItbBWwI+jf4eWWYh6NniaQf+mgo+sxqeoB4erKIeqdvKKU3BqbvCq2/hqnHkKrXB6/vULBfBrHHebLP+rfAeoPgemow+z5B+3h4e5qN+7R3hrqXB7XHe6DXe6K/84De+3OY+6ANfF2Y+7UHhrYPhNESzfb/ygPFF4e/T+jCD4fB9wrKx4XDx/w36EZeDoSDUfyLceFfCZks0qoiTU7HxwPIh6du8XxAYHzLz6TN93tgWgWweRrYR/1BmKdMuPqmr7Cn2UiBs5tqKgTQ7/sxRKnxy2A3YPzUt+k2UPzgL4Lh98vif6dBiH3J/w28t5fP1AP8KgTxjwPZP4+m5yY+eH7etyTfv3s1aJnjjag8IIJzHgTkb4N/mJQKswIgiDQCDwAhQAA8AoFDAGJkIgHUqqIgZTScgQWA0cQmCIkuIBJAMCPRZKNsxhIMaUYVMBDcqYJBlZFwAAXhtWdYpWZ3uMi4t/BUldc4SVlpecnYZ4mWhGmV/+bJqABKKRl6irqnWQVh9hUWoAXndcSUAFGb1oqgVlCbdMVU4AB2gHWg8Li2Z2q5CjBUdLfF5FV8nCxFGKCwy+sd4MsEjBXuAM3kxEbVXPVMdbT1kJCwZNB25PWIG8BW5qCGCSBkVEYhiBKhWJQi/zgBUGPgCAGDSgI0eNgkwbk77fj4oRJtDzUz4BAwUPbkkQI0Cw5EQFPAyYNHBIOZq9gEEjs9qXr69PSukcMzXVyetAWFixmlENQoI4DFZJRxRGMu1Tap48+tmT5SaVUIjBSKSy7CCwdgH4BWBQBgaeAgQAIAgbQQUZgPgBNFHHk68zq0IKgjCZtE8bI3LbdWTP8QsHVrMe7cutFGzSUcya87r1ToOGmw5MCBswQc7kPJBMqng2fZ7MLbD+PKKfsk5lrGuFNfQ88CA6BI+LEcvbEUz17j0ImDkJSJ5FW7k6v06Zs3TSG6Zp/kO2UMUMRogM7cspgbTnGi4HtWzdTbvwNLReFUKREglAOlFv6+YqOk1DEMX2LMsHfHBRZkgEF1Z0nT2lr/jRZgcSrB56A+T/Dnny5mYBadKpxRwcVywpCGGRb8MGhIIAoIdhBhsLGhxmwEAMKNROp9gcABgWyUGW9eHYEiZrvAl5yE3AxVJANg9ScFAqbphAeB7U0J1IeMIHmdUgKhoc13MVLECWpPOPT/JSnrUTnle67Id6MT3uFnUYWKQaDQjn8AeBWPPe7BQQcb+KfgF4EMsgBw/SgUoR0TuqLfhYbZ2dlgsXV4R1AVtUVcJxJBdoAaUNy24h02xTJSES/KhgYXF236hhRQWSQeX1H6+MegaxUqaX1mJGkclknsBR+kCEGm2qxoHouJpYv4SsUjZkXR1j6WUVHmQZwAeQeZ3ExbipTIpqJmWIaBBAcStahxkAJOOGbGfoaNugCiGy6zGwAaCCBBhlIIwK8EnDlQzgHnlPoKhFcpuhij7To6GrzYqbGOsZVa+e0pvqWi1TsApzMwF0UQeZ6RMlKRJHwOH+PpnhWvfIiyhzD7/wVKBzCgRqeQKNPUtqA4BKq2K+J8Jss+uSx0KKb0+ae+AfCLL8VFY5Kx009PcjEqUU+NsbdYU0n01tNp5fUkXYfNSEcGIgioR2RDTeDYa1N39duVgC03V27XbbTWeANwN9502wvCBx4EuvchcRdO5eGID7i4dH033sjfez8ut+S0Ql7vxD1VzZWApyhQRiGUEo655ZhXQvnpjKueenzHTG265qpLTDp0lHC+1V64N4JFqCqTHgqFgon+td6ziy11KENcJ92mec/eeht7EMBFBApgC62+ul0SO/CYLCFXQsqBiIS+vj/voSNQUs08dZ6Hksjqsjdy4x3C/+bKIuJFmv8Al1KMJr/jVUk6OqLE+0jWvio4zxPdW1v00FAsOSmBAHEBYMpkYzXjpQ8VDgGYApaQhF3EZ1w9UVwuEMCkKRwlNTBxAmK4oZe5tAoUSvECS4xyjL1sqoYi4YKFUpM57+2hfqzIH/6Id4juEGUd9wuiAC8RvUOAgTWNOOAkFsg26CWvIAEZRi4idgQn+c5E3MLgKRrIty024hEFSEikDvKITsinhG37kO3wN5o4VqFIsxECEgwiKyp0x38R0KMO26dEFg3rgIpznauYgpJhgKMADBiFF2wyjDuUB4YSNAQan6g2i7mKOAKpQiQdgJKXFCUCO5QCLRJoiU96zW11oQP/HNfHgPsIAh0LCEyMMpgsNYqiXAg4R3dEcycA0vFypoQEKv3DAM/5zDIxYQCHEKiNofzykEnwH5SERMPiODGNhkADg+oXR5BNxAzNQZFkHvMVI44TlMg7RYmeQMRmhcwOhMRid7DIPQ3KbWwUEctRIqhANoJIRwHg0S/PKFAhXoIBERjOEcrAoDlmjZn6vIghY6FHBCbhl8ooAiDPEq0xXcdExLGmudBiO0OxgZF1NATo0pEeUpCBPvAhjCVTaCYqiCFO8UTi7+hJieipBQ3WC6oRyjXT4gxlU97kx/YCqkVK1BJOEXyJHUKCE0xRi5Po+0sqFtCJsgAgLky4xwiV/7nRDVphXepKw15WqNKRwpAxoZqhSWrmqaE4oAw5ioVEaNaEC4LEY+QLZCOzRYRpjWI0wYnDH9kpsEUsD65NPCpSGxG9e0LgRpNdZEOJoqmXptSqEM3qJBTQxXPcEQL+YxAdiDrW82URisJcBAGUcQDdiOEOGgWmXKUDz7099pSKSUlj+sEYJpjUDA7bg0zsJ0/PfnYRUeRScPFHRX2mITa1UGVqZwTYJwA0lhF1YG/rhsYoYu2xP2Fp4ei7OFk+Ub6n0y/W+Dvf9pJzdvjdbuRqSmAB0xPAkPPv1Bj8tPi+d20FNvAiKqxcBYMSwvnV8NY4LDQJHw/Dy4JlfxGsOv8Hu9bChvPwfyf8NhEnmKOX2B11rukTEsPXxccjWi5J2NlDqMSSaCpAeAMIORCzTMYpRjEmbDwdHC/zuKXj8YoNQVUkBLmoxiGyTUnx0EuM4qrzRJwAKjCANKt5zWxus5vfDOc4y7kCAj6znO+M5zznmc40LtNonEIVTrwG0FOArTAcsL8dzgwWBBGMq+ZVmvHGZoW3QDLf0KznTGtaz3xmcVeutL4tqy+nRgXv5mZWNisXjQJMa7WrXw3rWMt61rR2NQUwwepa63rXvKb1ransZ/B4ZomdsgNEhr3Vg/wjEAUYAiUNkxcFTlo0A0EteLQjF0vnute6loAEuN3rX3v/umVO+6JEJqmkNPCCyEO+SjVI6dwV+a+b4XAhd1DkSVWPe99hC0qwY6SQ2uYWQwcxKCeIcICyyIt4HHrEI9jwJAhoSZyjOxa/+C00oqnl3LvScpPYrTPidec7KhEtH+Pp1gvrG+Msz/iHPFVagBuGE2q4iMxHk2wAeEYjTRjNwjVJBEeflhM0ysazLM21lbc8qVLbuMdfqatCgJzU2EkNybmx1H74rFlzOfDSv964oDDmdTdHrQNEAxBuKMTQN6FL0ENXsE7iqJROQaCqYvY/pKdJ6WDnbtMhwXEvyIFCU7fkEVbLrZLHxkRbjwuZ9d73yL/4iRARKVYrdnHJu+fv/5/yuBQ+5orCdwGxNoMCzlSCne9unXqBzLfmXz9LGJPNlns0scpXlnnY2032b0tAqSGv++CnifefVXGy+K57JbOMDghtsfCf/y3lVxn3yIe99HcM/exzjfhINT4Uq//661cO/NrPvvg7TP3yo+L8eoErOpCAzGN5X/30t/Om74///Me509Env+T7dkdcdgjxVwUF1H6+NSlWNDf+R3+6t23gBoGt5m0RSIGtJm7IknsNaFaVEIAGBFdTtFAIuA4K2C0aaILQw4ADlYJgpyy5cAsn5A0otDCHdoAFmAXIxEf+cR8JoQyVBmjNN38nKIQWt4Ko8IAV2C9FuHRdc3hz4v8gjeFl+vQrcPUdOBgy15OARgIB2xEQ61NxQwiGb5OBA/VtSGiBYQhaFGMfTeKEhLchUFWDinSAfMQhiTFxiKVb2oWGe/g0YyiGSriHyuImFOEsEvRT0BYbBGhqc5iINRJ0xCFbuGVGrseHlfhfgAgUmBiGLfhc6bIubvhDEBOHi4hMg1VvahcQLnUoMjOJwGeJr7h3heOHsLh7SxeEe3iEZqiLu8iLZvhtsqiJYMh+ZHOLaIgvvYiMyaiMunaBKkiLw2eLwQh9s/iMp4MB/jE41ViLLVeMmyiN2vgTGeAfHwCOWzGMYdONwviN5ZgKFuAfIMCOQ8N9JxaPqLOO9ej/CRfgHxqAj+s3j9PXj5lwjwFpCUmTIAQJFJimfwvJkHM2kNb3kAjZCB3ABBkgkbi2jBkJgc14kdR4kWHDAUxgAR9JkmSTixq5axOIkht5kUxwASUJk/9VhitJkxr5ixIpARsQkztZNB5ZfxH5dQLQATxJlJgHlJjjk+WoARxQlE2JJklZflDplFNJlbxxlEl2lVWplUIoleaXlVsJlj9pjF8ZlmX5NhZQk6+mkmnZaiO5ByfJlrK2lnHJjJ4Al3SJl7vIkWa5NhIQAg0JmIEpZyEgAbyhkIKJmIm5kPznDIepmI8JmZrGmHz5NhIwAa83AYVJZWH4SefIjWTJl5aJ/5maOT972Jn/+HzpSJk+IZqal5k0xpkK5pksp5qrmQqtKXmvuZlgeJrPWJu2eQq4GXm6WZpo2Ju0+JvA6QnCOTu+gArEKVFyc1sp5zXHCXvgk4eXp5xhw5yXkAu/dyzOeQrQGUqWsDzSpQRixQhQAQ/qWQkI8HiNEAD3QAdwI5vz2IXv5gn59DlOdQh0AJ7stZ1k052WQAZrNQZFI56hQJ4DZp5d5wnsiQoHQJ2VMJ+Jc58/AWWi4J+owJ/YFTHGNaBbU6CVcKBp8QBQcQTPVAdsF4oMQAd0sAXw0CK28DOjNJ6kGZ2G8AZ3sARtYQBwcBFBOg6fx54G4AQHcBFGhv+eVQA+YyAObFUHzZVwUjAEaxUQbGBLTZCdqTZAPoElLcGDSNFc5sAULUQENLEiM2RDp/hCQFR748AkR8ZAoGmWJUoJB6ouDUAG90AAUgGff6pAgDoHKqSketEA6iJvaKURbhGflNCglHOeQceehypxeqEbElqpbjAzBQCkp1UFF9qndxAXuNCoVHCh9bkAl0ShMeoW+BY0vKWh10FI2AahirFOrFEkIvIAZGERfFQ/oiVlZTWiU4OnV/R5RoAp4CNdz4QAoOEfD1Cf7QkBMuQf9SANC+oJkTphPapJw5AhccEjmgquG9FQzimudyCqmDIqoIEiqRoAdGEWzTatDwD/q14XTLPaCUNxhzu1Bt9RMl1wG1o3BdWiPlDAVMNap8VKopdpT7eqqVIxPWMgsToXr1QgGcDQaE/FAIDwqJPArZjgrQrUFodagJnKGptqBJ2aBOkaqn66rAVnEWTAI5Cgqpc0n/V6r16ar2BKq9dRiIJBWf3ALQGLK+E1TdkGdGxgIgq7Wwz7NMfaCCfans3EBHxqpWXaANNKBQ+AavPxAKSXoDkKm40wqUVwpHAwF0gqpzJxpEm6pC0LqqgKs53hBGWwpOmAE1eadrGhs0+7gZvzs3LEisogijhjtNBQLpGmVze6Pt6VBE6rnVArNFLLbyHbE6uqedb5islJuYtg/7n7hrmnMAQUurkZipx2WpahO26ja5qoC4ue+7mGwLqe5rrGCbudq7phWbvr6Z6WgAW/iyy362naigoXWmaf5gnFpYj0FGaxOrsV07u+1RbG2wgS13oW6lbIewnEOz13gAUYGxBHhyzcOwnOab5VYL2GkL6cuxqLwLzuB0rPyzmyG71VML2HIKGYsL+ekL6Y4L3wkABiBT7N4gWtkL1T8r+LsL7+W6HuK4eGEL8G9rz4er/fwpx9uwBSahIxOrNSUL1JoLYrkguhIqVvILcOQAaEhTBNwKxxcQ/lQElburFU4L0RkHA8EgHwebG7BADmK2lDKqSOWgAaERAvSsMfJP8FeiJtTHAFSZCz40UQzlnCI/zDD5yhPzYOkATCxAALCbAiyIRJeoKmM8Gl0OBDBYMNaPxuk/QLX1AOPtgFT4AuQERokTsFX0Q7F4wmzLkAv1uqdAAM6+qo3NFUFaqsgpTCNBtNfHqqV0y3ZNCx8OmqBYBvxPsPmqQRVwrJP3x0eTwaljoaRiZbYvWnxlaoMVwEC4w/KYe+4XGhluyoo4DI/dPJevhp5vS+dxBH8lKyODczYGV5ylEZuQIbR4sQwhEZ2bYfddGFOaMAZ/dnUTy0BBBtX8jH7cGcCfAs7Tqt3sqevsAAzPoAI/utirxWDSWh3Gyv6rq9BtDORiCtFxv/z1VwwzksSBmiF6oBxPTZUOEqntzspNH6t6xszq/8t74wsuOcrO2boTfFpd/hr4fyLjSEDBmCtPsEFuBkEniCVrExJAtDJ4aRGJ7yUNsUC2UnEXdkvxfsxwQss1t7saPwMyE8BMbWq/8robK8ouvsyDXLzxGRAB07Bn97BwH8VOrJyZqLwO58BnNhskLVCX88qHxR0KrBep/gylAMy11bBL5AyyBRHAiwylj8pQiU03NRWi6CiIgBzEw8zLGwJMbs0TLVKCOdRxfizJwUI/uj0i9FPC19vxl8xGyLt1wLPggQwn1bD/PhOxJ6W2qgwpgi0AGDEzAMGeEAo/R8yTpa/56+NQ0X27fkKwUJQJ9qW8hY+m4oIdNefdloNT1jgdCcXcglHBCN7dADxFyn91yFAcJ2IMb3QTyJSzA/RzB3rRBa7BhmVDNysSJ/jcfLINjRm7/bhdSpwMrSEU0JjCwQLHkVDLjZPCXV/VnXfbyI7GneHXngPbnirc0Om5ue7aCve9a66959DN/DKd+zmd65a4nTPbvkjVTm7Z3C2xPBqz8XWzTqTQkfup62Nx2ithUA/rkCTk8EbqAGrr17gL2HEMWw499i1qHI+rFccT/FtQdvIVTlkyGhQuGU65eRKeP4R5hla08aTgnp27+GwLUhFuKW4OAIWOJbIeGH4GxfQP9tcZe89+0TaImXcxmXblmcqbDCU2q4DMDBm31bS4yxVmrFH/4AlC3TMloLYMwV1umCeL3GN7UukJWlcEymtgFpZaymbEwS6sYuhdUWJQHcDXMfskJt0VZcL87kT5mVHMbISnrKD6EbgXwdOu6etgzmYi7Iv0EQhXTmIX54x+x2OZXRemUAzTwzh0VtgWBtxBxZuRJd7OIFIKTMU0gXNTzQf4q8g767hZ6JdYPoYs6skXUfrU2309MWDI2eky5IwD6ptzplsvoV99HRBhMvFf3pc1LS6kUbcwxxGi2wIK0hhdBT0NVxU8if4qG0So7LuD471ygF2Ug2u37si961Mc3/tV7Injf9EGVdnweKpMCuqPZ51oP4IHJCbbRXezNSBtlAJ3WxKUxyDkZr1wojeE936sDcpXCgG7aO7tsljlJAju7FFT6ttYYNKwoOPuPaFoyN7/FqijkC7GCb6Wd9LgEPH4yBLpB1d8rdeZ1Qd6cu12Zw3ArDWOp0gKMSSLXAIxif8UjljlIAjx5fiQweCht6B5XnE0XeHoSe9Fuhj1LAj07Ph1DvCVL/RkSeXd1961nfCAY5UKj5emA/hFiP9j5BkQFgkWLI9qdb3/999nF/CCEZAFLe7ncveW4vhHDP99gdAC8pho45440v45OZVIzv+JMfmZB/+JiTk3Vzl3nJ/zRQzvmwtpeNsPmfT/rhdvkCJJRjefqrb2BLqfqsD/vo3pWxT/sDqu5MwO61r/uUu/FM0PG7D/zFuvRM0PTBv/ujX/p5Gfphs/VM0PXGr/v2R/nTv2mWvzZqD/27z99NhjhzX/fZX/vbT4+F4/eAD/6wL/4AWTguef7hL/gsZviNkPntT/vp32Cqm/r0H/v274RAABAOiUXjEZlEDgRK5xPq1HCiVesVm9VuuV3vFxwWj8lcwYBICKwDC4fQUVgf3t5FAAJplwGIgMKKiW+QsNDwEDFRcZGxsegsLSACAOIggYEh4QCCcuHrjtMxSVC01PQUNVV1lRUKckhtEiAigP+gIeABSUFujeFurcCBIeBAjuFhDk9hT8EvIFgvAcBgT22NoK8Nr+FgDuBOgYE3gZO2oNtTiLSVvd39HT6+9VUotl6SFvtIE7DojmAYGzWeQC3zpIkBNQTZDCAzYC9BAAfO8BCr8+0PqEwHGOQD0K3fuiEUBJQ0eRJlSpUrWbZ0+RLmSwryaNa0eXMMPQD2ZtVSk8vIsoWwIq6JMOyAEI8F2wgFEJDBzwMLf7GB4KcfsjUE/3RjkA2CR6zqmjyqMABtWrVr2bZ1+xZuXLlz4VYoixNvXr17hei0V+nSRk4Q0gnhJ2RZ0lhI702SA8EgAIQKhXSrtRMXkbFDGHRzAE7/I0Kxf8ga0ckXjEjUq1m3LuWXTZuvAOLMuQhgFxtfa/wcJTZEzlRlzJwFUxpA2j02zUgvm4MNnDje5S5vVg3gtGst17V39/7dS3bwUa6LH/+E+3n169ebZ3+kPJr3UNLPt39fr3v8AOLvH3XXvwAFhEc//PprBJRW6huQwQYdKdA7r5YAsC/5hKhKkiGu4g0MUPQoTAzGAqHQwRJNTESn2ojRB8MCZlNuqxe52IwLEYeQED4SdUpQjQKmCQCBNwiQpYsEWVnwxCSV/IKejQD5ByNOoIQlQ57ewdGIAy/EQwg/GgqgAV14CaAzNjzRA4E0AdCqG8j24GarnnJRA6Bf/8hByhha4jwgKemQ48SPX/Thj8QlDT1UC3puAcoB5KIE4LFIJvkQTzL1vAwzo6z5EyMF0PQDAQacu6anc3C54wBA+HwqOK9245RQ0yx8NEoaizjs1gAM0IO3gaI0yKnFVtUkykYviQ1NIlYNjSMvqUmqNESlndYKejyqjEwMB21szVoCuibDx3wtosdO9fBRjkET6wkbzxb9KCkovQLF2GiJ2JHLbBS4I8yggCTiUjw+PA664Rb46987kJnEMt1+Y1UgeD8iEyysbESS2oynVTQz2hwFRWFyY8NGxARpicBISsak6o+B8/ksto4u82rgVcfyquFeYn1kVh6f+THInf+IlCzVe3z0cA/MHDM42AypWeNJMDl7WENHl8VjIwYsphpjjb1essnDoAxNaiqHFtEecZOe2ACnwHG5FnktnZnMmpOKdN6yh9ASo4iF2PBfInLrxQ/h8lg7OD/c9ATOjrNJ51Vi0GYDAU5W9bNyfS8u9OvODU2RlwNY5FIPOswmwkY9RYcxAmtANXePfBToBgGvPKJ5j1UdiKh2MiOHlm8Gu/ac+AEhtC/4AYcvnnn8jp8veQGXb5569p5/L/oAp6+ee/CuZy97VZxCZPvuzXfte0ewLCR8rTreFMh+AF7DgCds1CXwQ8o/n3++3CPAMsYZFTH6RQRebSsJtjrC+gj/kb10YcZH9hgXEYoCFC+MT3+c698GtWMeX83uEk5Zlz/WkJwvMHAQ0auXYSQiwQwZEEh8+oo5uvEAVKmqT+PghAIiQru+PUMYxDBG484EJFB9pQFFAdHeNMhBJ6LGPBGpAzIa4BTKoI5PiqOEEZ9hjYIB4lIkaxWZNkWOxymjOEEsBjEAMTjjFCF6A9sSBOC3RIwQAEq3k8i7rgaBrEVEARi847f+8K9YnAtStXAKFbPUxCc+Ei/isVEsBhgqkR1sD4iUQwPqBY604UFuLyoXRSAwGSAxxlcIeRccdTSrIaxQMi2UhBqG8srY/EuPDLDbxL6iuN8EqyiSmNykgAQ3/wLA74VE2B8kmTkPVw5BikKgolASc5tYsoEjA9PIb0DDpZPdrG4r0xdu/gWV33xogPljoqyQ8MByfdKCmElHRAyQy10yqzMcUci6FvOwpkXAmIJsZDMJmp9n3sMTIBSVIdVJjeT8Q5tY4+YfPgkBvJGpG23712ZMGapz7kET1lRmK5PgPqDYo0wFjEgoaPEAe+Yuh9PZIpASxhthUq1xuTAmAJLot5EWFKg3+V8A3zA+P1jwDrKIRkT9OFEwPoc2vPOK6zZKGtykkTEDG9za1skzEy0zqGFdRPrUE779gFWsaTUEWc9jVgM5Uq1xZQRbx+PW+6BVrnkNA13BY1fkwXVVr4EdBF+/41foAVawiRWDAM5CF8c+FrKRlewA7GKaxk4Ws5nV7Fwqq1jPGoIkMRHtaElbWtOaZCZFCO1pWdta14o2tZ+V7WxpW1vb3ha3udXtbnnbW9/+FrjBFe5wiVtc4x4XuclV7nKZ21znPhe60W1eEAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000 I-159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Narrow complex supraventricular tachycardia algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 609px; background-image: url(data:image/gif;base64,R0lGODlhLAJhAtUAAP///wAAAMDAwEBAQD8/P7+/v4iIiERERLu7uyIiIt3d3WZmZpmZmYCAgBERETMzM39/f8zMzO7u7lVVVXd3d6qqqvDw8CAgIDAwMNDQ0HBwcGBgYODg4JCQkLCwsKCgoFBQUBAQEC8vLx8fH19fXw8PD4+PjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAsAmECAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztH0ZAri5uru8vb6/wMHCw8TFxsfIycEWtc3NAyIE0tPU1dbX2Nna29zd3t/g4eLj2SUCzuiyAwXpjgTn7fGr6/KL7/X4pvT5h/f8/5/2ARzkb6BBTAIP/imosGGkhA73MIxIURFERwgCVDpgYMvEiiALXVRiIMAEIQk67snoh6WRAAiYcPQIL6RNQiOTGHDggAGA/5R8XAbVSGWmlo83k/LJicRASgcSgCYIECBBBAABGCRYwPFAAgAHqB6QQOHkEAMPiCh4QHXCWqoUAGSc6mACXABOHQR4IIHl2wALFCSIS4HvkAhsTSqACUAr2MQL8HIMsJgqX6ASHFT4G/kA5J9UU05ejODvBAZEF3TuOLXq1axboSBVSvsO0yNOMy8AOmQwVrOeFeBNIEHCAwMVHADgCmCCSiETDgyZcDKCAwQZYyaQjnp48ZQsJ0RW4CAC+QkJhJ9NK4R0468HqgeI4DTmkMUVnA5vPr78AekZKeBSfULAFN0Q3S23GhG+mSTFbLVFKMdtRuhXUgAGSLAAVYBhZf+fUaoJYcACEgRQwQEUMFAegz6h1OIBDLg0E0sGSAfWAiy1RpVPqFVQhAJ2PcCAe44ZlVWNQkQQ1o6ZISAkaBwyMNNiAhKFZIEIJNBiY6mtpiGHkTEWBYQSltkGhUXoB5oBqEkAwANhfqhSblF1NEFP1ilHxIHQyYcdUTNqhCR5MWoknlp1pYfbV1mBBV9HFVB25QJplejTblDxR8SUlGXk5pUe8ikXZWut1uabcT5Yk5msvoEmEWqiZsBfsYlpFFhifZopnD8m5lZiccnYEY0cnuRXYpQBNYFhIkaJl2XwcdjRlQjoNZVPi6n0F2WcKmBcVaDCZBquDvDKEa2pjrn/aqvsqvEqIKB+cWskZLZrLxjv/hGvF/NCUu+9AG+Rb8BZ/EvwwVQMjHAVBi/scBMKy7EvFkJ1EW/FdzT88MZIRCzGxLjZuAWNIkMBsmREYGyHxhy3PITHYZycZslZqGwyzWeVbDMdLLvcMsxfVAYYalSN56tTU/HFHFhx2RWAcq1ZhZVWOOqI8oY7IkEBhxGASXSHee3Vl0ac1dGzzxsD/cW+bYrqlLc9UUnl20Y0aJYDwwpaMqVImJhzEW3SCZ6h/V01x9loO6y2F1cygKxgW16pJVgGUBBZiEJ8WbSHAFA5Kso7hdbUVCQ2/viVB+CokY6NHr5u4rC/zM4caKEU/1ekQIosuU9Zrkg3l27yKibez0qGHwAUfNW1fUX0VPtPt0sqHaHhRZbx67HDvngX1gF24VQKmLa7EA+IvKQD6HLO5V5641rVV/FmZpkE3S/wvaTFfr6tenIgnn3A25NDk8LwAOZRwn//u1cA41CYeCAwge1aIOweCMFWSTBxFKygmS6ItgxqUEIc9JkHP1ibELpshCRUygBMUIAWuvCFMIyhDGdIwxra8IY4zKEOd8jDHvqQhiLAXgoXpoEBGPGISEyiEpfIxCY68YlQjCITMRACKVrxiljMohYHkIEhepESAhjAF8f4wTCS8YwJNCMa15g4NbLxjQ8rIhWNyAE42v+RYBrgUABCcMc+3ksAegSBHwfJLj1+gJCILNMAOFTHRDpSKR2gygUeScmbZIAqGqikJkESggB4YJOgdMgGAsCMUJpyIB/AwClX+Q8ONICVsMRHKWNJy1ra8pa4zKUud5m9Wyjjl8AMpjCV0UVe9nEAGCCHMpfJzGaGw4gYEKMx7zgAIabDjdN8YzX/gc1srnGb/OimN88IznyIc5xjLKceImWWP5wTnV5UZxEihaEk7aVZccmCXXy0J7+xcw1dY8/WnrOEd8IzhfLsZ1XsyZ6S5BML+yxCRP+phoBOwaAH/WBCM8cTtvhIL1S5EFUkoJW2IC8AB9DLAuyyIrYkJj//HGLPsywTqQe49FPSOumdKCDSBFSgROWqinBK6qB/2iV0VIHptDj00CJgNKMV3OiznOMgiz4rLhbdEAMGCgC9KAA1kWGLeXjSHL/100eRkk5YDOBQ0Chga3dp1liexqUDZDUrRsWQVUvCVgcp4alQTaBUWQeVvQYgLiKFC1f1IoF/irWrAZBARM8KgH8O1GkcqgBXK7sksdE1oIk9bF4NYFgDTDYJgA1s9jY6F+jodaHPioxVhbDYyDp2Pq21y5Zc6xPLYqgk1qNtPSGLgIACdaqzrew9j9q1rzyrr+1EQmpVqz3s2SWfkfqK036aGJLqqHL1ZOxtrXWV7skUAOb1/+1SubbZC930aXoZy3tyGpYEsMVOSeXrTA8rXWlSF6HWJOB80nDcM0z3vz6Tqhgei4YCm+HACP5ZgJ0B4QinbcLNqLCFFYe9tmbYvxsWbIcP62AwMFa50TWEhkN8sI16mAwnbsSKWQzAVRFNL3Eha0/RSpd7ssVpHUGMWIYK0rowtWsnIep5t5ZSwLD0KiAt6l5uut+O1LZ7wnHAV4h6kpratKt6GsKMaazAmjT3qmCGFUpBEwGLsuVPUINKRvjyNP6dGMnGNUJtv9qh3sAkrbjqa1zAd+WByuquDKDnPclKhDGTOYI1+WdbyXqimHZNOW6eD1AtWqLIYs1BdzbJi/+JUNvGOgiuSVUvZpN65eamVAKhpQBF+/vo1dZkzmgmq16Ku2g5+1jTdE2Ar2UqP/JQBr0myXMRSs3Okkhnn+oFLqn5q5erLEk+5501o8UM4loneFVwZUuOlePee6qIfWkR63GFjFIFdI0qxLsQBZA833sOgdkm+VZQK6De/c5HMCittnIHXG8MaTvMQnC0tzeIYSZIuxQKXzgIG641DskX4t2W+IW5mXGNc5jjHneZgtER8ZAnZeQU7rjJCYbyj+FMCztDQ8lXHpKWa01kKpKCzNQnJifY7Eo7z8LMaV4Rmx+ha+pBkc5fPoSeR+HnTP/C0IkeEaMf4Tidm8/XjMb/IQRsHWVDkMD5Pk2auTzNaXFZmpZYsnWh2Q9AeunJYzZnhalTvSFWr1Ba4tU29vQ8cDqLbNPtA5Ps/IQ7GlF7oYgAeBFJh3gqEjuAjl0Fu9/9IHkvQokiMDnHcQhyWPI8VRSwr60RT0yFB1TelmOjtWtE9NJzvOewooBu1V3ll7cgxZGwrEz5BnfUQXaWokf6lyPdrKkXQqD2U63F/15SDX38tKBi+8rjPvcMt0KkrHc/d09lKgjo/sXAtJzRJ59y+ktaT4hVFcrUD0nVeppPqk8Fy2P/H5mfAtI1Yf/75yP/T5ARIbUJ/ed/9QCArlCABhgPCNgKCriA6dCAI0MU/zJ2fRB4cruXBWzBP0IQc1DQL2/wgBf4DBl4BdWCdSlDgYwggiNICxIYBSvlGHJhNWWDNGLjPmMhdvCGfuzTKFmSNQZmgS0IEi/4BJnxU9fRVat3KORBH+mRGQxAJ8fhKUMwE/WkH3KXHDInhENIEUXoBF8DGJ6TI3oUha3HAJgzIidFPFYYE1ohNKMXhF04cWagdKOSGUulKX/zE1FIHHVyGNzSEYzhGHKnBiw4h6/whUywGIbzE2xiGWRzOmeIg2OzOW34HjMoOnKIiLShiKdwiJzICp5oCqAYiqowihhnihgIcqpoEwPQAT8Ui7I4i7TYQwLQAVzYiv9QRM7Ui//cIAIl4IvCeA1HlEm6SEkFQADHOILJuIwXWIrO6E3QGI3TNI3UyEvWeI26lI3aiEvc2I2VYAHDNI7kWI7k2AEYYI7quI7s6AuNRI0NcAFbNI/0WI/2SI9zdI/6uI/8SI8X8ErX2AAACRDfOAkCqY0HORAFKQkJCY8DyYr50JDRKJHhlIuzQJG6uAEDcAHyOACzhA8L+QgayZFG9JGqOEocMkkQKQ8oKUnO6AF6tAEEaZGwAJMcIpPLaAF69EkrGQ86ySE8uYwYwCEmWQ8h+QhDSRVFqYoNQBWqNJP80JQB8JTOCEgBYIw9GQ9WiZXOSBUlKAtH+QheeY0goIIV+Q//ZamNHSBICkmTsbCW2pgBHWAQYekIctmNS2mUbhkLeQmO8lCXflkGHNCOhBkM78h/e+kGg1mYjNmY5XiYsdMAIzCMlBkOI/CQmQCYSyCZldmZnvmZ1XCZENQAEMAIEICZmKCZSkCaDXGao1mai+CanKCaScCaCiGb/2ObioCbiAkIumkQvBmZsLmbqHkJtIkEvzkQwQk7yXkIy2mcidkGzfkPz4k201kI1VkJx3kE15kP2eky3UkHIHgE3zkJ22kE4VkP5ckx6dl0ayYFRmJATzCeRrCekXCeRdCeXfBprTMEHlgETlchIDUBOGUZHFgG9vkw+ul4U0Cf80lQSZCg/4+An0SwoFuAOUfwn08QKdjyACehJg/QVAhanNY5nA4nHUAxNwmQNAWKIVHCGEsiXz14Kc7ioEQgoY5AoUNgoVqAoZ3jK1FDiXPmGpzjNAg3AQ/VNbD2FX+IBjiKMBaKJCkqKU+IJz0Xn1IoiNPiXELANzY6BE+6gtHJBjyaBfzJAKIyIH44hQMWfDDxOwzyHHNDfmkQpgQTpSjaEXNzhjKofCoBE2mYKo6BVI/SBHaqCDoqBGWKBT46OR3YJSKiOiLCKAjgo9ORpJGlH3xTpyTqMxbKHKnzLMXnIstThfn0pn4IFIOYHn6TPOjHBIeaCIkKAIt6BT6apoInOAbgEv/CE36KAjiNshYf6ly84qSdCp4mmgR0ERMCuIHjI1IRQDSoERMx6iar6j4r+qpLEKuIMKu1agVnahrfEi0oVYl7IRwwuoOwMqCf4lyCAaFjwK328q14IK8qNqZrQK9poKF7YK/soq924K+E4K3Jmgf8qgcCyyoAWwcJKwgE25rH2jILSwcNGwgPe5sRy54F26DwegVfSp4Ze5/4qgYTu4hT0bFK8LEhYzFR5wQVKyHhGaBIoLIfKIjyqQQv604jmwYlm4IMSgEtmwTzEnQMygVIQrP1GbIKurGD1wRI6wRPKwQ56wcXywUY4xwcCytBW7RbQLTbqrQO051kFzVXAa3/nrE5mKEZP4ghX1cjJQEkOSUuMeUmSDC1fVC1S+AUlvFSjph1AAcuMPJ51bpfEfBp8yenYGK4mfhbKyo2S6N0Rio0fJEdR2Jx6Ee2Lgu2CxOz8jkYpap8k/dVW/YVxAOsSxoTdHOJ7WFWINsJeEsS6ZEtrNe3VDIgarWlxXEcn0sEXkpQ+8I3pTsccDMkpEKlB4ofGRFkjHG0BOUbhqq5UMq0WAIAmjM0XIp+VNIkQjJ7jSGJXWo9bagkzlK30Cumvim9MzO9UqqnnWIlt6sgkdqneAFShbqHhMq948MRlgO/SdJZi4eJKMMR1RtcX/uaSuA3pwInu2t7aKEnwft8/6PqHX8IqJXSn0nrujuLBgt6JcurVpHxtlTIvBKcEp97PK46tGlhwqT7HOPTO2X7q3xjKS7RNVdxIByRwASMs+V7p+iLNeljtuwrHCWiEvH3W6ERe9TLFlpms/F3LRG6w4iawWewwTbSwaPCPt7CFqLxqoNrtqFRv0miUkuSrUXMVpP4JuYDb02cFUKBNeVDOenzvAb8BdVCt2dgt3zwupEwQG2Ax0nRs0UQomrgx3qgx5DQQG5AyDYByHCgyHhgyPzgyCDByG8gyXYAyd4JxQBDyYmsyd0qxWbAyahgyRQhymxAynSAyfiAyg5hymvAynKgyurpyfNKArV4y7VIAv+0fK++acu4/MvAHMw/pMsQ9AH9yEQkecxMdEizCcplYMzKHM1HlMzSLM3MzEoYaU7OjArZHIrdrJcG8c2IKM5auc2nQM5diM7XZM6moM4t6M4pF867fHfw/GHy7Iz1XAuzSgj57EeL6ZjmuAEbANDIAJm8fAj/TNDGINAKPY4GHRLxWM0SPdHz+I+LsM/c2ZEUvdEc7UQWTRv9zAoh/cjszLPzXAojHZEnTQopfcklrcErPQotXQ8zfc4xHYIvPcU3HQo1HQ89jdI73QYYjZ5B/Qk/7Qwj2ZF9CQtJXZKfjAhHLdNFHQstGQAqiQ5VfdUHTQhN7ZHp0NVLbRA2iUn/7TDWAYCThzDUQ5DV7ZBHKXkTP0kVQekMce1JsprTZGDWaO0Mep0USUlK8fDXYU21eD0GdT3XzXDYSeHWVJkOUtnYW00Igh3YRJkUVjnVBEjWd30Ijy0Pna0UYykPof3UKqbZ7bCVnWiW6ZCWUYwIo90Or20TcFkPs73Zh8Da8oDbSXGX9cDbtm0ItR0PuBghgz0LxU3YiODb8aDcgXkHal0Ex82XzV3IhU10Cd3Q2P1LD1132a3Q0Q0FgNXd4s2O350E1z3ej0kHnAma7M3eoskFAdDe8l0OX9kEgBXf853f+m0OWbDe+g2a7y0HrkycXaDa7lDfTHDf6eBBA/7K/5gtBQ2OCBVr4I2AQo0mhBQeCwyOvoQAy8jJ4aEw4QeE4AWF4QtO4hUK4oLg4dyp4p8g4pNg4dzGBBkOCxvuCCyOni7uCTAuCTKecCaODjfeCDmenzveCT1OLyiOWkHuDEMuniibuep95HlLFXAQtQUM3yMudU0+BJiTHHTLiGeaWFHuu4zxF7s1BjJbhdZTdnpEM0++KTmVBvMigyXCPLxxow8eBZ+aw0Rw59pKBTaz5kWA5Tpc4IFA6Enw4wCg4EWAoYVYOz6qJjqxHQhCFTERfJFix2p+s2y+un9yoEMQ55+eEY1YhwTVp4dyhxc8B32eBF3jpyZY40tg6E+M6P9RwCEJ4Omdri5cTuNGgKFAixIdMenXu2wOEBhDkByREhOaMb1V+Blre7heMS5OM7nsUx5kdwShmnWhjgSkrnzW0xNdkR6fcW71dO1jkxE5hxdpoe5lNYAIwqVgvhwpJrV7DgWvPh3zwzpAaO/KRwE12LiXERqUO63xjj7XOhOYCxt+nuVbQOtH0Cg7oQaKDu5LTmtLoNoYqqR1XH5RklhFAD4pWBqMgXq7FR/IZh29pRzB0Ry6YxhsSq3pwu16lHpdVwThfiNcUnsPIBxM6B8PhRbBs6v1BIVdFYUyz1aKUufXqxl8XARFnuJPgKFE/yZGL+sp6G6UEfROOLwukbz/WPI7RALG0PMbU5DkTtAox0c1035SVGEen+G2KAUcAv8Z28Lri57xR+DovEvAx4E5xp4EFJDs6sGfMPHs6qP1WXHztacSjgryReMSIaLo3e7moi4EO++/r8o6McIWdsWfkup4FfAVoo85Tk9qp3HsYJrvT7Dvkg8YwmIE+hsZnr87YU+BgBpcZU85A7z4UKD2TdAou4H2SV9ZysG6Xk8gAYJ0Xs8nF38EjO73Xk7AeWEfgw+7JeMemi54VQgplFGIWu82zPI58GtWO8Hpl596mQ8Am0/ARrHqEmU/5S8UiwEUVz+p35Hq1wsEkcDDADAejZAGktl0PqHRYwMiRS4W/0fDQ3JEBIwHSpPhcCAAk6z2YEwwvt3vMYAwJBR0BuCQ4BsYAroesuqsnJQOFY3AFhkDAhIiAAwVIC8V7gIWJBIuAxgM2sIMKLI8LxneGNEcCQQcFwUGrBqvPhEkIo8WPkP9rIqOLNEUHiD3kA4uixBQ/Q6EjSEn0lLnALCyIRUmhI8O1oi/8pxeY5+onMKVpY+5lyMnJ65tsx26rJEljh0SvgEEYgbgWLkmidAlVKROUa9LCOghwyYw2ZEEo6ZxE+WGAb9I2CihiecAgAFID6AZyJigUKtYCBU6sacIFBJDABxURJJTDZKNRsqcSbPGyIRqQlwqOhcTyqxaTKEeiv8WVYoEfFCXQmVIlStVmF2ZbgU7liy6r1RnHqpJp5UzSAmsnpSQMUCmUW4wvqsbwdOxpIeygnUqJW3ZmFMNgw0cU2xix4iWPHbUWHJlsmejFra8eTHXwVE0bxbtuHNCyqPLYkaN5PRq14pUMw39mmzpqJ+hzKa9G53tWK15M43tGnhw48MV6jaOFRZZ3E+UL5fexPfkKtOjIkddnLbJ6JK1o/uO3VXzsc9lklcfpfoi7uujhBf93smCu1AQI1ak668UbD+5ks+RtPRD4oubXgMQMPMEo4WwAiCMUMIJKazQwgsxzFDDDTnssAARGGSMBA9JLNFEC0mIzDj6FCrQESH/YgFpLAEXIRCgI4go6b7k+nPRCQWtaE8h9JoYwMgjkUxSySWZbNLJJC+44MkpqazyyQyo+sDKLZeMkssvk/xAOvoi4qKXNryTpCRmUpnKuwcmGQIZJFCxT5Q3Lskiowme2QgBBwLIqaQE+srnEBppasJHnNAAMiEEY3GUvRA9cxA+KxpQ8dJNWdOUU7De22KQIkSJwIFJKJgAKXCEiUaISeyjhFRgjMDmgAcMCkiQCe76rw0HiihDgjsUsEonKRBVS1FS34rAoU+IWqAaPsYoU4Iv+nEWE1BYcvMSvoqwxK5t5oymDyaETIjIT6fwlF34Mn13rPee3URHgd5SpR1S//QFwJmQAqLV30YQY0AvBVaptRFRxGVkXAASPtRdqGw0FdVqDAGSHCEy4YIgA74QqSVGpnUVwX8AEFfBBR7gA1fqKKVq3XfjlXfTmm2mKlSP2bD4iFXDGOOPV9Now5B+FSbFjTEqqItXLwTRESdS8fkpYiuSfYqJaPDdJeMd/zCFXEgWwEabm27iWmCUVUYT0F0WTRedmdnFOWf17L6bseukiKimjbyzN/AIKPJ2iDjRQHpgpdeMpK49PfqnjT8D3cPqY+ObWLZlfWarpJaZCKpRnhfPppAKWCEFaD6yMMkuS1CnICVzYr7N0pw3GMDLASzQW7rcd+/dd9P4dsSo4f8dyZqwZRu31xBT7aXzLr/haEQbh4hRevADC9ooHkL/oL0sujfd4JMLkDdOg/PTR4fFIwIRqn2sNY9pPL3ljoX8Sz34ZIP5d9O/S/wPgAspXgG7ojzQIBBm47udzSzwCQ8wcDURvMQEKRiF92WQfmO5393y54j9XQoDlxAeBzdTQkicEIVM2AoFSBeTP+VqeArMTQtDKIsH2qwBkMBAC+fjQyA6gSEKcEAe+sUfiwACWgeCBJrAxgSALKNWgFKTZSDFBBtCZxFGxNw6hGYgSPTnMTlUxAjhIwBIaGCIllFjANjYRtZcZwFCQ1pPBiYBxZEDCbqgoREk0ItvOMQIwAL/AAw3k0UkbDE9DRFawihwlzIAwCp/yRE6frIoKZjxEGiEDyRqJ0cPBiCUKGRIAlAXsCNU4CrSUiXUaHjJYSzAAWE8JBHAIAQ5zERONXFLTbi1gD1lpHWEGkIgMQEZDyrCEvlIGMeCZgSx7YSMwYjiIjhpBU+uBwQfFKVCuvnNKVynLkARmAMqUEld5cmJN1kAQCwhsEEpIBCl4yMdqIaTPbCSEtN6WlH0dCpiGQtgT2BkE75jMItUJEeWmAQA+MmLt8QKYtXLlr9QETg7NQ5OLiNbA52zQ5t1AATifEwHRDpEhpTzldKcQL/2yFJe3EgBtAwjKr4VNRkBjByfqMtN/yKGU1BcrqDKBMt3DECUiG1BakawBBMMQdE3hIx1U2OD6gIAqzYcYHIyNUI2pbBN9WSgAyZ1DFnNespUKk4Il4xpLG8ESEEioZ5WRaRN0CA7feK1KNMjSlNXEYBU/vMIB4WqIpK60CPogi8VeSpfpVo9I2ChYUbIJCCA8a+pVPYIYI2CWNXDQrOSRbRyZEgdgfKJIhQktez0qh+jAJC6Uu6KdHgLGn7ph5sM82BExZ78Clu/5ChCoRxBwgQecBUjRNRzd/BXTsyWBUNaFnQmm8dWw+VVAHi2KSkd7XfBa4QiHpErkqJYNbtSAbAZ1ibMjBrEPgHR6EnzrwBD2BCga/+9LFAuAAaA3kbfNInNape7TwBteBHMwRfGUCEzJIsiK8NeOiwCtYdQZ3AK7IQRckAAHfbwh0EcYhGPmMQlNvGJUZxiFGOpCRZQ8YthHGMZzxjGHCjLBk0qYUZ0UVBWEMNyMtyEETZgBAQw8pGRnGQlL5nJTXbyk6EcZSk/WQQiFUAJppxlLW+Zy12e8giEu7cEQ0HHlMBhKWMy5AOOWQoFsDIB2JyQMot3zVcFyzKuudNYeFERDu7gUc/swEPgOMFu1jCc4/ySMCsEOOZVy19YaSi86tkRFWZHyurQTihKbJkoDDIT1JzoQxhayIgWNWwWTTwoOLoWf2E1pd2bj0v/j+O12jVqV7xps08jIdSnjgKpQW1qXyMr1e6rs2WN6TFrWUIuIfNpOZjNrWaFZA6RdXYopg0/0FUV0wi4J47iepBi1yjQIR30sYcNAGDzWtjpNui4rbNqPBhLVB8bhmC/IIwsAikBY8g0GKzdXwD4LFU+IUo8HtLOVrzzz7gu93m8O0d3O2HdRxBAuyeuRXi7B92Xq9cCIoBwyabOJ21A5kf/nY1RTLURXRNYYsMgjn/TkOHE9uCJcJ5znINI0JhC97ArboSLZ5zMGzfgqlceCtKxjJKgAIlgpdiGQAyiJXNw7p9G3rnQbXvWM2eCLIs+FjCN3Ui7I/vYWQzxc28K/8K7CToAhk70W4Oq40nXh9Ot6HRbYO+qK6k6GO6b3JE376/NjLlTvb5YW4vbd3nzXa+hBheVSwGnEyiHKk6CXpp4O9dQgDUZ5KnuN3+q7byZMwAIvZ4KI/aaGm+80dcDeYWxZPJRWIUC+iCBpiWj5vbTvGQUZ4S3x50JX5A8RZ8Q7QCEEfND+H2rP5+Q6NM19EmAvc/nx+dD+NnmenO83mQ/sEAgIFaU67FiC1mBCdhSit961h7MhQe9cD5l7xgDyqxSgV/C/05lgATIAM/+BqVQAgJshg/jBob2kM8JGgYBHqAadm+ywm1Ans8xgi+4buznEOz0NuP77ib8yKEPYv/FkISFTirCXL5o4BSJ6W4lD/4p5Y7HVOzAD5xLUPipBakFatLgKM5goASFAQxw9JrgC8av/ADl/DCtHHRp/VbN/VLhD/qALugvI+6vCPJv/6DwDd4GAOsPEsbgDggQCN8tA9ONAy3DA3MGBPfiiSrLqyIGnfAI9HzibWanolhhDhLmADriDB6AAZSvLhDDAQPgACIAD5NBD4lKvZrgAJ0gBLvFqkoQ8QyiDvTwCVaHF1oGB1+Q/mKwB2nQD2yQJHDwx5KmE2ewWH7wmk4v9UTJDCsDDW1GDfPgTKzKAJTLuHDPD5pGGHoPaGDnkOowBmHwKKIqAa4CCV1EDeZAGO3/wO6egBGHcA0HsQ0NorKWsL7g5+XoMHzskNrAIA/30AH98NkC8RgI0RDDIBTsThHnritYUY5cUTJgUV5kEdMm5wiPpfLywRafKCkG53vqkC/kZAoFENOEIbe48XsKMQC9ELAsJ/SgsfjKiRYNyRYNpQEJQb548Rt8Eer0CjGYcRmJEQ0WwBi7ABlvRBnBgBmJKnNubER0LiZlciYvJEVeb37CL+MiUozywBLusXKQQPm+gR8H0R+/BSC5USD9Yg6oEPEO8hkSslmYUgCJyrnakSu05Oy0skukZCu9Mkxusn1ycuJ2Uu4wsIXm0SxR7/rIYyzdrSzVMh5XhC1PLS3Z/8Ut0w0uzVIug8Mu5c4vOQUveYPV3E4I1fIsTYku4wx4urK0YjHixoksKGAtokCTLKv1eEMvH8MyWwQgFGT6SkfRUIgxjcQxzdJ8LgF9kEcwE8IquCoqCJM24FIC/Ib9pCnbHMbHJvAwPPM+QBM0r7KAUBMSVPMwkUCAIIGAhoc10aEMGkYThuAdUMdwOipw2uD9srApsSVQJiFNHoor4PIBPMYBnUBVdtAm/oh57qw3xcgKgJPxOAg54cg4mcCCIAGDlhMy6WwsfsxN8MASiiBWrEvlVmVlMvFlTJGqwoHgpgU8DdMIdIkJnuE7D6lBKSE9//EdsgBfiqlQtvNUMP+qXDzTGI9pKhtyT+YAXIhJR1xnkRRzU+wzAPCTPo1AhQLANOlRP1FPA/fsE2hwFL7mD/rFGfoFcLYRMcAxulwOLMryX56g37yAvOplEJFgdV7z26bOB6tHZPbqBkdUAjqBC02RsL6AL9CgJ4woAu6gP/hyN2wUR82yhwLgh9KHOR2BqSgJnX4iSAeUV4iGV37xI4UhJPVL65j0QVUwV04uelSBQi9UDlklCQ0GEy4nuv4Q99iTddCRD1ShIr6gltzAFySlTWljfeaURkFtjcRSR9/RCVBmsrwBSBsFuzgKVk5iq96iDrVTvwjvUA+tCcQzD8QxajLyViQtN5nASrP/C2GYpi4qlVdRsuRSJr/OEynItA4MKQ6byvVQ6I1elM1AaVXXTi3hEvcgoZb87lLpAEOPclnTxFmTLrpCFG488xKqwUSXrwsDYAJS1AGEqbeiiFRpI1xRFQnCSVyxj1wRNS6/dVMGoPN8jaRwklV5VNQ0k+gE9jUktmCRAK0QVgpadbQuNuMy1jU8lmOPAE5zdFxdo/QuZWQnrmRdQ2VRFvwo9jHw5VWnIuW29WUX1jgKJDZj8zIatmaNVodY1jCKdLruEGJfA2bFw14bMTqCFjMvEzVk9mgL1k6ZAmmYamdzayPeT/n8UEMH5SSk8zGgNhZ8KauiUSoyNbasNjWK/5bDaOxu8TZv9bbD0i5l9/ZvATdwT8zGtOlmLZBW5gBsfeUKtk1U0FSg/lPgFrAs1nZA9knyvPMZoo3BbuWj/AQf9TVWAwYBVjT+wELCiMzLVHd1Wbd1CaDKhAzLXHd2abd2mwzMOslwE8NrM7EIeNZI32KyPEao1DF1hpYpKrdG7DUCGHSnYEcgoIEY1fRXggUfCEsUDMYFAyrkXuZ0izZkzSroiM845YNrY2Jp+c8bu4BhPNIPkE9b93RW1fZnZSMZkMvlsCHknnBfKEEdqXGpACWViJczFQJ1KzbRxBcB5a58dVdpLyEPfTcXjkFy+CBX20klANZ45xYqkpcm7P+XEEFUYbqA6XThWKaiacalIq33LrZg/IaCf73XHQ84zhIYVRk4aYmug9XiEqozTyKHtigzDAbic4FyTzYiEMoWEwhYzr53htmshmn0hhPWLHU40Qz4MKGYPqUYZJ14zKo4zq5YYUvNhlPNfJ+YfjG2idmuAkcji8m3jBs4h9GYZNVYjI7Paivv8lDhAdg4N+ivK97zAt34MLdYg7q40OY4OI73NcI48rJgcpvg9nIvArNhNzePNgR5h8b3k/p4NAoZCsDXpL74ECYzBWH4RzaYNhpZYYrwJ5GwG3FC/WxTC5xQRKNw/vC1CvNU/1CB//rA//orlwfwmApwETUZAY3/b4QxU/mYb487WSb+mCsCufoA4JPT4ZARbJSrwgFeEyoW2TVWeWBycQSrV9IiBgUtcQUP1AVlVSQHzhMHpUtF8WVIcXFMUUuLmQkGefYeeZnLyQEhcC16j0cwmZqtmYhgkiYVeqEZ2gQSWSGcs5ygUzwhYTqZ5XCa5zqfMP529aK8k2hlWCIVQAimkaXcsCLgEBvNaQ6DF0mTIeXAsZL68FLLcRAXshsRcR2DcIyjsZWfCyjvTQl3ZZYtq5ZrgqNxmSHzFf/QCQvjD5i5sCnBkJjFMDiFTEez8iu1equ5WkniKNjKoj9nRQEAdPIG1D4K9D5YEEF5kPNEhkFBmisa/4OPKJJqzHkPclEjJfBndqt9uZFQq7UYj1EnkrFsVnIkW5Lijnlqx5l6A+IWOYsSU/AShddl2LlpqxWea3Cf5jkP6tmdZRCfqxo+w0pHtXaTqUL5flSDhTSz3gAYgJdejYtTldRH41pnDoiPfPKnX1kfLettDsAoIUF/IyEg+yLlmtIgawUq80MqlfoL7c4qkWCfxZmkD4AagxpCd0WlW6okjlQYEgamDzEcZ5ocD9IcbxocE1EV4VhrO0mBmQJP8y9+paZPCdFtAdWvQXIko8tQZ6SOqXixo3EWqVSFL/KfM3IX91q7WyFQg5G/D1sFSdIk9ypSj8uwA7sZZzvsCv/XvbUJvmPiVbNBdAHGey66oxziAXC1uLlxVyerdfLktqMilMWJunWbSs1PJ4RSC4BbuLMKKRFDKZG7IMt6XutQIYW5Kg26vT38s0A8ZgFc7qh7gZm8yQ3syd0tnHVSwLW4yq2cp7s8pNXjm9uYy984d7/8yslYzMGilHVTbtdjytMYzdMczM9crrE5ClwzleFcPeTcOMgca728zoUOy8swyqkiovNgotOWOrvzEjTaluWvIT/00eXBV8G6LNxcCjgz0D150AkdtfcS0aNCrOeprAXUv9wWrYMUEy07s92adeC6K/48JvYcNvkcnEG9zkWdytk8tW2bvk18SF/7aon/sg6TVL+WlNbNvCsU/Wyjs6LDJ8Ayemx8edLztdIbp7YSaNfTvNfnHM/BQr71VFbrW9Wv60+vW78HFcJf3L8d1M67wtSJBdWxi2hYXX5dXRPbWkFBDkQL7r/pnNAtTgQY+uARniZtUty7QsSlRdhpldpTfMXBBzFc3HR6ldnlHdgfuKn4FLOWu0jdpqXBe7xru+MFvsMJ/ggyoKtd/uW5WkwYPsA3HjZBZ77N3cTVXd0d/K/d3XTgvdsHfuWJHoe3vOahwuFJ/ONrlVxUvIJZ3OIFUF41Ssa7q+ixfoqlvNkZduiz/uslTowzPcxVHuzNfj/Fnt3WvOzPHuxp/Jtq/z3Lvb3tV/7tRSnuXaNqrUnQvZ7ui74BEjrhBX/wM8Shkd5+pPZt39zO+lw0DtrvCT6rYX7yKZ9KvtriDN1yB8ZRQ7My4xbp+J7tIX/0zRLck+Ny17dZNJeHj7VzBceV9+CXDOCIE4B0zdZ0hV70SX/33c30H2V5m3cmnrelpXcjSBAfmBZ7EXR7cTCGdZ/3oV/UfF887LcPfTR/RW5r9M1/TZqz+FGAfWGJzWLuo7/8w2v62faDtS4OsqFlSlj75SuF7Tr5rf9M/0r8RfP5zX//vwsIBAQAsWg8IpOAADPwiAAMzYXkEUggHNcA43hoGqIHQDbg6JYDBsOYwVVYmf+KQ1hpvxMhDTxRMOADBgoOEhYaHiImKi4yNjo+QkYWCklWWi7qAfpdcnZ6foKGio6SVlKWokZm8m2mur7CxsrO0h6e1uLareK15vr+AgcLD/cNEefu3vUeMzc7P0ML3oLSQVYXsRkhBPBtGybbLUePk5eb004TSUw0USRRMCVAFQUo8F074otpc+N5F4JTIu4cwYIGDzpKB+DBAwlkHiSZAGXCBCP17tXJl3FfkX93PA4KmGQgwpImT6IEkC5CAIdGEsSbR4RCRXr2kEhhEuFAnAUA3DDxaSABzIbbrDiAggAmFwD6hmoxyg0OE3dUA0zwFiGBgatC6VwsIhIJyZT/Zs+iPZZuqZ0E7ohksbegCZMxRVgiKHJgzLabP1sOVSDhzLa8B3yeAVDBgdONQyVI4OqNIoAIDhBMsEsmwNa8E3wqSDo075GxR8qmTa16tauVYdXNDUqEgbwjr4vQNlJNQT0GceplA5CAwb8FC3jTnePY7mFvw4kcoN0Frpm3TJkwCF56D6s/rL+DD/9JIUN7CB64cfjAJ0+XFv3eDUC6MQDeCtwqBm53eHHE06EvVx9h3FCGV2YdyedAGJ8ZoZ0RphmBmngTUlhhIArNwYQDFFyVwHF0vXYbNk3sFIZ9OcGkQHD89WMcGUwlQN+ITFTkzVVWxZEVN5Yd95uKmj3I/x0v3llYpJFHnmYMkoBAWISES0IZpVkKSbmdJkRWmaWWJVG5ZZN9YLmlmGOO06WWX6oUJplrsimMmVmi+WSbc9KZyptVxqlmnXvyOcqdUubZp6CDgvJnlIESmqiikBgKJaKLQhqpIQKIUICll2Kaqaabctqpp5+CGqqoo5IgpDJ6SpqqqkdkMICrr8Iaq6yz0lqrrbfimquuu7r6wZWrAhussHIKW6yxa2owAAYhuMrBsc9CiyxdIURbrbVSCkAXCNdy262FdPnqrbjjqjZAE86Sm666JnXAxAXrwhvvORkwoYG89+LrTAgBeJCvv//+skEAFgBcsMGwfIDBwQszLP8KB6Y2HLHEkBA8scUXY5yxvxYI0LHHH4Mcssgjk1yyySejnLLHGWjc8kkClECAzDPTXLPNN+Ocs84789yzzwSIgKrLQ5eppJEFCE200s00uhrSS0Nd9JJPR10100YXSbXVW7uJtYVacx12Lk2rBrbYZ8tCdmpmo922nV6bI98ibLtdtyhqK/EFExulIrcidNsdeCd4J3HYZjL1PR8igAveuCSEI2E4AGfACAUXHpZxxn3uUPCAAQ44ZEBDejN2AFOmm2FP5UsofgjjjsPeCORe+OSGX/hhRYSCP4Ee2gQJqN4Fi+7t9VdeXL3kjt+JvB6784jMrlsTDEgQWwA+yW3/HxEXuVEBEWxUECMA8OxezT90VD8F63Mn/bz7hESvl0+ztbQQ9qTt/rkEvgMPwGCeG4ElytkMgNJjv/X9rX3vWyAr4FYIydUnDh5CYOYYcJ8FNWR8oNuMbMzXDzp06H7sYyAJJ+XAVOgjFc0rIQsjdMJSVKB+sFhhC1sYv5PQsIYlvKFJcqhDBvIwFw4yhA9/+L4gWmJ5euFbEoZYiCIa8XlIrIQSB+FEQkAxirEzFDx0soD9EMcJV7AcbRZQOQYwJgoQYYcTJHAUM0TAerwpYzVywhnknWgM1usCHUzHhyxq0XGGCoD3iPBFIrBoIhXJXfIG04UziE49BiiMU0S4/4Sa0AEvRcCjfoywAIjwBD52AGQgBWeooVyvemD8x1DWlz7ZgC9G1rtefxDoNzrkZpMm6uTn4iGjPyqwlFJ8IRIgGaMshJEI61mfAZfJG+RFEkGGxF4hb2kATUJHKPrhjfcoEKMUjjKYwtwiMf2nhTbexwkDYsID7JE9Cc5vARsEABu5UMvY8IY0dSTRNsT4I6fE45tMVAIpx+m2G4KEIAU1KNoQ2g+DLJShYpsiRMUp0cBRtCARvejWMqpQi3L0oOV8BDgVUdJGbDSkUeNhFfM20ERUo6UjVOkRR8oHmUbupYg4KSNSSlOl3VCOq7PjTnoinDAMpgJL2RtQricGKf8ooJ5hkA9y2jjTnzqPpa1zCzadwpfexCg3uztCekYThf7FdD7cvCpWYadV/1lvAbkEUH3qMZjzWPA1vmnCPwHgIvrIZyfTY2tbG8dS7zVzAV3dzUVEl8axCscdMezrYyIzVQR80n9NSWBhyckIfMIzCiRirD0koAa4nHMN8eik/5CCPPmUASb/WRxIO1s1jw4iC+6hhU9tizHcCuIBb8FFb31rMeCWo7jGlRhyyaHc5TasueN4LnQXJt1oULe6BrsuNLKrXYBRalTiHS95y2veApigtt/VWKt45d73KotZ8J1vruy13vsS6776DUV+9+tfTvT3vwKORIAHbGBGFPj/wAq2hXoX7GBpNPjBjsuAyips4QsLoAMYwDCHOywylkl4XMqiL4lLbOITwxcDEQ6xpAYgAEklmMWpcjGMVyzjRdE4UjG+MaRyDKkd83hQ7Q2Biu1LqA7E11UvDvKxQNQBRX0AROhicrFAQBcQE4oDdFEYlY3VLiZQa1EYaIKRuxwsejFhW4vSQBP6ZeZi7SsA4VKUB5rwZmMJLABTTpQFmGDjO7cpyu+KlLkgBuhUabnMimpAALB86FVdwM2QykCYHw0sDVQsUhuwdLD2DKlMczrUonaGh0tt6lOj2mOgpliqW31qR486EgH4Ga1rbetb45rWJVjy42KW618De2dB/4t1EulEAF4T2KbH8G6sH8qmY1uCu6Fg9qidvSZom0LZxKC2qK1NJmw/TtvD4HaovT0mcCe7osSmorGRzShxe+KKgiA3p739V9POhyuzzA5ddOqYd2KHGjqVXD77WZcjoPvdTWxCTULhIO0tJCMLaHgR6G1pe8+PnvPbRvUyflY8DEUzQPFMRWK420vwlOCwFVEREv4IKrXygqJ4eFhaac5CGsHij8Z4ERbjkIn71eM2f4cDjtNzB8QwL0jfnuJ4IhuvPLUebGQMiiLwxqQ0dbbyI0LBWU4ElycEbjb/DBugysaGRCBHoh3jEmjzBaUAJiZrDwCQII5v3iVB54fmef8RkH5Xv9KF33Z+yW0Kk09bzvYAFWFJBBgUmgiYNTBEsAwUaEJJw6UcRAgweBXBLjuxx8gy2cGCGiUpurskZXyLxKRPPkN51WuS5n6ZgDtKqndA830mE8jlX78nPqIbHfB0yUI1m16HywU+OL1v6hVqmfL5dV2ULXf3y8WuPuXT5TjsQA/zY+S3uPSGLsMRn+yPDvEj3P7Oua+ME+rQ+4/fIeRGODxlTK6bMEyWQdiwi+Qrk3rqTJNTvIX+6Ab0rZz0fR31hV0T/R5HRNMRDMXr0UO+JcAYSCD7TUTd3YYDPACQ5NyfrZsS2NvwLURY7NvQxd/8Adxm6QUYRBBfaQf/6czdAtQSUDDABPCNym2e1wGA5yEY6DWIZtST4DWFHVmS8XyP+sRGB6pgE4wBPGhdxYFgCCKBuckCTzXCYJxcIfjgIkgbKKTfm1lhLGChLHShInzhJ4ShmY2hlpxhIqShJ6xhl7Vhlrwh9MBbMMwhldVhldyhLeQhMOwhk/WhlPyhCakbFT5CAJxXIzriI0KipoiAAspOpUTiJT5ieiniI6BYJ9IKkXliKL4KrD1Ce4nirCzLKdKKom3iSfjYogBZKy7JKypKLMrikdBiotjiLRZJLhLKLvKieAxZkSkKkqWiLwZjljgZlElZMq6JlTUBKfKJljUBlznjmHxZAFRa/6KMWb1cI5mgWQComaKwGRNI2jduSZzNWaLUGROgI5nkmacNSp8FwBS+Y2oIWosFgKHdY5QkmqQwmjT2I5REmqRQ2kCKCaalyqYhpJbIo6KsWkNKpDNSmKtZ5EWmWkQaAQdgZEd6JEby4gCIQLCRZEmapM/s2h00wAicZEu65EvuTCGG2gAUwLdRIhE0AAQkikxyGk3apErqJKHwpKX55LndJADk5E6GZE0aJVAq5S0WpZh0YVIK5VL+pB1Q5aAM5aNF5TmwBERcwlQG5UlIwXB9wlYeWlcGwjldQRRaAeIoATyEgRZs4SF8JSeI5SKwhBPCpWmlER685V02QlmKAv9aAppaAgJdRsY8JQJdNoJgWkJeKsJdHoVeOoEjEGYoGOadISYfOOZbwsMEbAg7VJ4LxhBDeI4a1BMFaAEUOEADSoDeJEA3YcWGbIUZXKZg0Z1gmMEXrANnGIJkJsJd+qVf+qYDMEZsxoP3WAE7VABpsmUMHRMjTV4cHABvOoBvAoUWuANt0Mj41CYFsATFJcJmvlln4gFdhkaMdFEA0ARnEOYXVEAMsZMUzGX9wAMFuMFGOOdiSkB7ehNn3GUCgI4bUAFd/CZcBoJwIsJdusEEmFYTDAZj9CeBVkETPKeAXmYJVsBcKI6FHkWE6sQViJZ4XuZcMACAjmcjmKeZoef/HbDlAZRmHZCmc4InBcRQTdjn5NQPS1QgY/KoehCSXGoWY3zlXjZBQ5gBIzCoXdIFhPpl3zHGZxLSWxIBaQqmFIgmWE7eZUZolOZHRZSlHVUFkcqaVRKCYxaBmZJmfBJSjibhfd4EG3kcPRGSf5opcrrRZRKoX4CpnSooIDSpIUBmkUqpnVaAf1opoProJgXcS4BOiC7pZkBEWRaqma4oI7Rol72oHajpTJwWoIKnGeAfI+1oTkiWThyBcjoBbdYBfVoBROgmVvwpaQbnUWZlg26oOkzq5CSn3jwAcwKnqLIRbTZgddYFdq4pO7nnT1yHAWAqdSrCplJZp8IQ3QHD/6DigpkSA7UymbWSgnxmK66O5S/oKTN4a5CB65Foa52kK4+tq5G0K528643Fa5HM65zUq4zdaykkVCzkayfIGyI4SELhlEW0TiHsK4uppZYikk79RTxkhB1NAAIKgjcMrCFk7EtEYcBSrPSh0aNCRxTihAcuQsFa28FO4LSiKTYgp/BAbC59Thh4ExTMQcLm1sISwnMgHLneQc3WxwEkrH5GwV86BclCoMkqAsraBs42LctCJVNiA1eADjSxE+LM1ektnRJMnXDI3eXQ4HXsQwXxBtxJQNW1nYe0J+TxhRYkhtM5lXAkbL5ubRHskREshm6Q7FKpwVAUxf4k6Z4ihf/lxEEXQB3KWkFtyI3eHIBDdK18VEFFnN2ebgPSLkHL+t5gmNE1Aech4cbveQMP9l/yXJLuhAHGjsHuoFFstp5ipR5NlO4S4Fw2qC7oFE9fyC0S5CsPZhbXzWbE0sURQFZgOFIRcNPlYU8YtJLjiQaQbIMisU5lec7oVqnyZpDnbAPEXm7UQmCM5IQB5BJbfC42QERiJEHvvZJTZc9FoC7E1QP4KUD3IRAqUQEbuO8Aac8DzK3PeqrW9RKJ+p/WRQcSnN+KMMCsJlPQMVOMXAcXMO3HycdfGYBxeJwZgOUs0WAf6qyENaz4wATnZqARyGxieFNe3OzU3kRiIVD+cAP/7SrvBhGFBf4f0wlvdqTuC8fmLllsD/JvXJLeHHTP+HhvbXgByQ4vGGWWaSWwi8hNbujf9zhvPyyTfFQWV1Cvb4zBAxIQHmzwg3Uw/Sjv1YpwE/Cs8F0PfJBOCCEQUFjB2LrtdLgBaRihK51TQ2RDBdGH9rDg9DnlHcRVhlwBAweeXuxtahlwbNlTi4hQblwFa1EHO7mTYdSFQ8gg5DLEb2LHv1Yh5rphDwtKFztYv1ZIwLIJKC+YKFMIKa+JKSsYKk+IKpMJKx+YK4sHLKfCA3+ELN+BLg8YLRtCVTXrLw1CGeKlJ1tDkiKgykIxP3QDL4sgJ1+C9pwHeTKDLT+Q/08MxkApM0cAoD84cxJ8s3/5ciFAHEvk8Ny1rRlYEH50zjmL0R53gjUTguE83otgh1DJXYMQaBvZSBzgCI1oBfJMbtnx4CKE836NMyGcn3xkEiHtQ+3ujwP8jj3ElPIeazH3sSTojRM8UhfkbRW5RVWpSAJAhmQQyOJdxoFQR2eUXsSZVbFx7yeUc0vgEvldZ1hwj0MDVl7MlSfI8zDPjxQgqRzITfrWaXA0BzfwbHSU8TZsiCFl38YaNDRbgjQvU0OHcP70jkSj1WU5ayj8tCBIjv6Y7/YgVv0sUxAKSDIViHyo9GZkgfW6h1RDrSwm9CAAcx1UQ2xUIBm8scxNwP/oeHVPx7MxkxQZowGMCJ8aNwjDEdCNvCBWaEXR2Sl20HV5UnUqPPEvhHWVHLR+3XUjAOsOz0JnS8ln31doq4ZpRwlqr5dqpwZrQ4lrfxdsRwIxo4JsLwlta5dta9ZFg7PT0lUu6HYiWI/+0jAhaHLfZDbBPsBlLAJul0JxI8JfzUWgQgNvV5dv69v8oA7dwYQDRDJA0Z3juuDqgC0ewy1oGNUjUPch9B7trY9Urd0TbANzZvBZ/S1zx3QjcJxueRUSvhYCSO8adDXpMhJE367UgcYMM6lhh0LvZQMVi3djMJ5fjcFiHAjGAk/xooJ2Q5dt7xt9nM9lSTAFA4hRr8///ZJWA1vurWY0KcS38mCWd4Ov+IjvXDgE6iLSi3cCiC8XbCfV94DS6X7QZVWxgZc0+KK1JWn1OdvHZrs3hIOCdV8EFZO0ZV34gYTPgnNEGZMCkBsXbKOR8XKGB9HV4k7yhb5mV4TW971xHtdDI5M2F1L5Jxz3PFiyxNa31XFGZOS3AfO3XUvtlrx3JUSGj+eCmPuWb5/FoUOCEz4Do9uWo5sFpFcIpXeWpacEplOIphcWpwPCZeOCpz/CcgcDqLeVqCMSw5lHC4/BNUj3K7B2UyFPEtJInXszNzMCqR+CqmMVqwuH4ZrOXMe69pb6nQPCCNNsbZwwIqA6MAD7Twl7/xkjHepmXTWcUXLwbRdswfWwU2HHeCFkbfniHBJ0LXqXEd/Cul+rc9luxtl+bRmt7R3H+XrXdStW+3/QAY/L+kbgRzZNjkczxmmZkQIcXlgqOx/MVeha7OhukvLUxO7wuIK37uvBLiPp9EOHweouuK7vcnM3grUrVbv/u4pXAWiAyOEFxzYrQq3/ntYiLfrG1YqzL6zfL/zKr9/Q79ne9E3UA2lhdn9XwnPMwXTuwwG8BS41eRVkRFmvT8sLdyPA/PeQ8A8LLQrTj3o4eRhzfNE6RAz7H+JUESTdMNgLPSJMO01VO8PteLvbIAjBE5lunmLLjdRjNFaWK7kjtt1OAf8aa4ga+w0btzseI+EM0jE7+by7v60ODz2hX6US5GqfrL1KCXtJmLp4VH5IXT5CZH54bD5Hdf5BfD54hP5Fjb5BlP4Wk4PLb4/IL8mgph2fEwIua+bUN/PTBsLpS1TqF0SThkZQU3MhRPsxuP72Qn5T6j0EcmkLlvcSFO6owidfiC3U9VED4jtBA3LjVjZjoPcODq7Xst23L+Fj/4ZnKL4d8D5DDYAJYOL7w//7T+K4T3D3QgYAnVYrbbwLExAQTBYAhSNyeCgAy+VhAogEIoYEAkCVSB4GqpK5TFAAAQSCDDgMmeGxAbBIKBRkM2ByWJINDwlg+wUMABwkLDQ8REz/VFxkbHR8hIyUnKSs/NIYyNTc5Oz0/AQNFR0lLSXNOGyAAKQCXFAzGDpjSLhKCFiQMDiYU6q7DQhmOHADJM5j2F16XYplXpJYCMYdKxN8y5UOlrVSrv5lyEPQ3ja8tkRPV19nb3d/h4+Xn4dUBSx6uprAkkhwm63FxEEyPA7cGBAk5MsxY24qBFDgjZ+/LksYBOjzgFsdbBczcruC51vCJ1EQ7OnD5M6gc/RcvoQZU+ZMmjVl2gOE4EGwPweCHegDUIIDnrrwXAywk8jOYAoYLpx2UCSan318BnCggGmCjddeaQ3GtVpIcXUi3NppZcK0cA6sBLIZV+5cunXt3o2E/5PuU7yEKkz90rLvYMKFDR9GTEjvXL6JCQl2HFnyZMqV866yTBhyZs6dPX+2uxi03M2jTZ9GnXqSaHre+jYWx6i0atq1batmbQn2F9c0d6MpFuitotm3jR9HHjm3vN4zf+8+s6h4curVrcddTggpNSo8mVYAfoVnBPE/37AFfiAOUzFU0PZZmzQlIAlXHQBAQHTgdgbkwh1DKCnyoiPuOgMPRDCm7AzxqIs53FgAD2KiIC9Ck8hiYoEH0EjCjpLc6mKoZPjwI7gvzJjPIAAYcKA+E9/YcEIp3sCDwESmSzBHHXdkZEFAGGAKIm/OUIYYWpZAIIEjyTKAqABqYUjJJv8IAqO/aaghhAKsDOglD6eKaTIs4JZMcizpeEQzTTVTwUwRNh6KSCQiJTSAQjsOsPOOOcCjAMpiJihJD5GUROmLlQaJooiDWjxAjD0B6BO4PGsc7sY1L8UUTR95C0tIObuhs7wHKuRJwrD8XAKsANobNJz4AmirUjPKyQ+rcJAa5tTwAhzVzAIzBTZY6zZF7C+7cBQ2WWU7I3bZMZyFNlpm25T2sWqvxfawZpdFNltvv3VpW2W7Bbdcc9cRN1lyz2W33Xqo/XZdd+el15B0hZW3Xn31bYCEAv4FOGCBBya4YIMPRjhhhRdm2OB894W43Q9Mobhiiy/GOGNOIua4Y49MPwY5ZJFHJrlkk09GOWWVV2a5ZZdfhjlmmWemuWabb8Y5Z5135rlnn38GOmihhya6aKOPRjpppZdmummnn4Y6aqmnprpqq6/GOusgAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000 I-162.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Stable ventricular tachycardia (monomorphic or polymorphic) algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000; 102:I-163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9481=[""].join("\n");
var outline_f9_16_9481=null;
var title_f9_16_9482="Treatment and prognosis of cerebral venous thrombosis";
var content_f9_16_9482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of cerebral venous thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Jos&eacute; M Ferro, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Patr&iacute;cia Canh&atilde;o, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/16/9482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/16/9482/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/16/9482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral venous thrombosis (CVT) is an uncommon but serious disorder. Clinical manifestations can include headache, papilledema, visual loss, focal or generalized seizures, focal neurologic deficits, confusion, altered consciousness, and coma.",
"   </p>",
"   <p>",
"    Many cases have been linked to inherited and acquired thrombophilias, pregnancy, puerperium, infection, and malignancy. Infarctions due to CVT are often hemorrhagic and associated with vasogenic edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment, which is started as soon as the diagnosis is confirmed, consists of reversing the underlying cause when known, control of seizures and intracranial hypertension, and antithrombotic therapy. Anticoagulation is the mainstay of acute and subacute treatment for CVT.",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of CVT. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral venous thrombosis (CVT) can result in death or permanent disability, but usually has a favorable prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early deterioration and death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients die in the acute phase of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Most of the early deaths are a consequence of CVT.",
"   </p>",
"   <p>",
"    In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) that evaluated 624 patients (age &gt;15 years) with CVT, 27 patients (4.3 percent) died during hospitalization for the acute phase, including 21 patients (3.4 percent) who died within 30 days from symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of mortality at 30 days in the ISCVT were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed consciousness",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Thrombosis of the deep venous system",
"     </li>",
"     <li>",
"      Right hemisphere hemorrhage",
"     </li>",
"     <li>",
"      Posterior fossa lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early mortality in children with CVT is similar to that in adults. In a European cohort of 396 children with CVT (median age 5.2 years), death in the first two weeks after presentation occurred in 12 patients (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main cause of acute death with CVT is transtentorial herniation secondary to a large hemorrhagic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes of early death include herniation due to multiple lesions or to diffuse brain edema, status epilepticus, medical complications, and pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to be able to predict which patients are going to deteriorate after admission, as this will occur in about 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/5\">",
"     5",
"    </a>",
"    ]. Neurologic worsening may occur several days after admission; symptoms and signs may include depressed consciousness, mental status disturbance, new seizure, worsening of or a new focal deficit, increase in headache intensity, or visual loss.",
"   </p>",
"   <p>",
"    About one-third of patients with neurologic deterioration will show new parenchymal lesions if neuroimaging is repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with depressed consciousness on admission are more likely to deteriorate. Seizures are more likely to recur in those with seizures at onset and to occur de novo in patients with parenchymal lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main ISCVT report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ] performed a meta-analysis of seven prospective series, including the large ISCVT itself [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6-12\">",
"     6-12",
"    </a>",
"    ], and found that acute CVT was associated with a 15 percent overall death or dependency rate at the end of follow-up, which varied from 3 to 78 months.",
"   </p>",
"   <p>",
"    Mortality after the acute phase of CVT is predominantly related to underlying conditions. In the ISCVT at the end of follow-up (median 16 months), death had occurred in 52 of 624 patients (8.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of poor long-term prognosis in the ISCVT were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central nervous system infection",
"     </li>",
"     <li>",
"      Any malignancy",
"     </li>",
"     <li>",
"      Thrombosis of the deep venous system",
"     </li>",
"     <li>",
"      Hemorrhage on head CT or MRI",
"     </li>",
"     <li>",
"      Glasgow coma scale score &lt;9 on admission (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental status abnormality",
"     </li>",
"     <li>",
"      Age &gt;37 years",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These predictors of poor long-term prognosis were validated in an independent cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ISCVT, complete recovery at six months was significantly more common for women than men (81 versus 71 percent), while dependency or death was less likely for women than men (12 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/14\">",
"     14",
"    </a>",
"    ]. These differences were driven entirely by the more favorable outcome for the subgroup of women who had gender specific risk factors (mainly oral contraceptives, pregnancy or puerperium) for CVT. Women without gender specific risk factors had outcomes similar to men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intracerebral hemorrhage present at the time of CVT diagnosis was identified in 245 patients (39 percent) of the ISCVT cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/15\">",
"     15",
"    </a>",
"    ]. In this subgroup with early intracerebral hemorrhage, predictors of poor prognosis at six months were older age, male gender, thrombosis of the deep cerebral venous system or of the right lateral sinus, and a motor deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, several studies have found that a good outcome after CVT is predicted when intracranial hypertension is the only manifestation of CVT at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/1,7,11\">",
"     1,7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with CVT presenting with isolated intracranial hypertension, a subgroup analysis of the ISCVT cohort found that poor outcome was associated with a longer diagnostic delay [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ISCVT study, complete recovery at last follow-up was noted in 79 percent of the entire cohort of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recanalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few studies, available data suggest that cerebral vein and sinus recanalization occurs in 40 to 90 percent of patients after CVT, mostly within the first four months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/17\">",
"     17",
"    </a>",
"    ]. A systematic review identified only five small studies that evaluated recanalization after CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/18\">",
"     18",
"    </a>",
"    ]. In the pooled population of these studies, recanalization rates at three months and one year of follow-up were nearly identical (59 of 70 [84 percent] and 60 of 70 patients [85 percent]).",
"   </p>",
"   <p>",
"    The likelihood of recanalization appears to vary by location, with the highest rates observed in deep cerebral veins and cavernous sinuses, and lowest rates observed in the lateral sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/17\">",
"     17",
"    </a>",
"    ]. In adults, limited data suggest that recanalization of the occluded sinus is not related with outcome after CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent CVT is approximately 2 to 4 percent, while the risk of recurrent venous thromboembolism in other locations ranges from 4 to 7 percent. These estimates are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that prospectively followed 145 patients with CVT for a median of six years after discontinuation of anticoagulant therapy, a recurrent CVT developed in five patients (3 percent), and other types of venous thromboembolism developed in another 10 patients (6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/20\">",
"       20",
"      </a>",
"      ]. The risks of recurrent CVT or other types of venous thromboembolism were 0.5 and 2.0 per 100 persons-years respectively. The risk of venous thrombotic events was significantly higher in males and in patients with severe thrombophilia.",
"     </li>",
"     <li>",
"      In the ISCVT study, which evaluated 624 patients with CVT over a median 16 months of follow-up, 14 (2 percent) had a recurrent CVT and 27 (4 percent) had other thrombotic events during follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"       6",
"      </a>",
"      ]. The risks of recurrent CVT or any venous thrombosis were 1.5 and 4.1 per 100 persons-years respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/21\">",
"       21",
"      </a>",
"      ]. The risk of venous thrombotic events was significantly higher in males and in patients with",
"      <span class=\"nowrap\">",
"       polycythemia/thrombocythemia.",
"      </span>",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 706 patients with first CVT who were followed for 6 to 297 months (median 40 months), CVT recurred in 31 patients (4 percent) and venous thromboembolism in a different site occurred in 46 patients (7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/22\">",
"       22",
"      </a>",
"      ]. Previous venous thromboembolism was the only factor predicting recurrent events.",
"     </li>",
"     <li>",
"      In the European cohort of 396 children with CVT (median age five years) followed for a median of 36 months, recurrent venous thrombosis occurred in 22 children at a median of six months, including CVT in 13 children (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/3\">",
"       3",
"      </a>",
"      ]. There were no recurrences of CVT among children younger than 25 months. Factors independently associated with recurrent cerebral and systemic venous thrombosis in children were nonadministration of anticoagulant therapy before relapse (hazard ratio [HR] 11.2, 95% CI 3.4&ndash;37.0), persistent occlusion on repeat venous imaging (HR 4.1, 95% CI 1.1&ndash;14.8), and heterozygosity for the prothrombin (factor II) G20210A mutation (HR 4.3, 95% CI 1.1&ndash;16.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE ANTITHROMBOTIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the overall aim of treatment for cerebral venous thrombosis (CVT) is to improve outcome, the immediate goals of antithrombotic treatment are [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To recanalize the occluded",
"      <span class=\"nowrap\">",
"       sinus/vein",
"      </span>",
"     </li>",
"     <li>",
"      To prevent the propagation of the thrombus, namely to the bridging cerebral veins",
"     </li>",
"     <li>",
"      To treat the underlying prothrombotic state, in order to prevent venous thrombosis in other parts of the body, particularly pulmonary embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/4\">",
"       4",
"      </a>",
"      ], and to prevent the recurrence of CVT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main treatment option to achieve these goals is anticoagulation, using either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin (LMWH).",
"   </p>",
"   <p>",
"    Where available, endovascular thrombolysis is another option, but its use is typically restricted to patients with a poor prognosis who have not responded to anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiplatelet drugs may be used as alternatives when anticoagulants are contraindicated, but there is no evidence, even from uncontrolled series, regarding their effectiveness and safety in CVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although definitive evidence of effectiveness is lacking, there is a general consensus that anticoagulation with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin (LMWH) is appropriate treatment for acute CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/27\">",
"     27",
"    </a>",
"    ]. As an example, more than 80 percent of the patients in the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) were treated with anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized controlled trials of anticoagulation in acute CVT have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/25,28\">",
"     25,28",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef69484 \" href=\"UTD.htm?41/57/42908\">",
"     table 2",
"    </a>",
"    ). Both have methodologic problems, most importantly their modest sample size.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Berlin trial of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      versus placebo was stopped prematurely because of excess mortality in the placebo arm [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients randomized to the heparin arm had significantly better outcomes on a nonvalidated composite CVT severity scale than those in the placebo group. The average length from onset of symptoms to anticoagulation treatment, four weeks, was exceptionally long [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Dutch trial of subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      versus placebo enrolled 60 patients, but excluded those who needed lumbar punctures for the relief of increased intracranial pressure. More patients treated with LMWH followed by oral anticoagulation had a favorable outcome than controls, but the difference between the groups was not statistically significant. Despite randomization, an imbalance at baseline may have favored the placebo group, as there were more cases with isolated intracranial hypertension in the placebo group and more patients with infarcts in the nadroparin group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of these two trials found that anticoagulant treatment compared with placebo was associated with a pooled relative risk of death of 0.33 (95% CI 0.08-1.21) and a risk of death or dependency of 0.46 (95% CI 0.16-1.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/29\">",
"     29",
"    </a>",
"    ]. While these data suggest that anticoagulant treatment for CVT may be associated with a reduced risk of death or dependency, the results did not achieve statistical significance.",
"   </p>",
"   <p>",
"    Two other trials were performed in India, but they were not included in the meta-analysis because only abstract information was available, and because the diagnosis of CVT was confirmed by computed tomography (CT) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These trials included 57 and 40 patients, respectively. Both favored",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    compared with placebo: 15 percent versus 40 percent fatality in the Maiti trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/30\">",
"     30",
"    </a>",
"    ], and recovery in all patients versus two deaths and one residual hemiparesis in the Nagajara trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that LMWH is more effective than unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and at least as safe for the treatment of CVT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label trial, 66 adults with CVT were randomly assigned to treatment with LMWH or unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/32\">",
"       32",
"      </a>",
"      ]. In-hospital mortality was significantly lower in the LMWH group (0 versus 19 percent). At three months, the proportion of patients with complete recovery was greater for the LMWH group (88 versus 63 percent), but the difference was not statistically significant. Small numbers limit the strength of these findings.",
"     </li>",
"     <li>",
"      In a nonrandomized case-control study, a greater proportion of adult patients treated with LMWH (n = 119) compared with unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (n = 302) were independent at six months (92 versus 84 percent, adjusted odds ratio 2.4, 95% CI 1.0-5.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/33\">",
"       33",
"      </a>",
"      ]. Treatment with LMWH was also associated with slightly lower rates of mortality (6 versus 8 percent) and new intracranial hemorrhage (10 versus 16 percent), but these outcomes were not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anticoagulants appear to be safe to use in adult patients with CVT who have intracranial hemorrhages, either intracerebral or subarachnoid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"     34",
"    </a>",
"    ]. In the small Berlin and Dutch trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/25,28\">",
"     25,28",
"    </a>",
"    ], no new intracranial hemorrhages were detected in patients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and only one case of major extracranial bleeding was reported. Case series have also reported relatively low risks of intracranial hemorrhage (&lt;5 percent) and systemic hemorrhage (&lt;2 percent), and such hemorrhages did not influence outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. These findings are in accordance with the hypothesis that hemorrhage in CVT is caused by the probable mechanism of venous outflow blockage and very high intradural and intravenous pressure, leading to both rupture of venules and to hemorrhagic transformation of venous infarctions.",
"   </p>",
"   <p>",
"    Similarly, observational data from single and multicenter case series suggest that anticoagulant therapy is safe in children with CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/39-45\">",
"     39-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endovascular thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with CVT worsen despite anticoagulant therapy. Direct endovascular thrombolysis has been used as an alternative treatment in such cases. Direct thrombolysis aims to dissolve the venous clot by delivering a thrombolytic substance (urokinase or rt-PA) within the occluded sinus through an intravenous catheter. In some cases, mechanical endovascular disruption of the thrombus has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized controlled trials have evaluated systemic or local thrombolysis for the treatment of CVT. The published literature consists of case reports or uncontrolled case series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/48-52\">",
"     48-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review published in 2003 that included 72 observational studies and 169 patients with CVT who were treated with local thrombolysis, death during the acute phase occurred in 5 percent, and dependency at discharge occurred in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients who were treated with thrombolytics had generally more severe clinical involvement than cases described in other series such as the ISCVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ]. The results of the systematic review suggest a possible benefit for severe CVT cases, indicating that thrombolytics may reduce case fatality in critically ill patients.",
"   </p>",
"   <p>",
"    Intracranial hemorrhage occurring after thrombolysis was reported in 17 percent of cases, and was associated with clinical deterioration in 5 percent. Extracranial hemorrhages were reported in 19 percent of patients, and were severe in 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"     53",
"    </a>",
"    ]. The case fatality was not higher (7 percent) in the 44 patients with intracranial hemorrhage present before thrombolytic treatment by CT or MRI scans compared with cases without previous hemorrhage. Similarly, overall, hemorrhagic complications were not significantly higher in cases with previous hemorrhage by head CT or MRI compared with cases without previous hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the results just cited suggest that thrombolysis may be useful and safe for CVT, there is concern for the possibility of publication bias and under-reporting of cases with poor outcome and complications. Furthermore, there may be bias in the reported outcomes, since treatment and evaluation were not blinded in nearly all the studies.",
"   </p>",
"   <p>",
"    These concerns are highlighted by the experience with endovascular thrombolysis in two prospective series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ISCVT, 13 patients were treated with local thrombolysis, and death or dependency at six months was seen in five (38.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In the Dutch center series of 20 patients with CVT who were treated with endovascular thrombolysis, eight patients (40 percent) died or became dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These high rates of poor outcome after endovascular thrombolysis contrast with the generally lower rates of poor outcomes reported in the earlier literature. We suspect that the disappointing outcomes seen in these two series after endovascular thrombolysis may be a more accurate reflection of actual outcomes with this technique in clinical practice when used to treat patients with clinically severe CVT.",
"   </p>",
"   <p>",
"    The findings from the Dutch center study also suggested that patients with large infarcts, including those with hemorrhagic infarcts and impending herniation, do not benefit from endovascular thrombectomy and thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and doses of thrombolytic drugs used for endovascular treatment of CVT has varied widely [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"     53",
"    </a>",
"    ]. Total doses of local urokinase reported in the literature range between 12,000 international units (newborn) and 13,790,000 international units, with a mean dose of approximately 2,300,000 international units (&plusmn;2,270,000 international units). Total doses of local rt-PA range between 8 and 300 mg, and the mean dose was 78.4 mg&plusmn;64.7 mg. Mean duration of treatment was 41 hours (&plusmn;49), with a range of &le;1 to 244 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choosing therapy for adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current consensus guidelines support the use of anticoagulation for the acute treatment of CVT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Federation of Neurological Societies (EFNS) guidelines on the treatment of CVT, published in 2010, recommended that patients with CVT and no contraindications for anticoagulation should be treated either with weight-adjusted low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) or dose-adjusted unfractionated heparin, with a goal of two times the mean of the control activated partial thromboplastin time (aPTT) value or the upper limit of the normal aPTT range [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The EFNS guidelines also concluded that there is insufficient evidence to support the routine use of either local or systemic thrombolysis for CVT, but state that endovascular thrombolysis may be performed as a therapeutic option in centers with expertise in interventional radiology for patients with a poor prognosis, such those who worsen despite best medical treatment and anticoagulation, provided that other causes of worsening are excluded and treated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guidelines from the American Academy of Chest Physicians (ACCP) issued in 2012 suggest anticoagulation over no anticoagulation during the acute and chronic phases of CVT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/55\">",
"       55",
"      </a>",
"      ]. Either dose-adjusted unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or LMWH can be used as initial treatment, even in the presence of hemorrhage within a venous infarction. Patients who have stabilized can be switched to oral anticoagulation, which is generally continued for a period of three to six months.",
"     </li>",
"     <li>",
"      The 2011 American Heart",
"      <span class=\"nowrap\">",
"       Association/American",
"      </span>",
"      Stroke Association",
"      <span class=\"nowrap\">",
"       (AHA/ASA)",
"      </span>",
"      guidelines for the prevention of stroke in patients with stroke or transient ischemic attack state that anticoagulation is probably effective for patients with acute CVT, and that it is reasonable to treat acute CVT with anticoagulation for at least three months, followed by antiplatelet therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2011",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines for the diagnosis and management of CVT conclude that initial anticoagulation with adjusted-dose unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or weight-based LMWH in full anticoagulant doses is reasonable, followed by vitamin K antagonists, regardless of the presence of ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57\">",
"       57",
"      </a>",
"      ]. These guidelines also note that endovascular intervention may be considered if neurologic deterioration occurs despite intensive anticoagulation treatment. For secondary prevention in patients with provoked CVT (associated with a transient risk factor), vitamin K antagonists may be continued for three to six months. For patients with unprovoked CVT, vitamin K antagonists may be continued for 6 to 12 months. For patients with recurrent CVT, venous thromboembolism after CVT, or a first CVT with severe thrombophilia (ie, homozygous prothrombin G20210A; homozygous factor V Leiden; deficiencies of protein C, protein S, or antithrombin; combined thrombophilia defects; or antiphospholipid syndrome), indefinite anticoagulation may be considered. In all cases, the recommend target INR is two to three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon available published data and guidelines, we recommend anticoagulation with subcutaneous LMWH or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for patients with symptomatic CVT who have no contraindication. As already noted, the presence of hemorrhagic venous infarction is not a contraindication for anticoagulant treatment in CVT. The available evidence (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Anticoagulation'",
"    </a>",
"    above) suggests but does not establish that subcutaneous LMWH is more effective than unfractionated heparin, and is at least as safe. Therefore, we prefer subcutaneous LMWH unless the patient is clinically unstable and invasive interventions such as lumbar puncture or surgery are planned.",
"   </p>",
"   <p>",
"    For patients with CVT who develop progressive neurologic worsening despite adequate anticoagulation with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous LMWH, endovascular thrombolysis at centers experienced with this therapy is a treatment option. However, the limited available evidence suggests no benefit for patients with large infarcts and impending herniation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choosing therapy for children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for children during the acute phase of CVT is similar to that for adults, but the evidence is weaker since there are no randomized controlled trials in this age group.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with CVT but without significant intracerebral hemorrhage, the American Academy of Chest Physicians (ACCP) recommends initial anticoagulation with unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin (LMWH), followed by LMWH or vitamin K antagonist treatment (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) for a minimum of three months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/58\">",
"       58",
"      </a>",
"      ]. Anticoagulation for an additional three months is suggested if there is still cerebral sinovenous occlusion or ongoing symptoms (the latter presumably meaning new venous infarcts or increased intracranial pressure) after three months of therapy.",
"      <br/>",
"      <br/>",
"      For children with CVT who have significant intracerebral hemorrhage, the ACCP suggests either initial anticoagulation as for children without hemorrhage, or radiologic monitoring of the thrombosis at five to seven days and anticoagulation if thrombus extension is noted at that time [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/58\">",
"       58",
"      </a>",
"      ]. The ACCP suggests thrombolysis, thrombectomy, or surgical decompression only in children with severe CVT in whom there is no improvement with initial anticoagulation therapy.",
"     </li>",
"     <li>",
"      Guidelines from the American Heart Association (AHA) Stroke Council state that it is reasonable to institute either unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or LMWH in children with CVT, whether or not there is secondary hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/59\">",
"       59",
"      </a>",
"      ]. This is followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy for three to six months.",
"     </li>",
"     <li>",
"      The 2011",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines for the diagnosis and management of CVT conclude that, for children with acute CVT diagnosed beyond the first 28 days of life, it is reasonable to treat with full-dose LMWH even in the presence of intracranial hemorrhage, and that it is reasonable to continue LMWH or oral vitamin K antagonists for three to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57\">",
"       57",
"      </a>",
"      ]. For neonates with acute CVT, the guidelines state that treatment with LMWH or unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may be considered, and that continuation of LMWH for six weeks to three months may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest initial anticoagulation with subcutaneous LMWH or unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for children with CVT with or without significant secondary hemorrhage. There is limited data that subcutaneous LMWH may be more effective than unfractionated heparin for the treatment of CVT in adults (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Anticoagulation'",
"    </a>",
"    above), and is at least as safe. We suggest endovascular thrombolysis at centers experienced in using this therapy for children who develop progressive neurologic worsening despite adequate anticoagulation with IV heparin or subcutaneous LMWH. The limited available evidence suggests no benefit of endovascular thrombolysis for children with large infarcts and impending herniation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE SYMPTOMATIC TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Elevated intracranial pressure and herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute phase, elevated intracranial pressure (ICP) may arise from single or multiple large hemorrhagic lesions, infarcts, or brain edema. Elevated ICP or space-occupying lesions may cause transtentorial herniation and death.",
"   </p>",
"   <p>",
"    General recommendations to control acutely elevated ICP should be followed, including elevating the head of the bed, intensive care unit admission with sedation, administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , hyperventilation to a target PaCO2 of 30 to 35 mmHg, and ICP monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34,59\">",
"     34,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although glucocorticoids, in particular intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , are prescribed in many centers, no randomized clinical trials have been performed to demonstrate their efficacy. Their routine use cannot be recommended, mainly because there is no evidence that they are effective for CVT. This conclusion is supported by a study that analyzed data from the observational ISCVT cohort of 642 patients with CVT (including 150 patients treated with glucocorticoids) using three different and complementary case-control methods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/60\">",
"     60",
"    </a>",
"    ]. All three analyses failed to demonstrate any benefit of glucocorticoids, even for patients with parenchymal lesions.",
"   </p>",
"   <p>",
"    In patients with impending herniation due to unilateral hemispheric lesion, hemicraniectomy can be life-saving, and limited data from a retrospective registry and a systematic review of published cases suggest that a good functional outcome can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronically increased ICP, successful treatment of intracranial hypertension can prevent visual failure and resolve headache. A",
"    <span class=\"nowrap\">",
"     diagnostic/therapeutic",
"    </span>",
"    lumbar puncture will decrease the cerebrospinal fluid (CSF) pressure and offer headache relief.",
"   </p>",
"   <p>",
"    Although its efficacy is not proven,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    (500 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (for patients who cannot tolerate acetazolamide), are therapeutic options for patients with increased ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57\">",
"     57",
"    </a>",
"    ]. Repeated lumbar punctures, a lumboperitoneal shunt, or fenestration of the optic nerve sheet should be considered if severe headaches persist, or if visual acuity is decreasing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57,62\">",
"     57,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CVT, recurrent seizures are more likely to develop in those who present with seizures and in those with supratentorial brain lesions (focal edema, or ischemic or hemorrhagic infarcts) on admission brain imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/63\">",
"     63",
"    </a>",
"    ]. The risk of developing seizures after CVT diagnosis is very low in patients who do not have these risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Younger children with CVT may have a higher frequency of seizures than older children or adults. Consensus guidelines state that continuous electroencephalography may be considered for children with CVT who are unconscious or mechanically ventilated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited regarding the effectiveness of seizure prophylaxis with antiepileptic drugs in patients with CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"     34",
"    </a>",
"    ]. In the ISCVT cohort, early seizures (those occurring within two weeks after CVT diagnosis) were observed in the following patient subgroups, comparing those not treated with antiepileptic (AED) prophylaxis versus those treated with AED prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with no supratentorial lesion and no seizure at presentation, early seizure occurred in 5 of 197 (2.5 percent) not on AEDs versus 0 of 11 (0 percent) on AEDs",
"     </li>",
"     <li>",
"      In those with no supratentorial lesion who presented with seizure, early seizures occurred in 1 of 14 (7 percent) not on AEDs and 0 of 35 (0 percent) on AEDs",
"     </li>",
"     <li>",
"      In patients with a supratentorial lesion but no seizure at presentation, early seizures occurred in 11 of 134 (8 percent) not on AEDs and 1 of 35 (3 percent) on AEDs (odds ratio [OR] 0.3, 95% CI 0.04-2.6)",
"     </li>",
"     <li>",
"      In patients with a supratentorial lesion who presented with seizure, early seizures occurred in 24 of 47 (51 percent) not on AEDs and 1 of 148 (&lt;1 percent) on AEDs (OR 0.006, 95% CI 0.001-0.05)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, antiepileptic drug prophylaxis was associated with a reduced risk of early seizures in patients with CVT. The risk reduction was statistically significant for patients in the highest risk group (those with a supratentorial lesion and seizure at presentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/63\">",
"     63",
"    </a>",
"    ]. The strength of this study is limited by its observational and retrospective design, but it represents the largest experience in the literature.",
"   </p>",
"   <p>",
"    Based upon these data, we recommend seizure prophylaxis only for patients with both seizures at presentation and supratentorial lesions such as edema, infarction, or hemorrhage on admission head CT or brain MRI. Prophylaxis is not clearly required for a single early symptomatic seizure with CVT in the absence of supratentorial lesion, as there is often no seizure recurrence. Furthermore, seizure prophylaxis is not clearly required for patients who have focal cerebral lesions without seizures.",
"   </p>",
"   <p>",
"    Our approach to seizure prophylaxis is not universal, since there is no consensus among experts. Some advocate prophylaxis for all patients with CVT because of the moderately high incidence of seizures during the acute phase of the disease, while others use antiepileptic drugs only for patients with seizures regardless of the presence of parenchymal brain lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57,64\">",
"     57,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When AED prophylaxis is used,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    is preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    because it has fewer pharmacologic interactions with oral anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/65\">",
"     65",
"    </a>",
"    ]. General recommendations for the selection and withdrawal of antiepileptic drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT AFTER THE ACUTE PHASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Duration of antithrombotic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of continuing anticoagulation after the acute phase is to prevent cerebral venous thrombosis (CVT) recurrence, which affects 2 to 7 percent of patients, and to prevent extracerebral venous thrombosis, which occurs in up to 5 percent of patients with CVT, mainly from deep venous thrombosis of the limbs or pelvis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no clinical trials assessing the effectiveness of oral anticoagulation for the prevention of recurrent CVT in adults. Extrapolating from the evidence and recommendations in systemic deep venous thrombosis, we suggest anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a minimum of three months duration after acute CVT, aiming at an international normalized ratio (INR) target of 2.5 (acceptable range: 2 to 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34,66\">",
"     34,66",
"    </a>",
"    ]. European guidelines recommend three months of treatment with oral anticoagulation for patients with initial CVT secondary to a transient risk factor, 6 to 12 months of oral anticoagulation for patients with idiopathic CVT and those with &lsquo;mild&rsquo; thrombophilia, and indefinite oral anticoagulation for patients with either recurrent CVT or one episode of CVT and &lsquo;severe&rsquo; thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"     34",
"    </a>",
"    ]. &lsquo;Mild&rsquo; thrombophilia was defined as the presence of heterozygous factor V Leiden mutation, heterozygous prothrombin G20210A mutation, or high plasma levels of factor VIII; &lsquo;severe&rsquo; thrombophilia was defined as the presence of any one of antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies, or combined prothrombotic conditions.",
"   </p>",
"   <p>",
"    Available data for children show that CVT recurrence is more frequent in children who are not administered anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, approximately 70 percent of the recurrences develop within six months after initial CVT onset. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therefore, after the acute phase of CVT in children, we suggest anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for three to six months, aiming at an international normalized ratio (INR) target of 2.5 (acceptable range: 2 to 3). The 2012 ACCP guidelines suggest a similar duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic oral anticoagulation is reserved for patients with recurrent CVT, severe thrombophilia or combined prothrombotic conditions, including those with the antiphospholipid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Seizure prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antiepileptic treatment after CVT is unknown. However, the risk of epilepsy after CVT ranges from 5 to 11 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6,8,67\">",
"     6,8,67",
"    </a>",
"    ], and the risk is higher in those with seizures in the acute phase or with hemorrhagic parenchymal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/67\">",
"     67",
"    </a>",
"    ]. The 2010 European Federation of Neurological Societies (EFNS) guidelines for CVT state that it may be reasonable to continue antiepileptic drug treatment for one year in patients with early seizures and hemorrhagic lesions on admission brain scan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General recommendations for the selection and withdrawal of antiepileptic drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches severe enough to require bed rest or hospital admission afflict 14 percent of patients with CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"     6",
"    </a>",
"    ]. Repeated brain MRI and magnetic resonance venography (MRV) are necessary to exclude the rare case of recurrent CVT. MRV may depict stenosis of a previously occluded sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumbar puncture may be necessary to exclude chronically elevated intracranial pressure (ICP) if headache persists and MRI and MRV are normal. In such cases, therapeutic options to treat elevated ICP include repeated lumbar punctures, placement of a lumbar-peritoneal shunt, or stenting of a sinus stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe visual loss due to CVT is fortunately a rare event [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/10,73,74\">",
"     10,73,74",
"    </a>",
"    ]. Nevertheless, elevated intracranial pressure must be rapidly ruled out and managed accordingly if visual acuity decreases during follow-up and is not explained by ocular causes. Fenestration of the optic nerve sheath has also been used to relieve pressure and prevent optic nerve atrophy.",
"   </p>",
"   <p>",
"    Because of the potential for visual loss caused by severe or long-standing elevation of intracranial pressure, serial assessment of visual fields and visual acuity is recommended for children with CVT during follow-up, particularly during the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. It is reasonable to do the same for adults with visual complaints, chronic headaches, or papilledema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cognitive and psychiatric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the apparent general good recovery in most patients with CVT, approximately one-half of the survivors feel depressed or anxious [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/75\">",
"     75",
"    </a>",
"    ], and minor cognitive or language deficits may preclude them from resuming their previous jobs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/76\">",
"     76",
"    </a>",
"    ]. Patients should be reassured of the very low level of risk of recurrence of CVT and encouraged to return to previous occupations and hobbies. In some cases, antidepressants may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subsequent pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and the puerperium are risk factors for CVT. Nevertheless, the risk of complications during subsequent pregnancy among women who have a history of CVT appears to be low in the absence of a prothrombotic condition or a previous thromboembolism (ie, a previous CVT or deep venous thrombosis before the index CVT).",
"   </p>",
"   <p>",
"    Supporting evidence comes from studies that together observed a total of 855 women with CVT, of whom 83 became pregnant, resulting in 101 pregnancies after CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/6,8,35,77,78\">",
"     6,8,35,77,78",
"    </a>",
"    ]. Outcomes were normal births in 88 percent; the remaining pregnancies were prematurely terminated by voluntary or spontaneous abortion. The rate of spontaneous abortion was higher than expected. There were no instances of recurrent CVT, and only two cases of deep venous thrombosis were detected.",
"   </p>",
"   <p>",
"    Thus, based upon the available evidence, CVT and pregnancy or puerperium-related CVT are not a contraindication for future pregnancy.",
"   </p>",
"   <p>",
"    The role of antithrombotic prophylaxis during subsequent pregnancies is unproven in women with a history of CVT. There is no worldwide consensus regarding this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In our view and that of many experts, antithrombotic prophylaxis during pregnancy is probably unnecessary unless a prothrombotic condition or a previous thromboembolism (ie, a previous CVT or deep venous thrombosis before the index CVT) has been identified.",
"     </li>",
"     <li>",
"      In the United States, many would prefer to treat with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or subcutaneous low molecular weight heparin (LMWH) during the late third trimester",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      up to eight weeks postpartum. Guidelines published in 2011 from the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      for the diagnosis and management of CVT state that, for women with a history of CVT, prophylaxis with LMWH during future pregnancies and the postpartum period is probably recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women should be advised not to become pregnant while on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    because of its teratogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it is a risk factor for CVT, oral contraception should be stopped in women with any history of CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/16/9482/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CVT is associated with a good outcome (complete recovery or minor residual symptoms or signs) in close to 80 percent of patients. Nevertheless, approximately 5 percent of patients die in the acute phase of the disorder, and longer-term mortality is nearly 10 percent. The main cause of acute death with CVT is neurologic, most often from brain herniation. After the acute phase, most deaths are related to underlying disorders such as cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predictors of poor long-term prognosis include CNS infection, malignancy, deep CVT location, intracranial hemorrhage, Glasgow coma scale score on admission &lt;9, mental status abnormality, age &gt;37 years, and male sex. Isolated intracranial hypertension at the time of CVT diagnosis may be a predictor of good outcome. Limited data suggest that recanalization of the occluded sinus is not related to outcome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent CVT appears to be uncommon, with rates ranging from 2 to 4 percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with symptomatic CVT, with or without hemorrhagic venous infarction, we recommend initial anticoagulation therapy with subcutaneous low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) or intravenous heparin (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choosing therapy for adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with CVT, with or without significant secondary hemorrhage, we suggest initial anticoagulation therapy with subcutaneous LMWH or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing therapy for children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults and children being treated with acute anticoagulation for CVT, we prefer subcutaneous LMWH over unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      unless the patient is clinically unstable and invasive interventions are planned (eg, lumbar puncture, surgery). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute antithrombotic treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For adults and children with CVT who develop progressive neurologic worsening despite adequate anticoagulation with or subcutaneous LMWH or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , endovascular thrombolysis at centers experienced with this therapy is a treatment option. However, the limited available evidence suggests no benefit for patients with large infarcts and impending herniation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute antithrombotic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to control acutely increased intracranial pressure and impending herniation, including decompressive surgery, may be required in patients with CVT. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Elevated intracranial pressure and herniation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CVT who have seizures and focal cerebral supratentorial lesions such as edema or infarction on admission head CT or brain MRI lesions, we recommend seizure prophylaxis with antiepileptic medication (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Prophylaxis is not clearly required for those with a single early symptomatic seizure due to CVT in the absence of a supratentorial cerebral lesion, as there is often no seizure recurrence. Furthermore, seizure prophylaxis is not clearly required for patients who have focal cerebral lesions without seizures. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the acute phase of CVT, we suggest anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for three to 12 months duration in adults, and three to six months in children, aiming at an international normalized ratio (INR) target of 2.5 (acceptable range: 2 to 3) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chronic oral anticoagulation is reserved for patients with recurrent CVT, severe thrombophilia or combined prothrombotic conditions. Antiepileptic drug management, headaches, visual loss, and cognitive and psychiatric complications are additional problems that may complicate the subacute phase of CVT. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management after the acute phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with a history of CVT who have a prothrombotic state or have had an additional previous thromboembolism, we suggest temporary anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable regimen is subcutaneous LMWH beginning in the third trimester and continuing up to eight weeks postpartum. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Subsequent pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescent girls and adult women with a history of CVT, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      using oral contraceptives (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/1\">",
"      Canh&atilde;o P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005; 36:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/2\">",
"      Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/3\">",
"      Kenet G, Kirkham F, Niederstadt T, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol 2007; 6:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/4\">",
"      Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand 1992; 86:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/5\">",
"      Crassard, I, Canh&atilde;o, P, Ferro, JM, et al. Neurological worsening in the acute phase of cerebral venous thrombosis in ISCVT (International Study on Cerebral Venous Thrombosis). Cerebrovasc Dis 2003; 16 Supp 4:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/6\">",
"      Ferro JM, Canh&atilde;o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/7\">",
"      Rondepierre P, Hamon M, Leys D, et al. [Cerebral venous thromboses: study of the course]. Rev Neurol (Paris) 1995; 151:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/8\">",
"      Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996; 27:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/9\">",
"      de Bruijn SF, de Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry 2001; 70:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/10\">",
"      Ferro JM, Lopes MG, Rosas MJ, et al. Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis 2002; 13:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/11\">",
"      Breteau G, Mounier-Vehier F, Godefroy O, et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 2003; 250:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/12\">",
"      Cakmak S, Derex L, Berruyer M, et al. Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology 2003; 60:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/13\">",
"      Ferro, JM, Canh&atilde;o, P, Crassard, I, et al. External validation of a prognostic model of cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2005; 19 Suppl 2:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/14\">",
"      Coutinho JM, Ferro JM, Canh&atilde;o P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/15\">",
"      Girot M, Ferro JM, Canh&atilde;o P, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke 2007; 38:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/16\">",
"      Ferro JM, Canh&atilde;o P, Stam J, et al. Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. Stroke 2009; 40:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/17\">",
"      Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry 2003; 74:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/18\">",
"      Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood 2006; 108:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/19\">",
"      Strupp M, Covi M, Seelos K, et al. Cerebral venous thrombosis: correlation between recanalization and clinical outcome--a long-term follow-up of 40 patients. J Neurol 2002; 249:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/20\">",
"      Martinelli I, Bucciarelli P, Passamonti SM, et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/21\">",
"      Miranda B, Ferro JM, Canh&atilde;o P, et al. Venous thromboembolic events after cerebral vein thrombosis. Stroke 2010; 41:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/22\">",
"      Dentali F, Poli D, Scoditti U, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/23\">",
"      Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy? J Neurol Neurosurg Psychiatry 2000; 69:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/24\">",
"      Bousser MG. Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? Stroke 1999; 30:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/25\">",
"      de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/26\">",
"      Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/27\">",
"      Coutinho JM, Stam J. How to treat cerebral venous and sinus thrombosis. J Thromb Haemost 2010; 8:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/28\">",
"      Einh&auml;upl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/29\">",
"      Stam J, De Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2002; :CD002005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/30\">",
"      Maiti, B, Chakrabarti, I. Study on cerebral venous thrombosis with special reference to efficacy of heparin. J Neurol Sci 1997; 150:s147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/31\">",
"      Nagaraja, D, Rao, BSS, Taly, AB, Subhash, MN. Randomized controlled trial of heparin in puerperal cerebral venous/sinus thrombosis. Nimhans Journal 1995; 13:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/32\">",
"      Misra UK, Kalita J, Chandra S, et al. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 2012; 19:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/33\">",
"      Coutinho JM, Ferro JM, Canh&atilde;o P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 2010; 41:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/34\">",
"      Einh&auml;upl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/35\">",
"      Ferro JM, Correia M, Pontes C, et al. Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. Cerebrovasc Dis 2001; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/36\">",
"      Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis--a review of 38 cases. Stroke 1985; 16:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/37\">",
"      Brucker AB, Vollert-Rogenhofer H, Wagner M, et al. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis 1998; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/38\">",
"      Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction: factors affecting the initiation and safety of anticoagulation. Cerebrovasc Dis 1998; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/39\">",
"      deVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998; 55:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/40\">",
"      deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/41\">",
"      Johnson MC, Parkerson N, Ward S, de Alarcon PA. Pediatric sinovenous thrombosis. J Pediatr Hematol Oncol 2003; 25:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/42\">",
"      S&eacute;bire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005; 128:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/43\">",
"      Schobess R, D&uuml;ring C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006; 91:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/44\">",
"      Golomb MR. The risk of recurrent venous thromboembolism after paediatric cerebral sinovenous thrombosis. Lancet Neurol 2007; 6:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/45\">",
"      Moharir MD, Shroff M, Stephens D, et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010; 67:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/46\">",
"      Bagley LJ, Hurst RW, Galetta S, et al. Use of a microsnare to aid direct thrombolytic therapy of dural sinus thrombosis. AJR Am J Roentgenol 1998; 170:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/47\">",
"      Scarrow AM, Williams RL, Jungreis CA, et al. Removal of a thrombus from the sigmoid and transverse sinuses with a rheolytic thrombectomy catheter. AJNR Am J Neuroradiol 1999; 20:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/48\">",
"      Horowitz M, Purdy P, Unwin H, et al. Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995; 38:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/49\">",
"      Frey JL, Muro GJ, McDougall CG, et al. Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. Stroke 1999; 30:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/50\">",
"      Kim SY, Suh JH. Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase. AJNR Am J Neuroradiol 1997; 18:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/51\">",
"      Wasay M, Bakshi R, Kojan S, et al. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis. Stroke 2001; 32:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/52\">",
"      Stam J, Majoie CB, van Delden OM, et al. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke 2008; 39:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/53\">",
"      Canh&atilde;o P, Falc&atilde;o F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis 2003; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     Unpublished data, International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/55\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/56\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/57\">",
"      Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/58\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/59\">",
"      Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/60\">",
"      Canh&atilde;o P, Cortes&atilde;o A, Cabral M, et al. Are steroids useful to treat cerebral venous thrombosis? Stroke 2008; 39:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/61\">",
"      Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011; 42:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/62\">",
"      Acheson JF. Optic nerve disorders: role of canal and nerve sheath decompression surgery. Eye (Lond) 2004; 18:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/63\">",
"      Ferro JM, Canh&atilde;o P, Bousser MG, et al. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/64\">",
"      Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992; 10:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/65\">",
"      Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/66\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/67\">",
"      Ferro JM, Correia M, Rosas MJ, et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003; 15:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/68\">",
"      Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/69\">",
"      Higgins JN, Gillard JH, Owler BK, et al. MR venography in idiopathic intracranial hypertension: unappreciated and misunderstood. J Neurol Neurosurg Psychiatry 2004; 75:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/70\">",
"      Higgins JN, Owler BK, Cousins C, Pickard JD. Venous sinus stenting for refractory benign intracranial hypertension. Lancet 2002; 359:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/71\">",
"      Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/72\">",
"      Tsumoto T, Miyamoto T, Shimizu M, et al. Restenosis of the sigmoid sinus after stenting for treatment of intracranial venous hypertension: case report. Neuroradiology 2003; 45:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/73\">",
"      Ferro JM, Canh&atilde;o P, Bousser MG, et al. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke 2005; 36:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/74\">",
"      Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol 1995; 52:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/75\">",
"      Madureira, S, Canh&atilde;o, P, Ferro, JM. Cognitive and behavioural outcome of patients with cerebral venous thrombosis. Cerebrovasc Dis 2001; 11 Suppl 4:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/76\">",
"      de Bruijn SF, Budde M, Teunisse S, et al. Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis. Neurology 2000; 54:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/77\">",
"      Lamy C, Hamon JB, Coste J, Mas JL. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy. Neurology 2000; 55:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/78\">",
"      Srinivasan K. Cerebral venous and arterial thrombosis in pregnancy and puerperium. A study of 135 patients. Angiology 1983; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/16/9482/abstract/79\">",
"      Jilma B, Kamath S, Lip GY. Antithrombotic therapy in special circumstances. I--pregnancy and cancer. BMJ 2003; 326:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1109 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9482=[""].join("\n");
var outline_f9_16_9482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early deterioration and death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recanalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE ANTITHROMBOTIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endovascular thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choosing therapy for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choosing therapy for children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE SYMPTOMATIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Elevated intracranial pressure and herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT AFTER THE ACUTE PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Duration of antithrombotic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Seizure prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cognitive and psychiatric complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subsequent pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 1\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/57/42908\" title=\"table 2\">",
"      Anticoagulant trials acute CVT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_16_9483="Risk factors for cord prolapse";
var content_f9_16_9483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors associated with umbilical cord prolapse unrelated to obstetric maneuvers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Fetal malpresentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unengaged presenting part",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prematurity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature rupture of membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal placentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiparity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyhydramnios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long umbilical cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic deformities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine tumors or malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomalies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9483=[""].join("\n");
var outline_f9_16_9483=null;
var title_f9_16_9484="CUP treatment schema";
var content_f9_16_9484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatments for specific subsets of patients with CUP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Histologic type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical feature",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment recommendation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Adenocarcinoma",
"      </td>",
"      <td>",
"       Women with isolated axillary adenopathy",
"      </td>",
"      <td>",
"       Treat as stage II breast cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Women with peritoneal carcinomatosis",
"      </td>",
"      <td>",
"       Treat as stage III ovarian cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Men with elevated PSA or blastic bone metastases",
"      </td>",
"      <td>",
"       Treat as advanced prostate cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colon cancer profile",
"      </td>",
"      <td>",
"       Treat as advanced colon cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adenocarcinoma or PDC",
"      </td>",
"      <td>",
"       Single metastatic lesion",
"      </td>",
"      <td>",
"       Definitive local therapy (resection and/or radiation therapy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Squamous cell carcinoma",
"      </td>",
"      <td>",
"       Cervical adenopathy",
"      </td>",
"      <td>",
"       Treat as head and neck cancer with involved neck nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inguinal adenopathy",
"      </td>",
"      <td>",
"       Inguinal node dissection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Consider concurrent radiation therapy/chemotherapy (as in locally advanced cervical cancer)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Poorly differentiated carcinoma",
"      </td>",
"      <td>",
"       Young men with midline tumor or elevated hCG/AFP",
"      </td>",
"      <td>",
"       Treat as extragonadal germ cell tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other clinical presentations",
"      </td>",
"      <td>",
"       Empiric platinum/paclitaxel chemotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       Poorly differentiated neuroendocrine carcinoma",
"      </td>",
"      <td>",
"       Diverse clinical presentations",
"      </td>",
"      <td>",
"       Treat with platinum/etoposide or paclitaxel/platinum/etoposide",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Approximately 40 percent of patients with carcinoma of unknown primary (CUP) fit into defined subsets with specific, recommended treatment implications.",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein; hCG: human chorionic gonadotropin; PDC: poorly differentiated carcinoma; PSA: prostate-specific antigen.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9484=[""].join("\n");
var outline_f9_16_9484=null;
var title_f9_16_9485="ACOG CPP Rx A recs";
var content_f9_16_9485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71859%7EOBGYN%2F82431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71859%7EOBGYN%2F82431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of recommendations for treatment of chronic pelvic pain from the American College of Obstetricians and Gynecologists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Recommendations based on good, consistent scientific evidence (level A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle2\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combined oral contraceptive pills",
"       </td>",
"       <td>",
"        Primary dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GnRH agonists",
"       </td>",
"       <td>",
"        Endometriosis, irritable bowel syndrome (may be given empirically in women with symptoms consistent with endometriosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal anit-inflammatory drugs",
"       </td>",
"       <td>",
"        Dysmenorrhea, moderate pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progestins (daily, high dose)",
"       </td>",
"       <td>",
"        Endometriosis, pelvic congestion syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic ablation/resection of endometriosis",
"       </td>",
"       <td>",
"        Stage I-III endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presacral neurectomy",
"       </td>",
"       <td>",
"        Centrally located dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine nerve ablation",
"       </td>",
"       <td>",
"        Not indicated",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjunctive psychotherapy",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA 2009; 302:955.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACOG chronic pelvic pain level B and C recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Recommendations based on limited or inconsistent scientific evidence (level B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle2\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GnRH agonists",
"       </td>",
"       <td>",
"        CPP other than endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adhesiolysis",
"       </td>",
"       <td>",
"        CPP attributed to dense bowel adhesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hysterectomy",
"       </td>",
"       <td>",
"        Reproductive tract symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacral nerve stimulation",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical therapy",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional supplementation with vitamin B1 or magnesium",
"       </td>",
"       <td>",
"        Dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injection of trigger points",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        CPP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Application of magnets to trigger points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acupuncture, acupressor, transcutaneous nerve stimulation",
"       </td>",
"       <td>",
"        Primary dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Recommendations based on consensus and expert opinion (level C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle2\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioids",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and modified from Clinical Management Guidelines for Obstetrician-Gynecologists. Number 51, March 2004: Chronic Pelvic Pain. Obstet Gynecol 2004; 103:589.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9485=[""].join("\n");
var outline_f9_16_9485=null;
var title_f9_16_9486="Long acting beta agonist in EIB";
var content_f9_16_9486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long acting beta agonist in EIB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of a single dose of the long-acting beta agonist salmeterol versus placebo in exercise induced bronchoconstriction. Salmeterol, but not placebo, protected against a decline in FEV1 with exercise. This effect was seen at both one (left panel) and nine (right panel) hours.",
"    <div class=\"footnotes\">",
"     EIB: exercise induced bronchoconstriction; FEV1: forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Green CP, Price JF, Arch Dis Child 1992; 67:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9486=[""].join("\n");
var outline_f9_16_9486=null;
var title_f9_16_9487="Theca cell androgen production";
var content_f9_16_9487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Ovarian androgen and estrogen production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 339px; background-image: url(data:image/gif;base64,R0lGODlh5gFTAfcAAP///2aZmQCnaP+ZM4CAgDNMTAAAAH9MGQBTNCBzOQAzmUBAQMDAwExychkmJr9yJgB9Tj8mDAApGl+PjxMcHBA5HKCgoFmFheDg4AAZTD9fXyY5OVJ8fPDw8B8vLwwTEzAwMAAfEyAgIDNtZ1BQUGBgYACcYQYJCQCHVJ9fH9DQ0O+PL2YzZixCQrCwsABoQUZpaQCSWxAQEAA0IAA+J3BwcN+FLDlWVgAUDS8cCc98KQByR5CQkE8vDx8TBgBdOq9pIwAKBm9CFoCZmQBJLV85Ew8JA2ZyhY9WHH+ZzBhWKggcDj9msgYVCr/M5RBAQBxkMR5rNa+/3xZPJxpdLgQOBxJAIFBzcwwrFQojEaCzsyBNTU9yuN/l8g8/n+/y+JCmpgAZGY+l0hRHI9DZ2V9/vw4yGAAMJvDz80BmZsDNzQIHA2+MxR9MpQAjac/Y67DAwC9ZrODm5p+y2AAvLwAzMwAvjwAsLGZ/jAAmcnCJiWY/bGZZeQyYZ1JIZmCAgFlBZgAsf3CNjQAjIz9eZgAzcjBWVgAshSZ7ZzllZgATEwAmJgAfHwATHwAGBgAvXAAWQmaSlWZmf2ZsghApKQAjNgAzZgAWIwAmPzlJT2ZMcpCgoAwMD2Z5iWZGb0ZXZgAZLAAZRgxFMzM/RhORZ2ZSdWY5aUxQZhM9MwAjYoCPj2aFjx+CZyx0Z186ZmaMkgAPDwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADmAVMBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9eVDAiIHUu2rNmzaNOqTcvgq9u3cEUSWLC2rt27denG3cu3r0SxPgH7HUy4MADBPBEbXsy4q2KdjxtLniw1Mk7LlDNrPorZZufNoEMnJlCw7cQOKg6iNrga4mfRsGPLfGxAIYMFCFXUOKjbYG/XpGULHz47+MDaAy1gAIDBwmERBNq6WEAidXMADFyUWND2OlkM17Nv/zdtYUEJ4wJfE1/P/iNtgtyx47YAggEGFyQ6YBDR4fbhBRioIIJ82DFggQwY+DdXgAPipx9yA6nX3oQUVvTeQPH55x8AJJxHgAgMKBhcbRt2UB+BgtVGggsCQZgeehXGKCNFFwqUIW4bLsBDiAz0h1uKBAJwnkAitghAfAC4eBiMMzbppEI1cshiediBkB4JAulXZJIEWoAlkT+OCEANpHWgpIRPphkjbQu0aQEDIpiH25ELOFcDCAuAkGCYRvpnAJ4LqLBlbR20WcOZTKqpaJNomtSBQPsV1OiilMo2KUkC5pkaQZdW6ulmnbIU6qdP9sdjiIXuttioKrFK6owMGP8g66yxzmlYZ7/F5OqrMZoqK6oG6GjeowCUpyOkNVDHYrLmbUpVZxvqmiiv1Mp63J8iGFDCmAbUQIIBPHQggwwEbAcAdDXIMGBV0NJ1LHYkkGAaARjQawF++c3FA5HxzjvdtukNm9Cu1MZobYu4mYmbumIFy4MBzjGHXbIyKBkVtCB2IAJ4G++3XLD0LlBDBzzUpzHHKCfpHAl2kjbdwNMWTOrBSc4ZbJLQiWUBAQaYBoALBqwIgsVQtWsjAzwER8C+EN54dNLpMf0iAOQ2DLPMWCcJ4c01c2hAdDur8KeBJPBMgAvZWmX0kWEpTVrTbeXY9tTIAdYzj1dnXTDNXN//3EEJFZP789Bfm2iACGmzG7PcKlh5ZGpwB8ld4zZCPvW7zhpEsN6cX7V2fASAAIKYR0veVuijG7kkAB2QIPqXB23e+eyVxVyT7LTn3hTuI/Gu+++clUCsTn/bDvx65WWuGc8ylOBzTQwA/vXxTYa13EELEN0XAVXMCt31MNWbraxVGE+9cNYfZgEPw8L5dXfblZDazhjw0NzZ8abGAAlt7ltZBVGwQhNmVafhpaQD5ZlVE6wQhQqY73yx4VlbZAWCbJXgQMFSjgxGN64jGaBitznc0AZUrrlA7H8JSCEUBCir5j2PJNGrmAEWCIUUJsCBEFxTz7qmMA8K5GHnyV4I/4mVPYEMjXU8cN30LlYBG9pwhQM8HL1EIj5Z0dCJKcRhDikkwa51rYiH0dZYMABGH/oQBDLgwcMeWBQCNBGLNqSCGbqXQQNiBIHZM0AVzEAFONpQi1tsTxf7hpvsuUAFYgOBCxhQAxWUEYxFPBwjl1i0N/oxjnP8oPMwEkM98vGSTgRkINczSJvhxgUV25cLCKenRyKniBaQVfbYSBQ3ghKOclyDFMH3kCqu4ZO3DCUtR0lMoNgymHCcAhZ0WUCG4NEAa8DCFJAJR1EW85qcsSQ1sajMNbgQITGM5jS3Wc1hYvOcNzkmOf04hSzsElIfMkAWxrnOcqLznkNRZz3hGP+FMbizTfIcQxT2eUlr4vOgkNEmHJXA0IFus58CJegtDYrQit5OoVg0QAUqUAV6SjSFBvgoRS1KUpjoE44hTcAUlpDClWahjypdwjwTQIUsLGGaUBhDBZYwhgQoQaM9VUIWsqCELEKhAjX040hLytSVnDSjKbQCFlSahShAoQpRmEITrDoGKDQBClFYAkOrQIUokBUKBlACFa4KBbYmwABLQGpBzdnUunrkqU6EaxOWMNAsYGGjVRAqPa0Q151WQAksvWETU2qFN1bACm8N5lLtSlm5YDSvPsVqApZgBYYqIaxFzSIWPAsFxGZxsadNbUpBOdnKurYjeLUhY1lagSz/pNCqFZgqTZWg2d0mtgl9NMBAqdCEFC4huJKl62uXG5HYgtSGWJiqGfb61ShgYa9NHAN1p6CENSyhCY5tghlu2ATwPneiymWuehni3I/a0LTuFeZ657uR9sYXvvHNYnrpy98IXfajSrBCZ/Nrz/6iE4F4SbBaFlDYjTr4wRCOsIOvOysF/lXCGM7wRpdAFwV7+MMgDrGI62IBOxq4JPszwAwQwOIWu/jFMI6xjGdM4xiHYFYhoAGNZxAEWYWgxkAOspCHTOQiG/nIR55B0F54YpGQAAEmEICUp0zlKlv5yljOspavTIQg/AACW6YyCn4QBCKE+cxoTrOa18zmNrtZ/8smQADsmiwSM0X5zXhecwxCEIIYtHnPfc6zoAdN6EIb2gQGMDGdO2KBGRj60VTeQZnz3OUdQPrSmM50oWcQsUWDhAAI0DShKz1oSZtZ1KhOtaqrjID9epq9oV41mwHtZ0LTWta4znWhW/3qT8da12E29aVJDexiG/vMvO71XX99bCu/wAAvyPSzo93sals72crmCKitXeVpi9rb3A63rrGdbY1sW9w7gHaqn21pcbtb1eQuN0bOHW4c/GDVP8DBu/ct6njL2yL0tvYL9C1rHFBb1yhgcbslsOUXHPzRDje2v/9NI2ZX2+C4HjiwESCBHUBAxwIwwJZZHGYJgHnNJP8v9sQp/heLH1vjucY4rlFAcClH2QA7kAANpBwDGkiA2iRHwQw6LmWOzwAFMcAByE3g81i/YMwQiLMEoCyAlG/c1SxPj8uNHYKHr/oFIcg1Ak5NZXXPINo4iPrZq46APcfABCb/gaNRsAMThODLAggBmIkQagngAAEfDzUCdm71cWM96wE/NgqCcGdcmyAIKMB14aUscrajgOECgICjWfyDqXMcAWB/upRNLgCas9jnAiC9AIIwZdZPXvKHZ3nijU2DnQO79hl3dJUrz2IIYN73bB88BIbvZwgQ4e+pBzME9D78yKu+8iFnu8RjT/HZA/vxkQf24huf6sefPAaW5n3/qBlf9Xv3Hgd3RgEKopzz1Fsa+1J2/slnYGnNS1/l1P+39XUN9mN3feYzEAISQHriJwA7wGc0EGUkB3YSEAI7cIANGHkQWHoC+GPJF38DKAGR93qytnJZ9xD7J3Zb14EjyG8m2GYe+IENEYKSV4Lw5oInGIPIln/yxoIkeGwcKIM6GGYpqIILYYOrloOphgMVxno7eIQ8SIPlBoQvWGw0UGG6d4JCiIRT1oM+ODAwuGoxUGv8V2H3FoNTSIVVp4TZxoRiqGcVln1SmIVIaIVXGDtseIZrdmMGUHNrKIdY5oZvKClxiIdoRgSyYntg2Ic6qId7GCGE6Idblm7qJoNh/0iFhniIh5GIiqhlssKFd1iJVUiGymaGmrhlDbiDj9iGnNhrnviJWTZ24uYKn9AKpGBlo3iEkXiIp4iKV0Z34sYCusgCgEAIiNAHRUeJUliKr1aLg2YCJ4cCw7eMJhADzZdpUTdlEMCF0ygAzggBalhlI7CN3NiN3viN4BiO3LiL5MgCfpAIqCCMJjiLe2iMgvYDBgBmLzB4f9d2nzcDgmhoKGAAv2YAv8ePVTd1+Hhl4liQBimO5biLpzACoqCO/MaOb+iOefZ3ggh8wShleidoQicBX6hjNWcANABmtSd4sZaRwEaO58gKVeiQ+waRVyiRb4YCIfB40oh594cD2f/4ZzhpAl/IeCGQfQYgdDGwYiQpZThZbL34i7DIku/mkj4Ik25GBPdGf1JmkQHJcfnoZj9AdgboaFtJealnciT3eTrXkkzpbk6pglDZZjgggEpXlTYpfJj4ZoVHAzjQgAQncsA3liE5l+EWi6JIjJ62lmsmkzZnhFYJmGEGAQQXeeSXd5EHfdKnmON2luKWlh9ImGomlVNGlYlpmVUogPQXhV8pmWMJmplGmWAomIummbZYiKh5baxJZ675moNoi5iJeLFpmw+5m82Wm7Lnm7yJlsI5fZIIgsU5nNymmsN4nA5Rm8rZlMl5dc65gtMZnTh4nWI3m00Gndj5l9oJe9X/CWvfaYtEOCtGWInAWX3hWZ6r9oSzEoWKuJ76157uuW5e+In0WYP2eZ+iFgNpqJ/ceWLe6Z/FRod2OJ8DamAFaqC6BoggiYr7uYT96aCYxohe54cTWoYVaqGXdokSuqD91aAeKmuhGKLj+YMdWqKGpooomqJYyKJyiIsvCqNwKKM4Kps2ihAkmqM+imYb2okrypvIeGYRh2tEEHnr15Iiyl89aqDweHJaRpmS6Wakl6RMuqM3+qN4RpE8N48cyXM+N3WZBwER9wI652dMp3PIyI/RtpGWFgNg+oVrGmuaNwNpJwAvUHwzMAMn9wI70Ke1hpXcp2lBaopD+poySZOZ/5d2JoADfpaRIIcAZeZwM4CM+jYD97YDSBePSNdncDd8jgqpebd3bQeqGWlySbeFpCoBRMCTO8d3BmiT/dak9PWk98mZnol5JmeYkxlrfjp6KEAD9Fdrldd5LDZ1Ftmr9ehzX3mBcRdrCHBvpAd8QdBiVZqatjpfuOqebel3O7esw4d5pzl6J0d6L0ADQQBmvBeSxCeuy7eMCRdrpCeW0tp3ysdw8biM8Lat69Wt3+mrNCmujxdlsppyX/momSdlsmoAUcaY6UewkBd/7VeqyeerGniBwBempdevWqo5iYqKnCll9CeuehoCfVqUAsB0fGZpCCCAEqCAIWBmDOiAJv8rkw0YakSQY6kKZi9rgRrLcCYQgCjrsR/LKSHLpTJ6qMWYtEpbokw7mE77tBYata05tVRroFZLm1ibtfe5td3ZtV5bnmBLoGI7tthZtgx6tmhLZcz5kP6qXgDbtijItnimtiNqt3T7tll6tIhIt9JZo347t4CrZnzblHHLXIRbuECqt26Gt07quGh7uGiZuMu1uIzLg5LLZpB7q5vrtZR7mZb7WpibuVP6uYY7uq5Vuqabh6ibZp3Lra/7tKH7l6pbWazbukspuEebu7rrtrM7g377t78rccGbhMOrdcVrvLz7sb67vLW7nLdLWc9bvIXHjFiGAlxZuck7ict7oA//x48IgAPtVmVWibjdW726u31lJ2UVm3NHl3nkyqZ6OoCxlnNEF5AJWKvpe7w+invtKwA/sHOB2ozoB3yy2n7ReHY014zRlsC0emmx+6/+i6PwV3YNGLMCgI8slnbWiq3WyHF/FwNednLXymLZ+mgTLLcVLKP9t3uNGmUcyYzAt6/ER77SFwMvq6/LKKWYtsKK28IsqqlWdqwMhwC614wb+4XKGHYCoGNbuLIix7E5CWlAfLlCXKITC8NShns724DOKLRE62g0IJqn2oDRNrR8Jp8SPL12pb6Zu3i2ecWkm8UWKndz7MZ1ZQEJ+r2i9qgZWok40GnDKwJU58eoxnGv/xln69K9KUaUSBbJkjzJlFzJkRwEkGzJmhzJSgYyI/bJoBzKoqxghNwVcOIDB5DKqrzKrNzKrvzKsBzLsjzLtFzLtnzLuMzKPhABudzLvvzLwBzMwjzMxFzMPgAiX0ECBzAAzNzMzvzM0BzN0jzN1FzN1nzN2JzN2rzNz/wARmAD3BzO4jzO5FzO5nzO6JzOA3AAc6YVZrIC6hzP8jzP9CzNvFzP+JzP+rzP/IzNK5BoXWEBPdDPBF3Q/IwEPgDPBr3QDN3QDh3NPVDKWEEAy/zQFn3R1pwCBgAEGN3RHv3R5XwAeowSFA3SJv3QGp0CJ73SLN3SIu0YFd3SMo3PKf890zZ90w390lxR0jjd0+Zc0z4d1EItzzq9FTzNzyvwANecAipd0EKgAwOgAwr90EhgAE290kAQAUKABA8AztP8AGD9AFC90EJw1c1sA16dzU9NzSsw1tWsAz0w1Rdd1Fpx1Ptc1Updzam8zQZgzhGg1Gvt0A8QAT7A0S39ABUmKxHQAwcABHnNzAagymbNzHuNzw8w0NDM1Nv819Hc11EtBNiMBDE91yN9Enatz6hcBMxsAylwABGABKtdBBFwz2Ct2SkQAUUAzisg20WQ1JGt0nAdARzN2q4N2wOw2/c8AJfdAz6g1CkAzsud1ykABD3QA17t2r2dzjZQBEZwAHL/fdI2UNWJPStFYNiQ/cxZLdwDMNsHYAO1rdK3ndvMHN8VHdyG3di4Dc0RkNbYrQNgPQApoANcvc647d95XdGcLQSzzdGIfQDPrdIr4NrePQDE/drNnAPf7dB0nRWnjc86gOFGwMwP0Nwr4APgnANKXQTLfABGUNYpENcjPgA9ANtAoAM2YABibQM5YAMr8Ncj/gAlfuKA3d47vgIovt5dbeI2YOLrLQQrgASqLQTLnNXb3NbQHOFGIN8gXeERYAQGYAQRMN4+gAQZHtmpHOAJzdoDUARFAOQs7uIw7gMDQN0rcOMUXuScbdUybtY93sxCoNo6AAR7TdgH8AB/HtWC/17Rns3ZHB3kNy7Wg73mK67aPx7klG3eFr3hEz3a+bzVMs7gEcDMf/3hlL3iFd0DeR0BOlAEPQAEXu3ZSMDLEh7pSK4DqHwAso0EoI3kSC7alA3bnB3p3Z3Knn3NWL7rzCzgu/zYHW3oOWAEjO3YaT0rWc7sz4zjYG3jRjDg61zRlY3qog7Xht3XsZ7K9+zZlS3iMW0EUz3oec3uzVzZi67Uht7lSu3Zwt7MIU7rnK3cnK7hpW0SHV7PPpADhE3poY7ktL7Xld3vnJ0C3H3vlN3mYO3eCe/jKJ7tDa/Uf13Z7q7coY7t/73UXm4AOSDgPWAE0D7ZFv3iRpADQmDtzv+cAzmQAhl+7c9sAwdg8N1e6qKe6oOd132N62ENzug+2g8Q08Xe8/2+9PL+80Bw8ryO7yHfzH3N73md9B2t6Z7z7/RM6se97xcP5PAu5T0/ALp+3HKe12ZvAPA84grt32O/AkYw1oGe8Ec+6jkQ7rwe6RYe1dY84okN7Ujg1h2dAj7gA89tzWldzUuP1sc99Lte2Wlf4gNg9v+s3Amd7ANw9M683c0cAU2tAx+/3qOf9naO5AcA2kZ+728f6q2u3AON9fPN8jkd8CUx8PPs6czc6rSfAjlQ3abOzLtN8xy987MNzzsP2sAfATng2GMf1QafA8ssBDlQBHmv1DtP/T//D/LH3QM0j9nSrANhPt6YfviJb/vlbACzrdU67vwq/f6kX9HF//zHPdtC4NnNb/+eDxADBA7IsUKgjggJgRw4MCDCg4MJIwBZ4SOCEAMCH67IEaFHDogHcgh5EGEAwoQ6BpTUCNGhjYExZc6kWdOmzQMEAOzk2dPnT6BBhQ4lWtToTgINby5l2tTpU6hRpQ60UcTAVaxYhUzl6hSIDx8puo51anCADR9SUygl21bmgyJu5Q7IedTuXbx5jSad29fvX6g6HgxGwtDwAbGAuaYwgETxXB0Wc6iUmiPx46iRYWKOWlfvZ9Chh/LlXNr0adQ0GV9O3dr167aeRc+mrZc0/+yxm3Hv/rua92/gwWXXJl5c6O3gZY0ASd5cKhADrJ1Pp+53uHHs2JFXpynkoUvu4QWuMCJd/Hn0S69nZ097O/oHRmwwTM+9R4/6+fXLXN/e/+f3zsuhIfr2Sw4II8wycMHz+vvvQbsCDE8kgQpkkLcezLtww+QchPDDoSzArz4bjHDJQg5dW8EABVN08bceLABxxqM6YLG+iwZC8cXTUhiRRyBfW7EDGoskigS2xENQwR2DxCxDJ6NE7QASjLQyKAZE8OEwLrv08kswwxTzACMiOCyhMdNUc00223RzTAOEeHNOOuu0804882zTBxEYuPJPnzpYICtCCzX0UEQTVf90UUYbdfRRSCOVdNJFRaiBgEEN8KAATjv19FNQQxV1VFJLNfVUVFNVdVVQPbiqBEBjBYABEjRl9VZcOfXgBFAdcCBXYIMVdtgCfCW2U1dJAKGACQJw9lloo5V2WmqrtfZabLPVdltuu6V2ggKqlPVPEZj19lx0n6WgAGk5TfddeOOVNwB3530WXAOatXdffvv1t9sJDCByXCMt+ODfeS9wtgAKpq0XYYgjxvbhfTXwQGKMM9Z4Ww9kJLhIAtjduFsKKNDghAYcFnlklv2l2N6XW5Z55n0L0OljGkOm+dqAr6JA32hj3nnobYWO12iik1ba4ZtxBlHnpaHVIKsTYGj/d+Wos77aZay19jppm52eEWqtXcXqBA62/nptpN9te224Mw5b7A/JzvqEs9NWO+6s30bXb74D73duuh+0e2kYsKJAYZUFj/oCxvkF3HHK4SW8cP8OV3oDn4Heu3LQs508dNK1vRxz9jRP+gMDfrZ29NIdhz122tttGvXUu06aAwMc8Lzx2oOnV3fhi6f2dNyNU33oFjYQnXjjKZ89+tKRT5645XfWwHToqb+2AfAb0Fvm6b0H3frr3eue7/KpN6DT7YNev+b5za8d/fRFy579+kk/wYMbjM9aBogWDHxlNWNdAHwa2J4GHLABxjlwAyLjgAccYDV6GdB5x+uf/ap3/7v81WZ/AZhAyrDFQJZ5YHsc+F3tsvKBDWggctJ6H6c0wIEPTOAC29vABhoArhO0gIEeKOHBYEDECxDwAoubgANSZoDtqZCDHrQf/kIIoPndwAAmfF0Hn0VAeDkxAC0Q4LyOlatDUaAFGITWFsHHgQuc4AYmrFe9PGBCB1QQgwS8wa+KxS4wGq19VGQfCK+ov/l9oAAb3GGxbuCsC2zAWAFYYAMfqLAJSHIDJXzfCi1otUY64JEklKTIGuABD3wgZTKkJCpNqIEjeoBxxdrkxM54q0P9qowBAOOzLsAwBwxvYSITYwCcWEwCLjJ8Cgsk9AZJSLhZ8ZB42R8HfnYCZ/81QJUT+IDCKJCyCdIriEMsYgAAGAAYwHGLcGSiE7X5w24G4JtjLMASLzCBeTrxAt3cp8Ic0IIJ3MB5LWCXAeOWFTWycVq9DADkSJjMFgzTWTeIKDfp+VBK5tBZaWvmFKEZPWlOM0Lra8EjPWC1BgTTmOJrmDDtiEcObOCkjANjHzn1q5Q6y4k45JQkKarTlDnxBiIrwCPFmFNecYqhCGtA/M4FQ1Ziq3e+asESHWCyhlIgj/XKZMms1sR/glEDWqWA1ToKvI8WL6Qi3cv6PqBVGFJSpe5UqbvqVUwxamADKOPlwnwIPgXOFXzffONdg9qAOrLrqMF0I/gyBsXA6Wv/n+l6Zlq1tla2EiV71nTWBLCZ05V6tlkEFWYAfmpRE5I2XxnVFwdA60TP6o0DBpXnYTlrzLQt1pij3OW/KIA2vuHwqr3lnmXVasjMUrN7JX3WSV+7Sgqgkl1c3YBX6aVV3103omO9KgyeGwBrXpVdLaBAdQ973XUBVa4k9EDJLoaxFhgAuISsrHGXhtnkBmWE9uVX4uRLXOPVl79Ew29+f7LfASfsbC0EqRcT7LUCG7gnCH5wvFjXOQ8KuMLkQ66Ei0LhDafLbBg2n4ZDPLIIexgAID6xt7SYFadSz8QtlluHVXwcB9N4W7y7igNmKOMc65hmKfYwi4Wsrd5pQKNV/wzykVtGZAkb2cnXYtyvCNzk5005mja+MVCkPLMfPqsBkRtzQ9/otQacgMEoxrIttcw2LnfZJ19uGe9W1rtsvo9ev/LABrNm5Z3NGFqCfnPN4ixnntBZYhUUpbMmeDBnGcCHAejhdEU2z6zFcc0aI7REC33ZQyN6xW2G2D5ZOEo1U0BvBqjgBTZlaWd9AMA762GgSd3FT4Na1B++9b9++qwjmjaiffUVYqf7qwd+LYk/ZvO/Op1ry4Ua0YqGGMU28IGrQpqAObWrD5kdtVrP7NnPhjZlpS1najMV0mlTs7NU3ddn2bXXGPPst+U2b7SWm8Dn7nK6EQbMk75X2PCWKP+5JafSJ+P7c/oONL9vjOASbjR84NPhmXPtWS42m2sMB5vDVYxgLa5ykYqs5x/7DO1ikU/h8uP4vnet2f4p0s+gLS2mC83NjHN65YPeecvPBWUD79eanhUzwusl64ylk3ZjTbize+7zbgE9v/tl7kmzaXRk+1lipKXdB2J8b6dDfcgeL3L93uqAuK7Xr2XWmFZrd0+WjfvpYjcd2aM8v9sSXe2l1VgSl1pne0dz7gan++vsHvT5MddZVqc54aU1NQMoFA8sOwHCzTh3noe98HE//NQxDzHOGWDYAcADC46wMb3Gk5JNtSQEG6qBYt0QlQo75QOblcDa15LRIjOgB2b/7dHBfX7zx+t8cv3dsgu31FlHML3GTqr4AozTYuV8JzeZJVDwKgz7PfwhHE3rPLQFFJ1IXHLRBi/84dvu5aNBf794fJUZMv/0EiP6bV+qU9cKdr0BbW8wuXqD/guAD2iBMOszTlGlqBs9yWm/9Iu34sus4xuZF7uKr5M/iTkZXzEAhTEsoPqunKKAGygh/7u0EMwp/lMzUQqfTaMWmlvABuS0B2SrL3O8ahkxSZMWC4QYqxujR6qX0zoYD2SsZnEgehm21SJCE/qmAngvHeoWHNK8F5QYqTO+JqNBasEbrIC0aMlBf9E78GoY6rKuIAwAJXugYLIqDihDSTKnkhk2//K6qsCrlr+7vCjEmCmEwCpkwGppGy7UMaQLvjqUwhgUqRnUQ+Cjlj5ssWJywUCstkGcpkK0NWxJxBDjOkZsRGd7xEP6MqajGayaxOajsUXaOEzMxPXDsXOJrZnhgHbLFkp8sBaEGUNMvzuUQSwLt5bBRVcMxRBLIlIsxcHRxCuiM1ZcQYRRRW7JwUn4F0bDoALQoIbyFHCJtxKCAUmarWQjJUCbFw0ERGAMxlPUrzb7xJHpxG6RPz5ggWXkF3tqoieKIg0ooQYgr9qiJDD0MVaEx3q0xHhZRFn8RnAMxwNrMyVDvq/bFuZjARYwhUjgF5v6I3irFxwaQueJodJqJv+eWiTLg5dwukSANCNhDCFq87py1EJvSUeFZAE+kJy/KrOOwicuQhtsushhagDCEh97sRhv/EiQFMiBfJeC3BiSPJeETEkWWAUWhIFO8RUH8Bl706bWikh22YBRWhhF8rRmQsbf45Y42kmePJqQzJ90G0qMCUp0OYI9MEpNoBYKOJT54a6yksoGmCqVSiJ9qZeOCq/0shebo8OvlJdaJMRbg4ETiEN7iSOFOpdIkASj7IRpmUDF2Upv0SuaaQEFBMxZHL7AhMReo0eJUaN5eYVSUMg9kBYDIpTLtBfVkxmb9Mi/NDefnLN5A02I8Ux7wQNPYAFJcBZrPAEQbEoDQED/8ylM+nlNsIzNCZu3ODrInCTOfkHLTPiAAYwg0TNG2pGifzROtwnL9InANEtNeWkBvmLHG/gAThiFMpqAxKyWCfi9jcQWhypL5cNM7dxO5Ew0hVuixTnMkjFMgLmB39qA9fQWDgDPNsoyMmTOfxFO+qzPv+HO64nAZxFPBe2WkzHQVLQYTYnHhNmeBrDGYpIgJYofVsqkfwKrenKsSHIAEo0l/ywagTuazNy8zdzEnoMB6azQE5LOAT2X3gRB6+wWbsNHI0KibdM/rEon7gMXdtkmKTpR7JuXevNLB/WWGh3GuVOyD5ijHStPsnyXmDqBLX3Rc+E2kSGgHTxSoLot/0/jFA5QqVNaqb2TF110mxktvCsVyc/Tq7YsLy6NlgYAwBP4Hx3VlgtoAekko4gx00iT0756rhZMLNDKKd06zFa0nDuluzwVy/oxtmBxACxsnR5qy6v4H2BJmQsA0BMQ0Ixh1L4irYD5QhL6pinVoQIYNndpt6KS01iMl01p0CqNOghNnv0qgDPIAGRNVmVdVmZtVmd9VmhV1jOQJE3pUaYawUZFUTBqr/ZKGRjALsjRKg5wl28tr9tLmV6FF20C1mAtmmHFHQuI0ePJAAWoV3tVACbIVybwgnvtV3/9V4ANWIDNgALg0JYjx3Qxy3bVlg/wmPu0EWMsAHr1V5/gAv+Bvdh/BQAnwNh7JVixI0wyZU8DqMqFvZYbEIH77AkSMJc9nNh+3QkFKAONrVcmkAInEAN+jVmbxVkvSAInkAKLbYMk4AIxcAKLldkuSII2UAA2+FmLjVmlZYOlVQCPFTvbTMUCAAEZIKKSZU8PkAE/SdmdoBVbERUHcNl7hVk2AIA5UAAuAAApEAO4VYAkgNsk6AImeIMvSII3AIA4YAIASNq+jQO5/QInIFwAEAMpAACLdQIA+AIAYIJ6zQA/uiXLvVzLLVtWSRYG6AASSCrMDV3RHd1gOQESGBix5YkOsAACaF3Xdd0FQFt77Yk34NfFTYK7BQAF+IIuqFcvAFz/J0iCOQCAJADcJHBb4lWAmd3dN1AAL5hbx83ZyV2A161e671e7M1e7d1e7u1e7/3e7JUB6gXf1rUA1AUAFyBf9V1f9m1f931f9a0BF0hdapLdet0Jue0CfnVc3MVd5d1YmtXY/s3X5DXe/71fAJ5Zx+3XDHhXgXQBGcAA+p1gCj4w+1Ve3XVcKWBauGUCLmjbxWWDmmWCL/iCMmACNjhhts1bv1VevG2DxeWCumUDBVjgjnVggawBEKhgHqZgArhgmG0DyC0Duu2CndhgL5gDyO2CNoiDxQ1cLgBcIzbheq1bv/WCxf0CMahXG7bXBu7h2QCBGgBjMkbOH+ZYNPZX/wNO43/94jL+DAyQAYd9YzqetgtmY4FdYzy+4TrWCxcwgDnuYzDGAB4gAB5QAeJQgQUI5LG54z22gzxwA2R1gzywgz1uYxyOTQsAZEEm4002gAUQAQMI29lgAAPIZC9zZIENhEKwhEfAhEoIA1meZVquBEx4BEsohEDYYzfu5LvYZB7w5QrGAAOQAURGXxXAAAJgABeQkRpYgAUoAURmAAJwgRJYgPlVZj/RZlO+GR5YABKYXwBQgWsmARmxAGgOZxFS5Xt1A0g4g0ZgBDowBD0YAnu+Z3zO5yHQA0OgA0ZohDOABDfg2F4W5qNwAREQAUY2aJ/kAQMY454wZRkAZf8AEAECqAEZQFkCKOZMwYBunpVT/ugaeOhacQFiBgECKIEqIYFLEWUJno0zvthDOANHoIQ72IIhkIPPkIMh2II7oARHOINDuNiCZmijsICEZmQZIIFDNuppO2UAwAoGMGWInpVnnugVG2UAGOmphupu/mgZ2GEbIQEVMABL4QEiUeZQ1mqYVmU7yABFWIQn+AM1qA01+IMnWARFyABLHlhUFlukVuieyAoRKAELeOmInmoGOOYiqQGPwRRGXoBxHmMMQGyhUIGqLooOuGYLyGzVZezJBoDODqE/lmwGAIFR/mj0NYBwRu2s9pON7mqd+GqopuiolmwXWICJBoE4BgH/CygBttYfR3aDS7hpLUAD7EADLfDpSxhoTHZqvQhs1z0UMRbnqHZdRm7d/6CVnbCAKjnfnTCAWZFsC1hon2AAyT6KEgjm3AYKzI7o9CYBUr4e1C6B005tqM7qahbl137tspYBTAlpqC7pjeYBBigBF2AAGQBb1kbv4A4NAjhWZs2DVBiEJ9CCB9GCJxiEUGjWM/jrCWbd1j0U6mVs8e6J3MZmAIBmAvBoBihv0Y7ml0bnErgZFSABFV+x3IYVn1iAl2ZxjyYB+Q7v8Z4VP9nsBaiB1ZVgDJAR9J4VHC8BIplqGN8JDCjsZSZvJpeRJgeADsAUHLfy9E6fzZ7opfbo//zuANROaPGO7f4e6cIWcJ3w3GKmbNQ2ABBAZOAO6wcHDWq23gUABTq4AuSGEDS4AjqAheudb+j+jKyobqA45fJVARHogC4vAfv+chlwbO/ugCxB39MlZgDAAN4WFD/hZHPuCUHhCUxfbBGo7FeP6iLXbt9G5gXwkyd/8mQGAB6AFQLYdIdVcwN/8lsv8ie/lBjniQUA70bHDlWoAwwnCsVmACYvZPMddcRmdKDQgjrYhGY3jsI+7KFI7cWOYwNHipvRbgAY8hW/cXEW729uXeqV9RW7HWpONJ0oZKQIZvF+8tZVgR1Wdlw3bcnuAB5QFslW954odmIf+CKXgSkf8/9l/vb2GAJBMApJX+YrtwAGqIEqUfgTJwpB0AOKp5GQt3ICAIGET/ebKfYVR++wbXP7nmoJPnGFn5Wm0W511+5+X/knF3hjl2wQQGt/NySGl+yjL/IT//kV0/aSpw17xvgJaxoiAXmjiPqn/5CTr2wvb3OIVnceGOMOQFlkt5FZqfSdQGSbvx0M4PF6H+eAXwC1n3UC6IAI9nIMUGd0Vnoi2fub34mk13uCBwAQ8JP23okSsOysh/ohwHjFnhUZOHekGN+NvvrGX/wHAWVorgFSX4Ba73wVUPfNBgEQmF9BSfITtwCVL316/3sQGJidJ/2b6fm3dwGV9/EsiebBR2r/3X/7Hnf43L/mIgd4EhB+Lw94CXvmcV7kzMJ6osj4sX1mTk5pxT55oXB+zMecgbnyvGBdGTRvkRoUkAZx7FhuqQcKUbf6otiCaM9+zKF0zwdtu6j1Q1L9K8KAZ1bnto9mRAaIBQYAMDBAAICKEgtIWADg8CHEiBInUqxo8eIWMBcBDHzoAoNDFSIAEDjosKNFMFs2smzp8iXMmDJn0qxp8ybOnDp3VuwgQwYBhRhkgCDwE4BAggYxGChaggTPqBPVPLmCxiJKgiBALFiggqRJjhbRXHmiRiratGrXsm3r9q1aHgYaAsAgtwQBgQySFiSgwoCIGjw6wNVJ9okWtlqq/14t7Pgx5MiSJxcmYIDBQ8t4S2LgaxCAiwUymlKmCWdLRjJRyajcAqc07NiyZ9N+/BcEAwskbrtgUEOFZwIMSvQ+WtullrJVwaimyVr5lcTHp1Ovbv26RxAGPrvQ3rTzwL4YvIP4iv3i8ydVh8BRI8eiHDVwhkBnfv4+/vz69+tnPSRNGk/U8QSAQ/wX4IAF2scfgw06+CCEhcU3H3vuRXghhhlquCGHHXr4IYghijgiiSWaeCKKKaq4IostuvgijDHKOCONNdp4I4456rgjjz36+COQQQo5JJFFGnkkkkkquSSTTTr5JJRRSjkllVVaeSWWWWq5JZddevklmGGKOS0mmWWaeSaaaaq5JpttuvkmnHHKOSedddp5J5556rknn336+SeggQo6KKEsBQQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ovarian androgens, mostly androstenedione and some testosterone, are produced in the theca cells which respond to luteinizing hormone (LH). The androgens diffuse across the basement membrane to the granulosa cells. The granulosa cells, in response to stimulation by follicle-stimulating hormone (FSH), produce aromatase which converts the androgen precursors to estrone and estradiol.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985; 6:371.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_16_9487=[""].join("\n");
var outline_f9_16_9487=null;
